MXPA05006676A

MXPA05006676A - 2-(1h-indazol-6-ylamino)-benzamide compounds as protein kinases inhibitors useful for the treatment of ophtalmic diseases.

Info

Publication number: MXPA05006676A
Application number: MXPA05006676A
Authority: MX
Inventors: John Borchardt Allen
Original assignee: Pfizer
Priority date: 2002-12-19
Filing date: 2003-12-08
Publication date: 2005-08-16
Also published as: HRP20050559A2; US20060160858A1; US7053107B2; RS20050430A; OA12977A; AR042510A1; PE20041006A1; AU2003286321A1; TNSN05164A1; EP1585743A1; JP3814285B2; DE60314013T2; CO5580767A2; CN1747950A; BR0317548A; US20040192735A1; ATE362928T1; ECSP055858A; AP2005003341A0; NL1025073A1

Abstract

Indazole compounds that modulate and/or inhibit the ophthalmic diseases and the activity of certain protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating tyrosine kinase signal transduction and thereby modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating ophthalmic diseases and cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma,rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.

Description

INDAZOL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS TO INHIBIT P ROTE I QU AS, AND PROCEDURES FOR ITS USE FIELD OF THE INVENTION This invention relates to indazole compounds that mediate and / or inhibit ophthalmic diseases and the activity of certain protein kinases, and to pharmaceutical compositions containing said compounds. The invention is also directed to the therapeutic or prophylactic use of said compounds and compositions, and to methods of treating ophthalmic diseases and cancer as well as other disease states associated with angiogenesis and / or undesired cell proliferation, by administering effective amounts of said compounds BACKGROUND OF THE INVENTION Several diseases and conditions of the eye segment endanger vision. Age-related macular degeneration (ARMD or AMD), choroidal neovascularization (CNV), retinopathies (for example, diabetic retinopathy, vitreoretinopathy, retinopathy of prematurity), retinitis (for example, cytomegalovirus retinitis) (abbreviated in English CMV), uveitis, macular edema and glaucoma are several examples. Age-related macular degeneration (ARMD or AMD) is the leading cause of blindness in the elderly. The ARMD attacks the vision center and makes it blurry, making reading, driving and other tasks difficult or impossible. Approximately 200,000 new cases of ARMD occur each year in the United States alone. Current estimates reveal that approximately forty percent of the population over 75 years of age, and approximately twenty percent of the population over 60, suffer some degree of macular degeneration. ARMD "wet" is the type of ARMD that most often causes blindness. In wet ARMD, newly formed choroidal blood vessels (choroidal neovascularization (CNV)) lose fluid and produce progressive damage to the retina. In the particular case of CNV in ARMD, two main treatment procedures are currently being developed, (a) photocoagulation and (b) the use of angiogenesis inhibitors. However, photocoagulation can be detrimental to the retina and is impractical when the CNV is in the vicinity of the fovea. In addition, photocoagulation often results in recurrent CNV over time. Oral administration of anti-angiogenic compounds is also being tested as a systemic treatment for ARMD. However, due to the specific metabolic restrictions of the drugs, systemic administration usually provides subtherapeutic drug levels to the eye. Therefore, to achieve effective drug concentrations intraocular, either unacceptably high doses or conventional repetitive doses are required. Various implants have also been developed to administer anti-angiogenic compounds locally in the eye. Examples of such implants are described in U.S. Patent No. 5,824,072 to Wong, U.S. Patent No. 5,476,511 to Gwon et al., And U.S. Patent No. 5,773,019 to Ashton. and col., each of which is incorporated in this specification in its entirety as a reference for all purposes. Neurovascular diseases of the eye As indicated above, the present invention also provides methods for treating neovascular diseases of the eye, including, for example, corneal neovascularization, neovascular glaucoma, proliferative diabetic retinopathy, retrolental fibroblasia and macular degeneration. In summary, corneal neovascularization as a result of injury to the anterior segment is a significant cause of decreased visual acuity and blindness, and an important risk factor for the rejection of corneal allografts. As described by Burger et al., Lab, Inves. 48: 169-180, 1983, incorporated herein in its entirety as a reference for all purposes, corneal angiogenesis includes three phases: a latent prevascular period, active neovascularization and vascular regression and maturation. The identity and mechanism of various angiogenic factors, which include elements of the inflammatory response, such as leukocytes, platelets, cytokines and eicosanoids, or unidentified plasma constituents have yet to be revealed.

Currently there is no clinically satisfactory therapy for the inhibition of neovascularization or corneal regression of new existing horn vessels. Topical corticosteroids appear to have some clinical utility, presumably limiting the inflammation of the stroma. Thus, in one aspect of the present invention methods are provided for treating neovascular diseases of the eye such as corneal neovascularization (including corneal graft neovascularization), which comprises the step of administering to a patient a therapeutically effective amount of an anti-inflammatory composition. -angiogenic (as described above) to the cornea, so that the formation of blood vessels is inhibited. In summary, the cornea is a tissue that normally lacks blood vessels. However, in certain pathological conditions the capillaries may extend into the interior of the cornea from the pericorneal vascular plexus of the limbus. When the cornea becomes vascularized, it also becomes cloudy, resulting in a decrease in the visual acuity of the patient. Visual loss can be complete if the cornea becomes completely opaque. Blood vessels can be introduced into the cornea in a variety of patterns and depths, depending on the procedure that causes neovascularization. These patterns have traditionally been defined by ophthalmologists in the following types: pannus (chronic superficial keratitis), trachomatous, pannus leprosum, pannus filctenulosuo degenerative pannus and glaucomatous pannus. The corneal stroma may also be invaded by branches of the anterior ciliary artery (termed interstitial vascularization) that produces several different clinical lesions: terminal loops, a pattern "of Brush-type ", a form of umbel, a network form, interstitial arcades (of episcleral vessels) and aberrant irregular vessels A wide variety of disorders can result in corneal neovascularization, including, for example, corneal infections (e.g., trachoma) , herpes simplex keratitis, leishmaniasis and onchocerciasis), immunological processes (for example, rejection of transplants and Stevens - Johnson syndrome), alkali burns, trauma, inflammation (of any cause), toxic and nutritional deficiency states and a complication in the use of contact lenses Although the cause of corneal neovascularization may vary, the response of the cornea to the lesion and subsequent vascular growth is similar regardless of the cause. be of importance since only those lesions located at a critical distance from the limbus will cause an angiogical response This is probably due to the fact that the angiogenic factors responsible for inducing vascular invasion are created at the site of the lesion, and must spread to the nearest blood vessel site (the limbus) in order to exert its effect. Beyond a certain distance from the limbus, this should not be possible and limbic endothelium growth in the cornea would not be induced. Probably several angiogenic factors are involved in this process, many of which are products of the inflammatory response. In fact, neovascularization of the cornea appears to occur only in association with an inflammatory cellular infiltrate, and the degree of angiogenesis is proportional to the degree of the inflammatory reaction. In addition, corneal edema facilitates the inward growth of the vessels blood by loosening the corneal stroma frame and providing a "minimum resistance" pathway through which capillaries can grow. After the initial inflammatory reaction, capillary growth in the cornea proceeds in the same way that it occurs in other tissues. The endothelial cells of the limbic capillaries and normally inactive venules are stimulated to divide and migrate. Endothelial cells project out of their vessels of origin, digest the surrounding basement membrane and the tissue through which they will travel and migrate to the source of the angiogenic stimulus. The terminal blind shoots acquire a lumen and then anastomose together to form capillary loops. The final result is the establishment of a vascular plexus inside the corneal stroma. The anti-angiogenic factors and compositions of the present invention are useful in that they block the stimulatory effects of angiogenesis promoters, reducing endothelial cell division, decreasing endothelial cell migration and damaging the activity of proteolytic enzymes secreted by the endothelium. SUMMARY OF THE INVENTION Within the particularly preferred embodiments of the invention, an anti-angiogenic factor for topical administration in saline (combined with any of the preservative and antimicrobial agents commonly used in ocular preparations) can be prepared, and administered in the form of eye drops. The solution or suspension of the anti-angiogenic factor can be prepared in its pure state and administered several times a day. As an alternative, anti-angiogenic compositions, Prepared as described above, they can also be administered directly to the cornea. In preferred embodiments, the anti-angiogenic composition is prepared with a mucoadhesive polymer that binds to the cornea. In additional embodiments, anti-angiogenic factors or anti-angiogenic compositions can be used as an adjunct to conventional steroid therapy. Topical therapy may also be useful prophylactically in corneal lesions known to have a high probability of inducing an angiogenic response (such as chemical burns). In these cases, treatment, probably in combination with steroids, can be used immediately to help prevent later complications. In other embodiments, the anti-angiogenic compositions described above can be injected directly into the corneal stroma by an ophthalmologist under microscopic guidance. The preferred site of injection may vary with the morphology of the particular lesion, but the purpose of administration would be to place the composition at the front front of the vasculature (i.e., sandwiched between the blood vessels and the normal cornea). In most cases this would involve perilimbic corneal injection to "protect" the cornea from advancing blood vessels. This procedure can also be used briefly after a corneal injury in order to prevent corneal neovascularization prophylactically. In this situation the material can be injected into the perilimbic cornea interspersed between the corneal lesion and its unwanted potential limbic blood supply. These procedures can also be used in a way similar to avoid capillary invasion of transplanted corneas. In a sustained release form injections may only be necessary 2 - 3 times a year. You could also add asteroid to the injection solution to reduce the inflammation that occurs from the injection itself. In another aspect of the present invention, methods are provided for treating neovascular glaucoma, comprising the step of administering to a patient a therapeutically effective amount of an anti-angiogenic composition to the eye, so as to inhibit the formation of blood vessels. In summary, neovascular glaucoma is a pathological condition in which new capillaries develop in the iris of the eye. Usually, angiogenesis originates from vessels located in the margin of the pupil and progresses through the root of the iris and into the trabecular meshwork. Fibroblasts and other connective tissue elements are associated with capillary development and a fibrovascular membrane develops that extends across the anterior surface of the iris. Eventually this tissue reaches the angle of the anterior chamber where it forms synechiae. These synechiae in turn unite, heal and contract to finally close the angle of the anterior chamber. Scar formation prevents adequate drainage of aqueous humor through the angle and into the trabecular meshwork, resulting in an increase in infraocular pressure that can result in blindness. Neovascular glaucoma usually occurs as a complication of diseases in which retinal ischemia is predominant. In particular, approximately one third of patients with this disorder have diabetic retinopathy and 28% have occlusion of the central veins of the retina. Other causes include chronic retinal detachment, end-stage glaucoma, obstructive carotid artery disease, retrolental fibropiasis, sickle cell anemia, infraocular tumors, and carotid cavernous fistulas. In its early stages, neovascular glaucoma can be diagnosed by high-magnification slit biomicroscopy, where it discovers small, dilated and disorganized capillaries (which lose fluorescein) on the surface of the iris. Posterior gonioscopy demonstrates progressive obliteration of the angle of the anterior chamber by fibrovascular bands. While the angle of the anterior chamber is still open, conservative therapies can be helpful. However, once the angle is closed, surgical intervention is required in order to relieve pressure. Therefore, in one embodiment of the invention anti-angiogenic factors (either alone or in an anti-angiogenic composition, as described above) can be administered topically to the eye in order to treat early forms of neovascular glaucoma. In other embodiments of the invention, the anti-angiogenic compositions can be implanted by injection of the composition in the region of the anterior chamber angle. This provides a sustained localized increase in anti-angiogenic factor and prevents the growth of blood vessels in the area. Anti-angiogenic implanted or injected compositions that are located between the front capillaries of the iris and the angle of the anterior chamber can "defend" the opening angle of the neovascularization. Since the capillaries will not grow in a significant radius of the anti-angiogenic composition, the opening of the angle could be maintained.

In other embodiments, the anti-angiogenic compositions can also be placed anywhere such that the anti-angiogenic factor is continuously released into the aqueous humor. This would increase the concentration of the anti-angiogenic factor in the mood, which in turn bathes the surface of the iris and its abnormal capillaries, thereby providing another mechanism by which to distribute the medication. These therapeutic modalities can also be useful prophylactically and in combination with existing treatments. In another aspect of the present invention, methods are provided for treating diabetic proliferative retinopathy, comprising the step of administering to a patient a therapeutically effective amount of an anti-angiogenic composition to the eyes, so as to inhibit vessel formation. blood In summary, the pathology of diabetic retinopathy is believed to be similar to that described above for neovascular glaucoma. In particular, antecedent diabetic retinopathy is thought to develop into proliferative diabetic retinopathy under the influence of retinal hypoxia. In general, neovascular tissue springs from the optic nerve (usually 10 mm from the edge), and from the surface of the retina in regions where tissue perfusion is scarce. Initially the capillaries grow between the inner limiting membrane of the retina and the posterior surface of the vitreous. Eventually, the vessels grow in the vitreous and through the internal limiting membrane. As the vitreous contracts, the traction is applied to the vessels, often resulting in cuts in the vessels and blinding of the vitreous due to hemorrhage. Fibrous traction of scarring on the retina may also cause detachment of the retina. The conventional therapy of choice is panretinal photocoagulation to decrease retinal tissue, and therefore diminish retinal oxygen demands. Although initially effective, there is a large relapse rate with new lesions that form in other parts of the retina. Complications of this therapy include a decrease in peripheral vision in up to 50% of patients, mechanical abrasions of the cornea, formation of laser-induced cataracts, acute glaucoma and stimulation of subrretinal neovascular growth (which can result in vision loss). ). As a result, this procedure is performed only when several risk factors are present, and the risk-benefit ratio is clearly in favor of the intervention. Therefore, in the particularly preferred embodiments of the invention, proliferative diabetic retinopathy can be treated by injection of an anti-angiogenic factor (s) (or anti-angiogenic composition) into the aqueous humor or the vitreous, in order to increase the local concentration of anti-angiogenic factor in the retina. Preferably, this treatment should be initiated before the acquisition of severe disease requiring photocoagulation. In other embodiments of the invention, the arteries that feed the neovascular lesions can be embolized (using anti-angiogenic compositions, as described above). In another aspect of the present invention, methods are provided for treating retrolental fibroblasis, comprising the step of administering a therapeutically effective amount of a factor to a patient. anti-angiogenic (or anti-angiogenic composition) to the eye, so as to inhibit the formation of blood vessels. In summary, retrolental fibroblasia is a condition that occurs in preterm infants receiving oxygen therapy. The peripheral retinal vasculature, particularly on the temporal side, is not fully formed until the end of fetal life. Excessive oxygen (even levels that would be physiologically in order) and the formation of free oxygen radicals are thought to be important in causing damage to the blood vessels of the immature retina. These vessels narrow and then structurally destroy with exposure to oxygen. As a result, the peripheral retina fails to vascularize and retinal ischemia occurs. In response to ischemia, neovascularization is induced at the junction of the normal and ischemic retina. In 75% of cases, these vessels regress spontaneously. However, in the remaining 25% there is a continuous capillary growth, contraction of the fibrovascular component and traction in both the vessels and the retina. This results in hemorrhage in the vitreous and / or retinal detachment that can lead to blindness. Neovascular glaucoma by angular closure is also a complication of this condition. Since it is often impossible to determine which cases will resolve spontaneously and which will become severe, conventional treatment (ie, surgery) is usually started only in patients with established disease and a well-developed pathology. This "wait and see" approach excludes early intervention and allows the progress of the disease in 25% following a complicated course. For the both, in one embodiment of the invention, topical administration of anti-angiogenic factors (or anti-angiogenic compositions, as described above) can be carried out in children who have a high risk of developing this condition in an attempt to cut the incidence of progression of retrolental fibroplasia. In other embodiments, intravitreal injections and / or infraocular implants of an anti-angiogenic composition can be used. Said methods are particularly preferred in cases of an established disease, in order to reduce the need for surgery. Protein kinases Protein kinases are a family of enzymes that catalyze the phosphorylation of the hydroxyl group of specific tyrosine, serine or threonine residues in proteins. Typically, said phosphorylation drastically disrupts the function of the protein, and thus protein kinases are fundamental in the regulation of a wide variety of cellular processes, including metabolism, cell proliferation, cell differentiation and cell survival. Of the many different cellular functions in which the activity of protein kinases is known to be required, some processes represent attractive targets for therapeutic intervention for certain disease states. Two examples are angiogenesis and cell cycle control, in which protein kinases play a fundamental role; These procedures are essential for the development of solid tumors as well as other diseases. Angiogenesis is the mechanism by which new capillaries are formed from existing vessels. When required, the vascular system has the potential to generate new capillary meshes in order to maintain adequate function of tissues and organs. However, in the adult, angiogenesis is clearly limited, occurring only in the process of wound healing and neovascularization of the endometrium during menstruation. See erenmies et al., Cell Growth & Differentiation, 8, 3-10 (1997), incorporated in this specification as a reference in its entirety for all purposes. On the other hand, unwanted angiogenesis is a hallmark of several diseases, such as retinopathies, psoriasis, rheumatoid arthritis, macular degeneration relative to age (abbreviated AMD) and cancer (solid tumors). Folkman, Nature Med., 1, 27-31 (1995), incorporated in this specification as a reference in its entirety for all purposes. It has been shown that the protein kinases that are involved in the angiogenic process include three members of the tyrosine kinase family of growth factor receptors: VEGF-R2 (vascular endothelial growth factor receptor 2, also known as KDR (receptor of the domain of kinase insertion) and as FLK-); FGF-R (fibroblast growth factor receptor); and TEK (also known as Tie-2). VEGF-R2, which is expressed only in endothelial cells, binds to the potent angiogenic growth factor VEGF and mediates subsequent signal transduction through the activation of its intracellular kinase activity. Thus, it is expected that direct Inhibition of the VEGF-R2 kinase activity will result in the reduction of angiogenesis even in the presence of exogenous VEGF (see Strawn et al., Cancer Research, 56, 3540-3545 (1996)) , as shown with VEGF-R2 mutants that do not mediate signal transduction. Millauer et al., Cancer Research, 56, 1615 -. 1615-1620 (1996). In addition, VEGF-R2 appears to have no role in the adult beyond the mediation of the angiogenic activity of VEGF. Therefore, it would be expected that a selective inhibitor of the kinase activity of VEGF-R2 exhibited low toxicity. Similarly, FGF-R binds to the angiogenic growth factors aFGF and bFGF and mediates subsequent intracellular signal transduction. Recently, it has been suggested that growth factors such as bFGF may play a critical role in the induction of angiogenesis in solid tumors that have reached a certain size. Yoshiji et al., Cancer Research, 57, 3924-3928 (1997). However, unlike VEGF-R2, FGF-R is expressed in numerous different cell types throughout the body and may or may not play important roles in other normal physiological procedures in the adult. However, systemic administration of a small molecule inhibitor of the kinase activity of FGF-R has been indicated to block angiogenesis induced by bFGF in mice without apparent toxicity. Ohammad et al., EMBO Journal, 7, 5996-5904 (1998).

TEK (also known as Tie-2) is another receptor tyrosine kinase expressed only in endothelial cells that has been shown to play a role in angiogenesis. The binding of the angiopoietin-1 factor results in autophosphorylation of the kinase domain of TEK and results in a process of signal transduction that appears to mediate the interaction of endothelial cells with periendothelial support cells, thereby facilitating vessel maturation blood formed again. On the other hand, the angiopoietin-2 factor seems to antagonize the action of angiopoietin-1 on TEK and interrupts angiogenesis. Maisonpierre et al., Science, 277, 55-60 As a result of the developments described above, it has been proposed to treat angiogenesis by the use of compounds that inhibit the kinase activity of VEGF-R2, FGF-R, and / or TEK. For example, the international publication WIPO No. WO 97/34876 discloses certain cinnoline derivatives which are inhibitors of VEGF-R2, which can be used for the treatment of disease states associated with abnormal angiogenesis and / or increased vascular permeability such as cancer. , diabetes, psoriasis, rheumatoid arthritis, Kaposi's sarcoma, hemangioma, acute and chronic nephropathies, atheroma, arterial retinosis, autoimmune diseases, acute inflammation and eye diseases with proliferation of retinal vessels. Phosphorylase kinase activates glycogen phosphorylase, increasing glycogen breakage and hepatic glucose release. Hepatic glucose production is deregulated in type 2 diabetes, and is the primary cause of fasting hyperglycemia, which results in many of the secondary complications that afflict these patients. In this way, the reduction of glucose release from the liver would reduce elevated plasma glucose levels. Therefore, phosphorylase kinase inhibitors should decrease the activity of phosphorylase and glycogenolysis, thereby reducing hyperglycemia in patients. Another physiological response to VEGF is vascular hyperpermeability, which has been proposed to play a role in the early stages of angiogenesis. In ischemic tissues, such as those that occur in the brain of victims of vascular accidents, hypoxia triggers VEGF expression, leading to an increase in vascular permeability and ultimately to edema in the surrounding tissues. In a vascular accident rat model, van Bruggen et al., J. Clinical Invest, 104 1613-20 (1999) have shown that the administration of a monoclonal antibody to VEGF reduces the volume of infarction. Thus, it is anticipated that VEGFR inhibitors are useful for the treatment of vascular accidents. In addition to their role in angiogenesis, protein kinases also play a crucial role in cell cycle control. Uncontrolled cell proliferation is the hallmark of cancer. Cell proliferation in response to various stimuli is manifested by a deregulation of the cell division cycle, the process by which cells divide and multiply. Tumor cells have typically damaged genes that directly or indirectly regulate progression throughout the cell division cycle. The cyclin-dependent kinases (abbreviated in English CDK) are serine-threonine protein kinases that play critical roles in the regulation of transitions between different phases of the cell cycle. See, for example, the articles compiled in Science, 274, 1643-1677 (1996). CDK complexes are formed by the association of a cyclin regulatory subunit (eg, A, B1, B2, D1, D2, D3 and E) and a catalytic kinase subunit (eg, cdc2, (CDK1), CDK2 , CDK4, CDK5 and CDK6). As the name implies, the CDKs show an absolute dependence of the cyclin subunit in order to phosphorylate their target substrates and different kinase / cyclin pairs function to regulate the progression along the specific phases of the cell cycle. The CDK4 complexed to the cyclins D is the one that plays a critical part in the initiation of the cell division cycle from a resting or latent phase to one in which the cells become involved in cell division. This progression is subject to a variety of growth regulatory mechanisms, both negative and positive. Aberrations in this control system, particularly those that affect the function of CDK4 have been implicated in the progress of cells to the highly proliferative state characteristic of malignancies, particularly familial melanomas, esophageal carcinomas and pancreatic cancers. See, for example, Kamb, Trends in Genetics, 11, 136-140 (1995); Kamb et al., Science, 264, 436-440 (1994). Multiple publications describe a variety of useful chemical compounds against a variety of therapeutic targets. For example, the WIPO International Publication Nos. WO 99/23077 and WO 99/23076 disclose indazole-containing compounds having type IV phosphodiesterase inhibitory activity produced by a bioisosteral replacement of indazole with catechol. U.S. Patent No. 5,760,028 discloses heterocycles that include 3- [1- [3- (imidazolin-2-ylamino) propyl] indazol-5-ylcarbonylamino] -2- (benzyloxycarbonylamino) propionic acid, which is useful as an α-integrin antagonist and relative receptors of cell surface adhesive proteins. The international publication WIPO No. WO 98/09961 describes certain indazole derivatives and their use as inhibitors of phosphodiesterase (abbreviated in English (PDE) of type IV or the production of tumor necrosis factor (abbreviated in English TNF) in a mammal. Recent additions to the virtual library of known compounds include those described as being antiproliferative therapeutics that inhibit CDKs, for example, U.S. Patent No. 5,621,082 of Xiong et al., Discloses nucleic acid encoding a CDK6 inhibitor, and European Patent Publication No. 0 666 270 A2 discloses peptides and peptide mimics that act as inhibitors of CDK1 and CDK2. WIPO International Publication No. WO 97/16447 describes certain analogs of chromones which are inhibitors of cyclin-dependent kinases, in particular of CDK / cyclin complexes such as CDK4 / cyclin D1, which can be used to inhibit excessive or abnormal cell proliferation , and therefore to treat cancer. The WIPO international publication No. WO 99/21845 describes 4-aminothiazole derivatives which are useful as inhibitors of CDK. Each of the patents and / or applications listed above is incorporated herein by reference in its entirety for all purposes. However, there is still a need for small molecule compounds that can be easily synthesized and are effective in inhibiting one or more CDK or CDK / cyclin complexes. Because CDK4 can serve as a general activator of cell division in most cells, and complexes of CDK4 and D-type cyclins govern the early phase Gi of the cell cycle, there is a need for effective inhibitors of CDK4 and complexes. D-type cyclins thereof, to treat one or more types of tumors. Also, the fundamental roles of cyclin E / CDK2 and cyclin B / CDK1 kinases in the G-i / S phase and G2 / M transitions, respectively, offer additional targets for therapeutic intervention in the suppression of the deregulated cell cycle progression in cancer. Another protein kinase, CHK1, plays an important role as a checkpoint in the progression of the cell cycle. The control points are control systems that coordinate cell cycle progression by influencing the formation, Activation and subsequent inactivation of cyclin-dependent kinases. The control points prevent the progression of the cell cycle at inappropriate times, maintain the metabolic balance of the cells while the cell stops, and in some cases can induce apoptosis (programmed cell death) when the requirements of the points have not been met of control. See, for example, O'Connor, Cancer Surveys, 29, 151 - 182 (997); Nurse, Cell, 91, 865-867 (1997); Hartwell et al., Science, 266, 1821-1828 (1994); Hartwell et al., Science, 246, 629-634 (1989). A series of checkpoints controls the integrity of the genome and, after detecting DNA damage, these "DNA damage control points" block the progression of the cell cycle in the Gi and G2 phases, and delay the progression through DNA. the S. O'Connor phase, Cancer Surveys, 29, 151-182 (1997); Hartwell et al., Science, 266, 1821-1828 (1994). This action allows the DNA repair processes that complete their tasks before the genome replication and the subsequent separation of this genetic material in new daughter cells takes place. Substantially, the gene most commonly mutated in human cancer, the p53 tumor suppressor gene, produces a DNA damage checkpoint protein that blocks cell cycle progression in the Gi phase and / or induces apoptosis (programmed cell death) ) that follows the damage in the DNA. Hartwell et al., Science, 266, 1821-1828 (1994). It has also been shown that the p53 tumor suppressor strengthens the action of a DNA damage control point in the Gz phase of the cell cycle. See, for example, Bunz et al., Science, 28, 1497-1501 (1998); Winters et al., Oncogene, 17, 673-684 (1998); Thompson, Oncogene, 15, 3025-3035 (1997).

Given the fundamental nature of the p53 tumor suppressor pathway in a human cancer, therapeutic interventions that exploit vulnerabilities in cancer deficient in p53 have been actively sought. A vulnerability emerges in the operation of the G2 checkpoint in cancer cells deficient in p53. Cancer cells, because they lack control of Gi control points, are particularly vulnerable to the abolition of the last remaining barrier that protects them from the anticancer effects of DNA-damaging agents: the G2 checkpoint . The control point of G2 is regulated by a control system that has been conserved from yeasts to humans. Important in this conserved system is a kinase, CHK1, that transduces signals from the sensory complex of DNA damage to inhibit the activation of cyclin B / Cdc2 kinase, which promotes mitotic entry. See, for example, Peng et al., Science, 277, 1501-1505 (1997); Sánchez et al., Science, 277, 1497-1501 (1997). The inactivation of CHK1 has been shown to eliminate the detection of G2 induced by DNA damage caused either by anticancer agents or by endogenous DNA damage, as well as resulting in preferential death of the resulting cells deficient in control points. See, for example, Nurse, Cell, 91, 865-867 (1997); Weinert, Science, 277, 1450-1451 (1997); Walworth et al., Nature, 363, 368-371 (1993); and Al-Khodairy et al., Molec. BioL Cell, 5, 147-160 (1994). Selective manipulation of checkpoint control in cancer cells could provide widespread use in chemotherapy and radiation therapy regimens for cancer and may also offer a common signal of "genomic instability" of human cancer to be exploited as a selective base for the destruction of cancer cells. Numerous factors place CHK1 as a fundamental target in the control of the control points of DNA damage. The explanation of the inhibitors of this and the functionally related kinases such as Cds1 / CHK2, a newly discovered kinase to cooperate with CHK1 in the regulation of the progression of the S phase (see Zeng et al., Nature, 395, 507-510 (1998), Matsuoka, Science, 282, 1893 - 1897 (1998)), could provide valuable new therapeutic entities for the treatment of cancer. The gadolinium receptor that binds ECM initiates intracellular signals mediated by FAK (focal adhesion kinase) that are involved in cell motility, cell proliferation and survival. In human cancers, overexpression of FAK is implicated in tumorigenesis and potential potential metastasis through its role in integrin-mediated signaling pathways. Tyrosine kinases can be of the receptor type (which has extracellular, transmembrane and intracellular domains) or non-receptor type (which are totally intracellular). At least one of the non-receptor type tyrosine kinase proteins, called LCK, is believed to mediate transduction in T cells of a signal from the interaction of a cell surface protein (Cd4) with a cross-linked anti-Cd4 antibody. A more detailed description of non-receptor tyrosine kinases is provided in Bolen, Oncogene, 8, 2025-2031 (1993), which is incorporated herein by reference in its entirety for all purposes. In addition to the protein kinases identified above, many other protein kinases have been considered to be therapeutic targets and numerous publications describe inhibitors of kinase activity, as reported in the following: U.S. Patent No. 6,534,524, issued March 18, 2003, U.S. Patent No. 6,531,491, issued March 11, 2003, publication of PCT international patent application No. WO 00/38665 (published July 6, 2001), publication of PCT international patent application No. WO 97/49688 (published December 31, 1997), publication of the PCT international patent application No. WO 98/23613 (published June 4, 1998), United States Patent No. 6,071,935, issued June 6, 2000, publication of the international patent application PCT No. WO 96/30347 (published October 3, 1996), publication of PCT international patent application No. WO 96/40142 (published December 19, 1996), publication of PCT international patent application N WO 97/13771 (published on April 17, 1997), publication of PCT international patent application No. WO 95/23141 (published on August 31, 1995), publication of PCT international patent application No. WO 03/006059 (published January 23, 2003), publication of PCT international patent application No. WO 03/035047 (published May 1, 2003), publication of PCT international patent application No. WO 02 / 064170 (published on August 22, 2002), publication of the patent application and international PCT No. WO 02/41882 (published May 30, 2002), publication of PCT international patent application No. WO 02/30453 (published April 18, 2002), publication of the international patent application PCT No. WO 01/85796 (published November 15, 2001), publication of PCT international patent application No. WO 01/74360 (published October 11, 2001), PCT International Patent Application Publication No. WO 01/74296 (published October 11, 2001), publication of PCT International Patent Application No. WO 01/70268 (published September 27, 2001), publication of European patent application EP No. 1086705 (published March 28, 2001) and publication of PCT international patent application No. WO 98/51344 (published November 19, 1998). The above patents and applications are each incorporated in this specification as a reference in its entirety for all purposes. However, there is still a need for effective protein kinase inhibitors. Furthermore, as understood by those skilled in the art, it is desirable that kinase inhibitors possess both high affinity for the kinase and the target kinases as well as high selectivity towards other protein kinases. Thus, an object of the invention is to discover potent agents for the treatment of ophthalmic diseases, such as age-related macular degeneration (abbreviated in English as ARMD), choroidal neovascularization (abbreviated in English as CNV), retinopathies (for example, retinopathy). diabetic, vitreoretinopathy, premature retinopathy), retinitis, (for example, cytomegalovirus retinitis (abbreviated in English CMV)), uveitis, macular edema and glaucoma. Another objective of the present invention is to discover potent protein kinase inhibitors. Another objective of the present invention is to discover effective inhibitors of kinases that have a strong and selective affinity for one or more particular kinases.

These and other objects of the invention, which will be apparent from the following description, have been carried out by the discovery of the indazole compounds, pharmaceutically acceptable drugs, pharmaceutically active metabolites and pharmaceutically acceptable salts thereof. (said compounds, prodrugs, metabolites and salts are collectively referred to as "agents") described below, which modulate and / or inhibit the activity of protein kinases. Pharmaceutical compositions containing such agents are useful in the treatment of diseases mediated by kinase activity, such as cancer, as well as other disease states associated with undesired angiogenesis and / or cell proliferation, such as diabetic retinopathy, neovascular glaucoma, arthritis. rheumatoid and psoriasis. In addition, the agents have advantageous properties relative to the modulation and / or inhibition of the kinase activity associated with VEGF-R, FGF-R, CDK, CHK1, LCK, TEK, FAK, and / or phosphorylase kinase complexes. In a general aspect, the invention relates to compounds having the following structures: ?? ?? ?? ?? The invention also relates to a method of modulating and / or inhibiting the kinase activity of VEGF-R, FGF-R, a complex of CDK, CHK1, LCK, TEK, FAK and / or phosphorylase kinase by administering a compound of Formula I, II, III or IV, or a pharmaceutically acceptable prodrug, pharmaceutically active metabolite, or pharmaceutically acceptable salt thereof. Preferred compounds of the present invention that have selective kinase activity - ie, possess significant activity against one or more specific kinases while possessing lower or lower activity against one or more different kinases. In a preferred embodiment of the invention, the compounds of the present invention are those of formula I which possess substantially greater potency against the tyrosine kinase of the VEGF receptor than against the tyrosine kinase of the FGR receptor R1. The invention also relates to methods of modulating the tyrosine kinase activity of the VEGF receptor without significantly modulating the tyrosinequinase activity of the FGF receptor. The compounds of the invention can be used advantageously in combination with other known therapeutic agents. For example, the compounds of formula I, II, III or IV that possess anti-angiogenic activity can be co-administered with cytotoxic chemotherapeutic agents, such as taxol, taxotere, vinblastine, cisplatin, doxorubicin, adrimycin and the like, to produce an enhanced antitumor effect. The additive or synergistic potentiation of the therapeutic effect can also be obtained by co-administration of the compounds of formula I, II, III or IV which possess anti-angiogenic activity with other antiangiogenic agents, such as combretastatin A-4, endostatin, priniomastat, celecoxib, rofocoxib , EMD 121974, IM862, anti-VEGF monoclonal antibodies, and anti-KDR monoclonal antibodies. Additional combinations are exemplified in WO 0038716, WO 00387171, WO 0038715, WO 0038730, WO 0038718, WO 0038665, WO 0037107, WO 0038786, WO 0038719, all filed simultaneously on December 22, 1999, incorporated in this specification. as a reference in its entirety for all purposes. The invention also relates to pharmaceutical compositions, each comprising an effective amount of an agent selected from the compounds of formula I and pharmaceutically acceptable salts, pharmaceutically active metabolites and pharmaceutically acceptable prodrugs thereof, and a pharmaceutically acceptable excipient or carrier. for said agent. The invention further provides methods of treating diseases / ophthalmic conditions and cancer as well as other disease states associated with undesired angiogenesis and / or cell proliferation, comprising administering effective amounts of said agent to a patient in need of such treatment. The compounds of the invention of formula I, II, III or IV are useful for treating ophthalmic diseases and mediating the activity of protein kinases. More particularly, the compounds are useful as anti-angiogenic agents and as agents for modulating and / or inhibiting the protein kinase activity, thus providing treatments for ophthalmic diseases and cancer or other diseases associated with cell proliferation mediated by protein kinases.

The term "alkyl" as used herein refers to straight and branched chain alkyl groups having between one and twelve carbon atoms. Exemplary alkyl groups include methyl (abbreviated Me), ethyl (abbreviated Et), n-propyl, isopropyl, butyl, isobutyl, sec-butyl, tere-butyl (abbreviated t-Bu), pentyl, isopentyl, tert-pentyl, hexyl , isohexyl and the like. The term "lower alkyl" denotes an alkyl having between 1 and 8 carbon atoms (a (Ci-C8) alkyl). Suitable substituted alkyls include, fluoromethyl, difluoromethyl, trifluoromethyl, 2-fluoroethyl, 3-fluoropropyl, hydroxymethyl, 2-hydroxyethyl, 3-hydroxypropyl and the like. The term "alkylidene" refers to a divalent radical having between one and twelve carbon atoms. Exemplary alkylidene groups include CH2, CHCH3, (CH3) 2 and the like. The term "alkenyl" refers to straight and branched chain alkenyl groups having between two and twelve carbon atoms. Exemplary alkenyl groups include prop-2-enyl, but-2-enyl, but-3-enyl, 2-methylprop-2-enyl, hex-2-enyl and the like. The term "alkynyl" refers to straight or branched chain alkynyl groups having between two and twelve carbon atoms. The term "cycloalkyl" refers to saturated or partially unsaturated carbocycles having between three and twelve carbon atoms, including bicyclic and tricyclic cycloalicylic structures. Suitable cycloalkyls include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and the like.

A "heterocycloalkyl" group is intended to mean a saturated or partially unsaturated monocyclic radical containing carbon, preferably 4 or 5 carbon atoms in the ring and at least one heteroatom selected from nitrogen, oxygen and sulfur. The terms "aryl" and "heteroaryl" refer to monocyclic and polycyclic aromatic or unsaturated ring structures, with "aryl" referring to those that are carbocycles and "heteroaryl" referring to those that are heterocycles. Examples of aromatic ring structures include phenyl, naphthyl, 1,2,3,4-tetrahydronaphthyl, furyl, thienyl, pyrrolyl, pyridinyl, pyrazolyl, imidazolyl, pyrazinyl, pyridazinyl, 1,2,3-triazinyl, 1, 2, 4-Oxadiazolyl, 1,4-oxadiazolyl, 1-H-tetrazol-5-yl, indolyl, quinolinyl, benzofuranyl, benzothiophenyl (tianaphtenyl) and the like. Said residues can optionally be replaced by a fused or bridged ring structure, for example OCH2-0. The term "alkoxy" is intended to mean the radical -O-alkyl. Illustrative examples include methoxy, ethoxy, propoxy and the like. The term "aryloxy" represents -O-aryl, wherein aryl is defined above. The term "cycloalkoxy" represents -O-cycloalkyl, wherein cycloalkyl is defined above. The term "halogen" represents chlorine, fluorine, bromine or iodine. The term "halo" represents chloro, fluoro, bromo or iodo. In general, the various moieties or functional groups for variables in the formulas can optionally be substituted by one or more suitable substituents. Exemplary substituents include a halogen (F, Cl, Br or I), lower alkyl, -OH, -NO2, -CN, -C02H, -O-lower alkyl, -aryl, -aryl-lower alkyl, -C02CH3, -CONH2 , -OCH2CONH2 >; -NH2, -S02NH2, haloalkyl (e.g., -CF3, -CH2CF3), -O-haloalkyl (e.g., -OCF3, -OCHF2) and Similar. The terms "comprising" and "including" are used in an open, non-limiting sense. It is understood that although a compound of formula I may show the phenomenon of tautomerism, the drawings of the formulas within this specification expressly describe only one of the possible tautomeric forms. It is therefore understood that in the invention the formulas are intended to represent any tautomeric form of the described compound and are not limited merely to a specific tautomeric form described by the drawings of the formulas. Some of the compounds of the invention may exist in the form of unique stereoisomers (ie, essentially free of other stereoisomers), racemates, and / or mixtures of enantiomers and / or diastereomers. All of these unique stereoisomers, racemates and mixtures thereof are intended to be within the scope of the present invention. Preferably, the compounds of the invention that are optimally active are used in optically pure form. As is generally understood by those skilled in the art, an optically pure compound having a chiral center is one that consists essentially of one of the two possible enantiomers (ie, it is enantiomerically pure) and an optically pure compound having more than one chiral center it is one that is both diastereomerically pure and enantiomerically pure. Preferably, the compounds of the present invention are used in a form that is at least 90% optically pure, ie, a form that contains at least 90% of a single isomer (80% enatiomeric excess (abbreviated "e. e" or diastereomeric excess (abbreviated in English "de")), more preferably at least 95% (90% ee or de), even more preferably at least 97.5% (95% ee or de), and more preferably at least 99% (98% ee or de). Additionally, the formulas are intended to cover both solvated and unsolvated forms of the identified structures. For example, formula I includes compounds of the indicated structure in both hydrated and non-hydrated forms. Other examples of solvates include the structures in combination with isopropanol, ethanol, methanol, DMSO, ethyl acetate, acetic acid or ethanolamine. In addition to the compounds of formula I, II, III and IV, the invention includes pharmaceutically acceptable prodrugs, pharmaceutically active metabolites and pharmaceutically acceptable salts of said compounds. "A pharmaceutically acceptable prodrug" is a compound that can be converted under physiological conditions or by solvolysis into the specified compound or a pharmaceutically acceptable salt of said compound. "A pharmaceutically active metabolite" is intended to mean a pharmacologically active product produced by metabolism in the body of a specified compound or salt thereof. The metabolites of a compound can be identified using standard techniques known in the art and their determined activities using assays such as those described in this specification. The prodrugs and active metabolites of a compound can be identify using standard techniques known in the art. See, for example, Bertolini, G. et al., J. Med. Chem., 40, 2011 - 2016 (1997); Shan, D. et al., J. Pharm. Sc, 86 (7), 765-767; Bagshawe K., Drug Dev. Res., 34, 220-230 (1995); Bodor, N., Advances in Drug Res., 13, 224-331 (1984); Bundgaard, H., Design of Prodrugs (Elsevier Press 1985); and Larsen, I.K., Design and Application of Prodrugs, Drug Design and Development (Krogsgaard-Larsen et al., eds., Harwood Academic Publishers, 1991). A "pharmaceutically acceptable salt" is intended to mean a salt that retains the biological effectiveness of the free acids and bases of the specified compound and that is not biologically or otherwise undesirable. A compound of the invention may possess a sufficiently acid functional group, sufficiently basic or both, and therefore react with any of a number of inorganic or organic bases, and inorganic and organic acids to form a pharmaceutically acceptable salt. Exemplary pharmaceutically acceptable salts include the salts prepared by the reaction of the compounds of the present invention with a mineral or organic acid or an inorganic base, such as the salts including sulfates, pyrosulfates, bisulfates, sulfites, bisulfites, phosphates, monoacid phosphates , diacid phosphates, metaphosphates, pyrophosphates, chlorides, bromides, iodides, acetates, propionates, decanoates, caprylates, acrylates, formates, isobutyrates, caproates, heptanoates, propiolates, oxalates, malonates, succinates, suberates, sebacates, fumarates, maleates, butyrate. 1, 4-dioates, hexane-1, 6-dioates, benzoates, chlorobenzoates, methylbenzoates, dinitrobenzoates, hydroxybenzoates, methoxybenzoates, phthalates, sultanates, xylenesulfonates, phenylacetates, phenylpropionates, phenylbutyrates, citrates, lactates, and-hydroxybutyrates, glycolates, tartrates, methanesulfonates, propanesulfonates, naphthalene-1-sulfonates, naphthalene-2-sulfonates and mandelates. If the compound of the invention is a base, the desired pharmaceutically acceptable salt can be prepared by any of the methods available in the art, for example, treatment of the free base with an inorganic acid, such as hydrochloric acid, hydrobromic acid, acid sulfuric acid, nitric acid, phosphoric acid and the like, or with an organic acid, such as acetic acid, maleic acid, succinic acid, mandelic acid, fumaric acid, malonic acid, pyruvic acid, oxalic acid, glycolic acid, salicylic acid, an acid pyranosidyl, such as glucuronic acid or galacturonic acid, an alpha-hydroxy acid, such as citric acid or tartaric acid, an amino acid, such as aspartic acid or glutamic acid, an aromatic acid, such as benzoic acid or cinnamic acid, a sulfonic acid , such as p-toluenesulfonic acid or ethanesulfonic acid or the like. If the compound of the invention is an acid, the desired pharmaceutically acceptable salt can be prepared by any suitable method, for example, treatment of the free acid with an inorganic or organic base, such as an amine (primary, secondary or tertiary), a alkali metal hydroxide or alkaline earth metal hydroxide, or the like. Illustrative examples of suitable salts include organic salts derived from amino acids, such as glycine and arginine, ammonia, primary, secondary and tertiary amines, and cyclic amines, such as piperidine, morpholine and piperazine, and inorganic salts derived from sodium, calcium, potassium, magnesium, manganese, iron, copper, zinc, aluminum and lithium. In the case where the agents are solid, those skilled in the art they understand that the compounds and salts of the invention can exist in different crystalline or polymorphic forms, all of which are intended to be within the scope of the present invention and specified formulas. The therapeutically effective amounts of the agents of the invention can be used to treat diseases mediated by modulation or regulation of protein kinases. An "effective amount" is intended to mean the amount of an agent that, when administered to a mammal in need of such treatment, is sufficient to effect the treatment of a disease mediated by the activity of one or more protein kinases, such as tyrosine kinases. Thus, for example, a therapeutically effective amount of a compound of formula I, salt, active metabolite or prodrug thereof is an amount sufficient to modulate, regulate or inhibit the activity of one or more protein kinases so that a disease state that is mediated by that activity is reduced or alleviated. The amount of a given agent that will correspond to said amount will vary depending on factors such as the particular compound, disease state and its severity, the identity (e.g., weight) of the mammal in need of treatment, but can independently be determined routinely by one skilled in the art. "Treatment" is intended to mean at least the mitigation of a disease condition in a mammal, such as a human being, that is affected, at least in part, by the activity of one or more protein kinases, such as tyrosine kinases and includes: preventing the disease from occurring in a mammal, particularly when it is found that the mammal is predisposed to have the disease condition but has not yet been diagnosed that he has it; modulating and / or inhibiting the disease condition; and / or relieving the state of the disease. The agents of the invention can be prepared using the reaction routes and synthesis schemes as described below, employing techniques available in the art using the starting materials that are readily available. In a general synthetic process, the compounds of formula I are prepared according to the following reaction scheme: 6-Nitroindazole (compound V) is treated with iodine and base, for example, NaOH, in an aqueous / organic mixture, preferably with dioxane. The mixture is acidified and the product isolated by filtration. To the resulting 3-iodo-6-nitroindazole in 50% aqueous dichloromethane-KOH at 0 ° C is added a protecting group reagent (abbreviated "Pg") (wherein X = halo), preferably trimethylsilylethoxymethyl chloride (abbreviated to English SEM-CI), and a phase transfer catalyst, for example, tetrabutylammonium bromide (abbreviated TBABr). After 1-4 hours, the two phases are diluted, the organics are separated, dried with sodium sulfate, filtered and concentrated. The crude product is purified by chromatography on silica gel to provide compounds of formula VI. The treatment of the compounds of formula VI in a suitable organic solvent with an R1-organometallic reagent, preferably an R1-boronic acid, in the presence of an aqueous base, for example, sodium carbonate and a suitable catalyst, preferably Pd (PPh3) provides, after an extractive treatment and chromatography on silica gel, the compounds of formula VII. The substituent R1 can be exchanged into compounds of formula VII or subsequent intermediates during this scheme by oxidative cleavage (eg, ozonolysis) followed by additions to the resulting aldehyde functionality with Wittig or condensation transformations (typified in example 42 (ae) ). The treatment of the compounds of formula VII with a reducing agent, preferably SnC-k, provides, after conventional aqueous treatment and purification, compounds of formula VIII. For the series of derivatives in which Y = NH or N-lower alkyl, the compounds of formula VIII can be treated with aryl chlorides, bromides, iodides or triflates or heteroaryl in the presence of a base, preferably Cs 2 CO 3, and a catalyst, preferably Pd-BINAP, (and where Y = N-lower alkyl, with a subsequent alkylation step) to provide compounds of formula X. To produce other Y bonds, add sodium nitrite to the compounds of formula VIII under usual cold aqueous acid conditions followed by the addition of potassium iodide and gentle heating. The usual treatment and purification produces iodine compounds of formula IX. The treatment of the compounds of formula IX with an organometallic reagent, for example butyllithium, promotes lithium halogen exchange. This intermediate then reacts with an electrophile R2, for example, a carbonyl or triflate, by the possible mediation of additional metals and catalysts, preferably zinc chloride and Pd (PPh3) 4 to provide the compounds of formula X. Alternatively, the compounds of Formula IX can be treated with an organometallic reagent such as organoboronic acid in the presence of a catalyst, for example, Pd (PPh3) 4. in a carbon monoxide atmosphere to provide the compounds of formula X. Alternatively, for derivatives where Y = NH or S, the compounds of formula IX can be treated with suitable amines or thiols in the presence of a base, preferably CS2CO3 or K3P04 and a catalyst, preferably Pd-BINAP or Pd- (bis-cyclohexyl) b-phenylphosphine to provide the compounds of formula X. Then exchanges of functional groups, such as oxidations, reductions, alkylations, acylations, condensations and deprotections can be used to derivatize subsequently these series providing the final compounds of formula I. The compounds of the invention of formula I can also be Prepare according to the general procedure shown in the following scheme: 6-iodoindazole (XI) is treated with iodine and base, for example, NaOH, in an aqueous / organic mixture, preferably with dioxane. The mixture is acidified and the product XII is isolated by filtration. To the resulting 3,6-diiodoindazole in 50% aqueous dichloromethane-KOH at 0 ° C is added a protecting group reagent, preferably SEM-CI, and a phase transfer catalyst, for example, TBABr. The two phases are diluted, organic products are separated, dried with sodium sulfate, filtered and concentrated. The product The crude is purified by chromatography on silica gel to provide compounds of formula XIII. The treatment of the compounds of formula XIII in a suitable organic solvent with a suitable R2-organometallic reagent, for example, R2-ZnCl, or a boron reactant of R2-boron and a suitable catalyst, preferably Pd (PPh3) 4 provides, after an extractive treatment and chromatography on silica gel, the compounds of formula XIV. The treatment of the compounds of formula XIV in a suitable organic solvent with a suitable R1-organometallic reagent (for example, boron reagent of R1-boron or R1-ZnCI) in the presence of an aqueous base, sodium carbonate and a suitable catalyst, preferably Pd (PPh3) 4 provides, after an extractive treatment and chromatography on silica gel, the compounds of formula XV. Then, exchanges of conventional functional groups, such as oxidations, reductions, alkylations, acylations, condensations and deprotections can be used to derivatize this series to provide the final compounds of formula I.

Alternatively, compounds of formula I in which R2 is a substituted or unsubstituted Y-Ar, wherein Y is O or S can be prepared according to the following general scheme: XVI catalyst, heat or OOQ modifications A stirred solution in acetone of 3-chlorocyclohex-2-enone (XV), H-2, and anhydrous potassium carbonate is heated to reflux for 15-24 hours, cooled and filtered. Concentrating and chromatographing the filtrate on silica gel provides 3-R2-cyclohex-2-enone (XVI). Ketones of formula XVI can be reacted with a suitable base (MB), preferably bis (trimethylsilyl) lithium amide and reacted with R 1 -CO-X (where X = halogen), which after usual acid treatment and purification provides compounds of formula XVII. This product, in AcOH / EtOH, combined with hydrazine monohydrate, is heated to a suitable temperature for a suitable period of time, preferably 60-80 ° C for 2-4 hours. After cooling, the mixture is poured into saturated sodium bicarbonate solution, extracted with an organic solvent, concentrated and purified on silica gel to provide compounds of formula XVIII. The compounds of formula XVIII can be oxidized using a variety of known methods to provide the compounds of formula I.

An alternative procedure for synthesizing the compounds of the present invention is the following: By means of which the conditions of steps a) to i) are the following: a) NaN02, Br2, HBr, 0 ° C - -5 ° C, yield 48%; b) Pd (OAc) 2, Pd (o-tolyl) 3, diisopropylethylamine (abbreviated in English as DIEA), DMF, H20, degassed, microwave, 110 ° C, 1 hour; 68% yield; c) Iron powder, saturated aqueous NH OH, EtOH, 45 ° C, 72% yield; d) methyl 2-bromobenzoate, R-BINAP, Pd2 (dba) 3, Cs2C03, toluene, degassed, 110 ° C overnight; 74% yield; e) KOH, MeOH: THF: H20 (3: 1: 1) 70 ° C, 2 - 3 hours; quantitative; f) Protected amine, HATU, NEt3, DMF, room temperature for 2 hours; 80% yield; g) TsOH (12% TsOH in AcOH), EtOH (10% aqueous); 44% yield; h) Tributylvinyltin, Pd (PPh3), 2,6-di-t-butyl-4-methylphenol, toluene, degassing, 105 ° C, 31% yield; i) Pd (OAc) 2, Pd (o-tolyl) 3, DIEA, DMF, degassing, 100 ° C; approximately 70% yield Other compounds of formula I can be prepared analogously to the general procedures described above or the detailed procedures described in the examples of this specification. Affinity of the compounds of the invention by a receptor can be enhanced by providing multiple copies of the ligand in close proximity, preferably using a scaffold provided by a carrier moiety. It has been shown that the provision of such multiple valence compounds with an optimal space between the residues markedly improves binding to a receptor. See, for example, Lee et al., Biochem, 23, 4255 (1984). Space and multivalency can be controlled by selecting a suitable vehicle rest or crimp units. Said moieties include molecular supports that contain a multiplicity of functional groups that can be reacted with functional groups associated with the compounds of the invention. Indeed, a variety of vehicles can be used, including proteins such as BSA or HSA, a multiplicity of peptides including, for example, pentapeptides, decapeptides, pentadecapeptides and the like. The peptides or proteins may contain the desired number of amino acid residues having free amino groups in their side chains; however, other functional groups, such as sulfhydryl groups or hydroxyl groups, can also be used to obtain stable bonds. Compounds that regulate, modulate or potently inhibit the protein kinase activity associated with VEGF receptors, FGF, CDK complexes, TEK, CHK1, LCK, FAK and phosphorylase kinase among others, and which inhibit angiogenesis and / or cell proliferation are desired. preferred embodiment of the present invention. The present invention further relates to methods of modulating or inhibiting protein kinase activity, for example, in mammalian tissue, by administering an agent of the invention. The activity of the compounds of the invention as Protein kinase activity modulators, such as kinase activity, can be measured by any of the methods available to those skilled in the art including in vivo and / or in vitro assays. Examples of suitable assays for activity measurements include those described in Parast C. et al., Biochemistry, 37 16788-16801 (1998); Jeffrey et al., Nature, 376, 313-320 (1995); the international publication WIPO WO 97/34876; and the international publication WIPO WO 96/14843. These properties can be assessed, for example, using one or more of the biological assay procedures set forth in the examples below. The active agents of the invention can be formulated into pharmaceutical compositions as described below. The pharmaceutical compositions of this invention comprise an effective modulating, regulating or inhibiting amount of a compound of formula I, II, III or IV and an inert pharmaceutically acceptable carrier or diluent. In one embodiment of the pharmaceutical compositions, effective levels of the agents of the invention are provided so that therapeutic benefits involving protein kinase modulation are provided. By "effective levels" is meant levels at which the effects of protein kinases are, at least, regulated. These compositions are prepared in unit dosage form suitable for the mode of administration, for example, oral or parenteral administration. An agent of the invention is administered in conventional dosage form prepared by combining a therapeutically effective amount of an agent (e.g., a compound of formula I) as an active ingredient with suitable pharmaceutical carriers or diluents according to conventional procedures. These methods may include mixing, granulating and compressing or dissolving the ingredients in a manner suitable to the desired preparation. The pharmaceutical carrier employed can be solid or liquid. Examples of solid carriers are lactose, sucrose, talc, gelatin, agar, pectin, gum arabic, magnesium stearate, stearic acid, and the like. Examples of liquid carriers are syrup, peanut oil, olive oil, water and the like. Similarly, the carrier or diluent may include time delay or release material known in the art, such as glyceryl monostearate or glyceryl distearate alone or with a wax, ethylcellulose, hydroxypropylmethylcellulose, methyl methacrylate, and the like. A variety of pharmaceutical forms can be employed. Thus, if a solid carrier is used, the preparation can be compressed, placed in a hard gelatin capsule in powder or granule form or in the form of a troche or lozenge. The amount of solid carrier may vary, but will generally be between about 25 mg and about 1 g. If a liquid carrier is used, the preparation will be in the form of syrup, emulsion, drops, soft gelatin capsule, sterile injectable solution or suspension in a vial or vial or non-aqueous liquid suspension. To obtain a stable water-soluble dose, a pharmaceutically acceptable salt of an agent of the invention is dissolved in an aqueous solution of an organic or inorganic acid, such as a 0.3 solution of succinic acid or citric acid. If a soluble salt form is not available, the agent can be dissolved in a suitable cosolvent or combinations of cosolvents. Examples of suitable co-solvents include, but are not limited to, alcohol, propylene glycol, polyethylene glycol 300, polysorbate 80, glycerin and the like in concentrations ranging from 0-60% of the total volume. In an exemplary embodiment, a compound of formula I is dissolved in DMSO and diluted with water. The composition may also be in the form of a solution of a salt form of the active ingredient in a suitable aqueous vehicle such as water or isotonic saline or dextrose solution. It will be appreciated that the actual dosages of the agents used in the compositions of this invention will vary according to the particular complex being used., the particular composition formulated, the mode of administration and the particular site, host and disease being treated. Optimal dosages for a given set of conditions can be ascertained by those skilled in the art using conventional dosage determination assays in view of the experimental data for an agent. For oral administration, an exemplary daily dose generally employed is between about 0.001 and about 1000 mg / kg of body weight, more preferably between about 0.001 and about 50 mg / kg of body weight, with courses of treatment repeated at appropriate intervals. Prodrug administration is typically dosed at weight levels that are chemically equivalent to the weight levels of the fully active form. The compositions of the invention can be manufactured in generally known ways to prepare pharmaceutical compositions, for example, using conventional techniques such as mixing, dissolving, granulating, dragee preparation, production of paste or fine powder, emulsification, encapsulation, wrapping or lyophilization. The pharmaceutical compositions can be formulated in a conventional manner using one or more physiologically acceptable carriers, which can be selected from excipients and auxiliaries that facilitate the preparation of the active compounds in preparations that can be used pharmaceutically. The proper formulation depends on the chosen route of administration. For injection, the agents of the invention can be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks' solution, Ringer's solution or physiological saline buffer. For transmucosal administration, suitable penetrants of the permeate barrier are used in the formulation. Such penetrants are generally well known in the art. For oral administration, the compounds can be formulated easily by combining the active compounds with pharmaceutically acceptable carriers known in the art. Said vehicles allow the compounds of the invention to be formulated in the form of tablets, pills, dragees, capsules, liquids, gels, syrups, pastes, suspensions and the like, for oral ingestion by a patient to be treated. Pharmaceutical preparations for oral use can be obtained by using a solid excipient in admixture with the active ingredient (agent), optionally grinding the resulting mixture and treating the mixture of granules after adding the appropriate auxiliaries, if desired, to obtain tablets or dragee cores. Suitable excipients include: fillers such as sugars, including lactose, sucrose, mannitol or sorbitol; and cellulose preparations, for example, corn starch, wheat starch, rice starch, potato starch, gelatin, gum, methylcellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose or polyvinylpyrrolidone (abbreviated as PVP). If desired, disintegrating agents may be added, such as cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate. Dragee cores are provided with suitable coatings. For this purpose, concentrated sugar solutions may be used, which may optionally contain gum arabic, polyvinylpyrrolidone, carbopol gel, polyethylene glycol and / or titanium dioxide, lacquer solutions and organic solvents or suitable solvent mixtures. Dyestuffs or pigments can be added to the tablets or dragee coatings for identification or characterization of the different combinations of the active agents. Pharmaceutical preparations that can be used orally include pressure setting capsules made of gelatin, as well as soft sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. Pressure adjusting capsules may contain the active ingredients in admixture with fillers, such as lactose, binders such as starches, and / or lubricants such as talc or magnesium stearate, and optionally, stabilizers. In soft capsules, the active ingredients can be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin or liquid polyethylene glycols. In addition, stabilizers can be added. All formulations for oral administration must be in dosages suitable for said administration. For administration buccal, the compositions can take the form of tablets or lozenges formulated in a conventional manner. For intranasal or inhalation administration, the compounds for use according to the present invention are conveniently distributed in the form of an aerosol spray presentation of pressurized containers or a nebulizer, with the use of a suitable propellant, for example, dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gases. In the case of a pressurized aerosol, the dosage unit can be determined by providing a valve for distributing a measured quantity. Capsules and gelatin cartridges for use in an inhaler or insufflator and the like can be formulated containing a powder mixture of the compound and a suitable powder base such as lactose or starch. The compounds can be formulated for parenteral administration by injection, for example, bolus injection or continuous infusion. Formulations for injection may be presented in unit dosage form, for example, in ampules or multi-dose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and / or dispersing agents. Pharmaceutical formulations for parenteral administration include aqueous solutions of the active compounds in water-soluble form. Additionally, suspensions of the active agents can be prepared in the form of suspensions of suitable oil injections. The solvents or suitable lipophilic vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate, or triglycerides or liposomes. Suspensions for aqueous injections may contain substances that increase the viscosity of the suspension, such as sodium carboxymethylcellulose, sorbitol or dextran. Optionally, the suspension may also contain stabilizers or suitable agents that increase the solubility of the compounds to allow the preparation of highly concentrated solutions. For ocular administration, a compound of formula I, II, III or IV is distributed in a pharmaceutically acceptable ophthalmic vehicle so that the compound is kept in contact with the ocular surface for a sufficient period of time to allow the compound to penetrate the cornea and / or sclera and the inner regions of the eye, including, for example, the anterior chamber, posterior chamber, vitreous body, aqueous humor, vitreous humor, cornea, iris / ciliary body, lens, choroid / retina and sclera. The pharmaceutically acceptable ophthalmic vehicle can be an ointment, vegetable oil, or encapsulating material. A compound of the invention can also be injected directly into the vitreous humor or aqueous humor. In addition, a compound can also be administered by well known acceptable methods, such as subtenon and / or subconjunctival injections. As is well known in the ophthalmic technique, the macula is composed mainly of retinal cones and is the region of maximum visual acuity in the retina. A Tenon's capsule or Tenon's membrane is arranged in the sclera. A conjunctiva 36 covers a short area of the globe from the eye to the posterior (the bulbar conjunctiva) and folds upwards (the pathway without upper outlet) or down (the lower dead center) to cover the inner areas of the upper eyelid and lower eyelid, respectively. The conjunctiva is disposed in the upper part of the Tenon capsule. The sclera and Tenon's capsule define the outer surface of the eyeball. For treatment of ARMD, CNV, retinopathies, retinitis, uveitis, cystoid macular edema (CME), glaucoma, and other diseases or conditions of the posterior segment of the eye, it is preferable to have a deposit of a specific amount of an active agent ophthalmic and pharmaceutically acceptable directly on the outer surface of the sclera and below the Tenon capsule. Furthermore, in cases of ARMD and CME it is more preferable to have the deposit directly on the outer surface of the sclera, below the Tenon's capsule, and generally above the macula. In a study using white New Zealand rabbits, a drug reservoir of 4.9 (11) -pregnadien-17.alpha., 21-diol-3,20-dione-21 -acetate, an angiostatic spheroid available from Steraloids, Inc. of Wilton, New Hampshire, was placed directly on the outer surface of the sclera, below Tenon's capsule and slightly posterior to the equator of the rabbit's eyes. Said drug deposit resulted in a concentration of the angiostatic steroid, averaged over the entire retina and measured on the day after the injection, approximately ten times greater than a similar concentration distributed by a reservoir located below the conjunctiva but above the capsule. Tenon of the eyes of the rabbit. Given the fact that Tenon's capsule of a white New Zealand rabbit is very thin, these beneficial results are highly unexpected. It is important to note that Tenon's eye capsule Human is also very thin. 4.9 (11) Pregnadiene-17.alpha., 21-diol-3,20-dione-21-acetate, and the relative compound 4.9 (11) -Pregnadien-17-alpha 21-diol-3.20 -dione are more fully described in U.S. Patent Nos. 5,770,592 and 5,679,666, which are incorporated herein by reference in their entirety. Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, eg, sterile, pyrogen-free water, before use. The compounds can also be formulated in rectal compositions such as suppositories or retention enemas, for example, containing conventional suppository bases such as cocoa butter or other glycerides. In addition to the formulations described above, the compounds can also be formulated as a delayed-release preparation. These long-acting formulations can be administered by intramuscular injection of implantation (eg, subcutaneously or intramuscularly) or by the aforementioned subtenon or intravitreal injection. In particularly preferred embodiments of the invention, the compounds can be prepared for topical administration in saline (combined with any of the preservatives and antimicrobial agents commonly used in ocular preparations) and administered in the form of eye drops. The solution or suspension of the anti-angiogenic factor can be prepared in its pure form and administered several times a day. Alternatively, the anti-angiogenic compositions, prepared as described above, can also be administered directly to the cornea. In preferred embodiments, the composition is prepared with a mucoadhesive polymer that binds to the cornea. Thus, for example, the compounds can be formulated with suitable polymeric or hydrophobic materials (for example, in the form of an emulsion in an acceptable oil) or ion exchange resins, or in the form of sparingly soluble derivatives, for example, in form of a sparingly soluble salt. In subsequent embodiments, anti-angiogenic factors or anti-angiogenic compositions can be used as adjuncts to conventional spheroid therapy. A pharmaceutical vehicle for hydrophobic compounds is a cosolvent system comprising benzyl alcohol, a non-polar surfactant, an organic water-miscible polymer and an aqueous phase. The cosolvent system can be a VPD cosolvent system. VPD is a solution at 3% w / v of benzyl alcohol, 8% w / v of the non-polar surfactant polysorbate 80, and 65% p v of polyethylene glycol 300, prepared up to a volume in absolute ethanol. The VPD co-solvent system (VPD: 5W) contains VPD diluted 1: 1 with 5% dextrose in aqueous solution. This co-solvent system dissolves hydrophobic compounds well, and it itself produces low toxicity after systemic administration. Naturally, the proportions of a cosolvent system can be varied considerably without destroying its solubility and toxic characteristics. In addition, the identity of the co-solvent components can be varied: for example, other non-polar low toxicity surfactants can be used in place of polysorbate 80; the size of the polyethylene glycol fraction can be varied; other biocompatible polymers can replace polyethylene glycol, for example, polyvinylpyrrolidone; and other sugars or polysaccharides can replace the dextrose. Alternatively, other delivery systems for hydrophobic pharmaceutical compounds may be employed. Liposomes and emulsions are known examples of delivery vehicles or excipients for hydrophobic drugs. Certain organic solvents such as dimethyl sulfoxide may also be employed, although usually at the cost of greater toxicity. Additionally, the compounds can be delivered using a sustained release system, such as semipermeable matrices of solid hydrophobic polymers containing the therapeutic agent. Various sustained release materials have been established and are known to those skilled in the art. Sustained-release capsules can, depending on their chemical nature, release the compounds for a few weeks to more than 100 days. Depending on the chemical nature and the biological stability of the therapeutic reagent, additional strategies for protein stabilization may be employed. The pharmaceutical compositions may also comprise suitable solid phase or gel carriers or excipients. Examples of such carriers or excipients include calcium carbonate, calcium phosphate, sugars, starches, cellulose derivatives, gelatin and polymers such as polyethylene glycols. Some of the compounds of the invention can be provided in the form of salts with pharmaceutically compatible counterions. The pharmaceutically compatible salts can be formed with many acids, including hydrochloric, sulfuric, acetic, lactic, tartaric, melic, succinic, etc. The salts tend to be more soluble in aqueous solvents or other protons which are the corresponding free base forms. The preparation of the preferred compounds of the present invention is described in detail in the following examples, but the skilled artisan will recognize that the described chemical reactions can easily be adapted to prepare numerous other protein kinase inhibitors of the invention. For example, the synthesis of compounds not exemplified according to the invention can be successfully performed by modifications obvious to those skilled in the art., for example, by adequate protection of interfering groups, by switching to other suitable reagents known in the art, or by routine modifications of the reaction conditions. Alternatively, other reactions described in this specification or known in the art having applicability for the preparation of other compounds of the invention will be recognized. DETAILED DESCRIPTION OF THE INVENTION AND PREFERRED EMBODIMENTS EXAMPLES In the examples described below, unless otherwise indicated, all temperatures are reported in degrees Celsius and all parts and percentages are by weight. The reagents were purchased from commercial suppliers such as Aldrich Chemical Company or Lancaster Synthesis Ltd. and used without further purification unless otherwise indicated. Tetrahydrofuran (abbreviated THF), N, N-dimethylformamide (abbreviated DMF), dichloromethane, toluene and dioxane were purchased from Aldrich in hermetically sealed and safe bottles and used as received. All solvents were purified using procedures usual ones readily known to those skilled in the art, unless otherwise indicated. The reactions set forth below were generally made in a positive pressure of argon or nitrogen or with a drying tube, at room temperature (unless otherwise indicated), in anhydrous solvents, and the reaction flasks were sealed with rubber septum to the introduction of substrates and reagents through a syringe. The glass articles were oven dried and / or heat dried. Analytical thin-layer chromatography (TLC) was performed on silica gel plates on 60 F 254 Analtech glass (0.25 mm) and eluted at the appropriate solvent ratios (v / v) and indicated when it is appropriate. The reactions were assayed by TLC and terminated as judged by the consumption of the starting material. Visualization of the TLC plates was done with a p-anisaldehyde sputtering reagent or phosphomolybdic acid reagent (Aldrich Chemical 20 wt.% In ethanol) and activated by heat. The treatments were typically carried out by doubling the volume of the reaction with the reaction solvent or extraction solvent and then washing with the indicated aqueous solutions using 25 volume% of the extraction volume unless otherwise indicated. The product solutions were dried with anhydrous Na2SO4 before filtration and evaporation of the solvents under reduced pressure in a rotary evaporator and described as solvents removed in vacuo. Flash column chromatography (Still et al., J. Org. Chem., 43, 2923 (1978)) was performed using Baker-grade ultrafast silica gel (47-61 μ ??) and silica gel: the ratio of rough material of approximately 20: 1 a 60 usual ones readily known to those skilled in the art, unless otherwise indicated. The reactions set forth below were generally made in a positive pressure of argon or nitrogen or with a drying tube, at room temperature (unless otherwise indicated), in anhydrous solvents, and the reaction flasks were sealed with rubber septum to the introduction of substrates and reagents through a syringe. The glass articles were oven dried and / or heat dried. Analytical thin-layer chromatography (TLC) was performed on silica gel plates on 60 F 254 Analtech glass (0.25 mm) and eluted at the appropriate solvent ratios (v / v) and indicated when it is appropriate. The reactions were assayed by TLC and terminated as judged by the consumption of the starting material. Visualization of the TLC plates was done with a p-anisaldehyde sputtering reagent or phosphomolybdic acid reagent (Aldrich Chemical 20 wt.% In ethanol) and activated by heat. The treatments were typically carried out by doubling the volume of the reaction with the reaction solvent or extraction solvent and then washing with the indicated aqueous solutions using 25 volume% of the extraction volume unless otherwise indicated. The product solutions were dried with anhydrous Na2SO4 before filtration and evaporation of the solvents under reduced pressure in a rotary evaporator and described as solvents removed in vacuo. Flash column chromatography (Still et al., J. Org. Chem., 43, 2923 (1978)) was performed using Baker-grade ultrafast silica gel (47-61 pm) and silica gel: the ratio of material gross of about 20: 1 to 61 50: 1 unless otherwise indicated. Hydrogenolysis was carried out at the pressure indicated in the examples or at ambient pressure. The 1 H-NMR spectra were recorded on a Bruker instrument operating at 300 MHz and the 13 C-NMR spectra were recorded operating at 75 MHz. The NMR spectra were obtained as CDCI 3 solutions (reported in ppm), using chloroform as reference standard (7.25 ppm and 77, 00 ppm) or CD3OD (3.4 and 4.8 ppm and 49.3 ppm), or internally tetramethylsilane (0.00 ppm) when appropriate. Other NMR solvents were used as necessary. When the multiplicity of peaks is described, the following abbreviations are used: s (singlet), d (doublet), t (triplet), m (multiplet), a (width), dd (doublet of doublets), dt (doublet of triplets). Coupling constants, when provided, are indicated in Hertz (Hz). The infrared spectra (abbreviated IR) were recorded on a Perkin Elmer FT-IR spectrometer in the form of pure oils, in the form of KBr pellets, or in the form of CDCI3 solutions, and when provided are indicated in wave numbers ( cm ") Mass spectra were obtained using LSIMS or electrospray All melting points (abbreviated pf) are uncorrected Example 1 (a) Dimethyl ester of 2- (4-chloro-2-nitro-phenyl) - malonic 62 To a stirred suspension of NaH (36.0 g, 1500 mmol) in NMP (1.0 I) was added dimethylmalonate (137.4 mL, 1200 mmol) dropwise. The reaction was cooled as necessary to maintain the internal temperature below 30 degrees Celsius. After gas evolution ceased, 2,4-dichloronitrobenzene (192 g, 1000 mmol) was added to the reaction. It was carefully heated to 65 degrees Celsius until the reaction was complete as determined by HPLC. The reaction was cooled to room temperature, and then poured onto 500 ml of ice mixed with 150 ml of concentrated HCl. The pH of the aqueous phase was adjusted to neutral using 1N NaOH. The solids were removed by filtering through a coarse sintered filter, and rinsed with water (3L). The yellow solids were allowed to dry overnight. The yield was 261, 5 gr, 91%. Example 1 (b) (4-Chloro-2-nitro-phenyl) -acetic acid methyl ester A solution of 2- (4-chloro-2-nitro-phenyl) -malonic acid dimethyl ester (195g, 679.4 mmol) in water (100 mL) and NMP (1000 mL) was heated to reflux for 3, 5 hours. The solvent was removed by rotary evaporation to give an oil. The oil was dissolved in ethyl acetate, and then washed with water (5 x 300 mL). The aqueous phase was then extracted with ethyl acetate (4 x 300 mL). The organic extract was washed with water. The organic phases were combined and dried over MgSO4. After removal of the solids by filtration, the solvent was evaporated to 63 produce the desired product as a brown-orange solid (160.0 g, 95%). Example 1 (c) (2-Acetylamino-4-chloro-phenyl) -acetic acid methyl ester A flask filled with argon was charged with (4-chloro-2-nitro-phenyl) -acetic acid methyl ester (40 g, 175 mmol), 10% Pd / C (2.5 g), acetic anhydride (64 ml). , 677 mmol), water (9 ml) and acetic acid (150 ml). The flask was injected with hydrogen at 30 PSI (206,850 kPa) by a vacuum system, and stirred vigorously. After two hours, more 10% Pd / C (2 g) was added, and the reaction was completed after a total of 4 hours of reaction time. The 10% Pd / C was removed by filtration, and the solvent was removed with a rotary evaporator. Example 1 (d) 6-Chloro-1H-indazole-3-carboxylic acid methyl ester To a solution of (2-acetylamino-4-chloro-phenyl) -acetic acid methyl ester (32.0 g, 133 mmol) in acetic acid (200 ml) stirred at 90 degrees Celsius was added ferric-butyl nitrite ( 20.5 mL, 172.3 mmol) for one hour. The reaction was poured into water (1.4 L) and the solids recovered by filtration. The yellow precipitate was dissolved in ethyl acetate, then washed with NaCl 64 saturated. The organic phase was dried over MgSO4, filtered, and concentrated to give a solid. The solids were triturated with hexanes and filtered to provide the desired material (21.63 g, 77%). Example 1 (e) 6-Chloro-1 - (tetrahydro-pyran-2-yl) -1H-indazole-3-carboxylic acid methyl ester To a suspension of the 6-chloro-H-indazole-3-carboxylic acid methyl ester (8.3 g, 39.5 mmol) in MeCN (200 mL) was added 3,4-dihydro-2H-pyran (5, 4 ml, 59.3 mmol) and p-toluenesulfonic acid (237 mg, 1.25 mmol). After allowing the reaction to stir for 10 minutes, saturated NaHCO3 (1 mL) was added and the solvent was removed with a rotary evaporator to a volume of 100 mL. The mixture was diluted with ethyl acetate and washed with water (50 ml) and then with saturated NaCl (50 ml). The organic phase was then dried over Na2SO4. After the solids were removed by filtration, the organic phase was concentrated to an oil with a rotary evaporator. The product was precipitated from the oil using hexanes to yield the desired product (7.667 g, 66% yield). Example 1 (f) 6- (2-Methoxycarbonyl-phenylamino) -1 - (tetrahydro-pyran-2-yl) -1 H-indazole-3-carboxylic acid methyl ester 65 To a solution of the 6-chloro-1-1 H-indazole-3-carboxylic methyl ester (2, 94 g, 10.0 mmol) in 2-dimethoxyethane (30 ml) was added K3P04 (5.32 g, 25.0 mmol), tris (dibenzylideneacetone) dipalladium (459 mg, 0.05 mmol), 2- (dicyclohexylphosphino) biphenyl (701 mg, 2.0 mmol), and methyl anthranilate (2.59 mL, 20.0 mmol). The solution was flushed with argon under vacuum three times before being heated at 80 ° C for 18 hours. The reaction was cooled to room temperature and the solids were removed by filtration. After washing the solids with ethyl acetate, the solvent was removed with a rotary evaporator. The residual oil was purified by chromatography (150g silica gel, AcOEt / Hex 10-30%) to give 1.23 g (51%) of the desired product. Example 1 (g) 6- (2-methoxycarbonyl-phenylamino) -1- (tetrahydro-pyran-2-yl) -1H-indazole-3-carboxylic acid To a solution of 6- (2-methoxycarbonyl-phenylamino) -1- (tetrahydro-pyran-2-yl) -1H-indazole-3-carboxylic acid methyl ester (2.05 g, 5 mmol) in 66 methanol (18 ml) and tetrahydrofuran (8 ml), a solution of sodium hydroxide (0.30 g, 7.5 mmol) in water (2.7 ml) was added. The reaction was stirred at room temperature for 3 hours and then neutralized with 1 N HCl to a pH of. The mixture was diluted with ethyl acetate (25 ml) and water (25 ml). After separating the phases, the aqueous phase was washed with CH 2 Cl 2 (3 x 25 ml). The combined organic extracts were washed with saturated NaCl (100 mL) and then dried over Na2SO4. The solids were filtered and the liquid was concentrated to an oil. The product was criatalized with ethyl acetate and hexanes to yield the desired product (1.616 g, 82%). Example 1 (h) 2- [3-methylcarbamoyl] -1- (tetrahydro-pyran-2-yl) -1H-indazolyl-6-amino] -benzoic acid methyl ester To a solution of 6- (2-methoxycarbonyl-phenylamino) -1- (tetrahydro-pyran-2-yl) -1H-indazole-3-carboxylic acid (0.50 g, 1.27 mmol) in DMF was added triethylamine (0.42 ml, 3.04 mmol), methylamine (1.9 ml, 3.81 mmol), and HATU (0.578 g, 1.52 mmol). The reaction was stirred for three hours and then concentrated by rotary evaporator. The crude oil was chromatographed (50 g of silica gel, 25-50% ethyl acetate / hexanes) to yield the desired product (214 mg, 42%). Example 2- [3-Methylcarbamoyl-1- (tetrahydro-2-pyranyl) -1 H -indazol-6-ylamino] -benzoic acid 67 To a solution of 2- [3-methylcarbamoyl-1- (tetrahydro-pyran-2-yl) -1 H -indazol-6-ylamino] -benzoic acid methyl ester (0.20 g, 0.49 mmol) in methanol (1.4 mL) and tetrahydrofuran (0.6 mL) was added a solution of sodium hydroxide (59 mg, 1.47 mmol) in water (0.3 mL). The reaction was heated to 60 degrees Celsius for 1 hour and then cooled to room temperature. The pH was adjusted with 2N HCl to a pH of 2. Ethyl acetate (30 ml) and water (30 ml) were added and the phases were separated. The aqueous phase was extracted with ethyl acetate (3 x 20 mL) and the organic phases were combined. After washing with water (15 ml), the organic phase was dried over Na 2 SO 4. The solids were filtered and removed, and the organic phase was evaporated to yield a yellow solid (193 mg, 100%). Example 1 (j) 6- (2-prop-2-ynylcarbamoyl-phenylamino) -1- (tetrahydro-pyran-2-yl) -1H-indazole-3-carboxylic acid methylamide To a solution of 2- [3-methylcarbamoyl-1- (tetrahydro-pyran-2-yl) -1 H -indazol-6-ylamino] -benzoic acid (50 mg, 0.381 mmol) in DMF (3.6 ml) Propargylamine (0.052 ml, 0.761 mmol), TEA (0.264 ml, 1.90 mmol) and HATU (217 mg, 0.571 mmol) were added. The reaction was stirred for 4 hours, and then 68 diluted with ethyl acetate (30 ml) and water (30 ml). The phases were separated, and the aqueous was extracted with ethyl acetate (2 x 20 mL). The combined organic extracts were washed with saturated NaCl (15 mL) and then dried over Na2SO4. The solids were removed by filtration, and the liquid was concentrated by rotary evaporator to a yellow oil (164 mg, 100%). Example 1 (k) 6- (2-propynyl-2-ynylcarbamoylphenylamine) -1H-indazole-3-carboxylic acid methylamide.

The 6- (2-prop-2-ynylcarbamoyl-phenylamino) -1- (tetrahydropyran-2-yl) -H-indazole-3-carboxylic acid methylamide (30 mg) is dissolved in 1.5 ml of a mixture. : 10: 1 CH2Cl2: TFA: triethyl silane and heated at reflux for 2 hours. The solution is diluted with toluene (40 ml) and concentrated with a rotary evaporator to an oil. Dissolve the oil in DMF (1 mL) and filter using a 0.2 micron syringe filter. Preparative HPLC is used to isolate the desired compound (12 mg, 50%). 1 H NMR (CDCl 3 -d) or 9.96 (1 H, s), 8.28 (1 H, d, J = 8.85 Hz), 7.47 (1 H, m), 7.34 (1 H, m), 7.22 (1H, m), 7.15 (1 H, dd, Ji = 8.76 Hz, J2 = 1.79 Hz), 6.99 (1 H, m), 6.86 ( 1H, t, J = 6.97 Hz), 6.31 (1H, m), 4.23 (2H, dd, J1 = 5.18 Hz, J2 = 2.54 Hz), 3.49 (3H, s), 2.29 (s, 1 H). Anal. Caled. For C19H 7N502-I .OMeOH-O.I TFA: C, 62.08; H, 5.44; N, 17.92. Found: C, 61, 78; H, 5.45; N, 18.4. 69 Example 2 (a) [6-chloro-1- (tetrahydro-pyran-2-yl) -1 H-3-indazoliI] -methanol To a solution of the 6-chloro-1H-indazole-3-carboxylic acid methyl ester (2.94 g, 10.0 mmol) in dry CH2Cl2 (50 mL) cooled to -78 degrees Celsius was added DIBAL-H (3 , 56 ml, 20 mmol) slowly. After the addition was complete, the reaction was allowed to warm to room temperature, where HPLC showed that there was 10% remaining initial material. Then extra DIBAL-H (0.35 ml) was added and stirred for 10 minutes. The reaction was diluted with ethyl acetate (1000 mL) and washed with HC1 N (2 x 100 mL). In addition, it was washed with 1 N NaHCO 3 (100 ml), and then with saturated NaCl (100 ml). The organic phase was dried over MgSO-v, filtered and then concentrated to a white solid (2.65 g, 99.5%). Example 2 (b) 6-chloro-1- (tetrahydro-pyran-2-ll) -1 H -indazol-3-carbaldehyde A solution of [6-chloro-1- (tetrahydro-pyran-2-yl) -1H-3-indazolyl] -methanol (1.75 g, 6.58 mmol), IBX (2.76 g, 9.87 mmol) and DMSO (27 ml) was left stirring overnight. The reaction was diluted in ethyl acetate and water. The phases were separated, and the aqueous was extracted with ethyl acetate (3 x 100 mL). 70 The organic extracts were combined and washed with a saturated NaCl solution (100 ml). The organic phase was dried over MgSO4, filtered and then concentrated to a solid. The solid was dissolved in CH2Cl2, and filtered. The organic phase was evaporated to yield the desired product (1.707 g, 92%). Example 2 (c) 1- (6-chloro-1 H-3-inda-2-yl) -2- (5-ethyl-pyridin-2-yl) -ethanol To a stirred solution of 4-ethyl-2-methylpyridine (0.458 g, 3.79 mmol) in THF (4 mL) at -50 degrees Celsius, a solution of butyllithium (1.5 mL, 2.5 mL) is slowly added. M, 3.79 mmol) and stirred for 10 minutes. To the reaction, a solution of 6-chloro-1 H-indazole-3-carbaldehyde (0.5 g, 1.89 mmol) in THF (4 mL) is added slowly. After stirring for 10 min., The reaction was quenched with 1 N citric acid (10 mL). The mixture was diluted with ethyl acetate (50 ml), water (20 ml), and a saturated solution of NaCl (10 ml). The phases were separated, and the aqueous was extracted with ethyl acetate (3.5 mL). The organic extracts were combined and washed with a saturated NaCl solution (20 ml). After drying the organic phase over Na 2 SO 4, the solids were removed by filtration and the liquids were concentrated to an oil by means of a rotary evaporator. Chromatography (40 g of silica gel, 60-100% ethyl acetate / hexanes) yielded the desired product (142 mg, 32%) and recovered 6-chloro-1 H-indazole-3-carbaldehyde (348 mg) . 71 Example 2 (d) 6-chloro-3- [2- (5-ethyl-pyridin-2-yl) -v] nyl] -1 H -ndazole To a stirred solution of 1- (6-chloro-1 H -3-indazolyl) -2- (5-etl-2-pyridinyl) -ethanol (232 mg, 0.60 mmol) in CH2Cl2 was added TEA. (0.25 mL, 1.81 mmol) and mesyl chloride (0.070 mL, 0.90 mmol). The reaction was stirred for 30 minutes, and then DBU (2 mL) was added. The reaction was refluxed for 18 hours, and then deactivated with 40 ml of 1 N citric acid. The phases were separated, and the aqueous was extracted with 20 ml of CH 2 Cl 2. The combined organic extracts were dried over Na 2 SO 4, filtered, and concentrated with a rotary evaporator. Purification by chromatography (12 g of silica gel, 50-70% ethyl acetate / hexanes) yielded the desired compound (135 mg, 71%). Example 2 (e) 2- Methyl ester. { 3- [2- (5-ethyl-2-pyridinyl) -vinyl] -1H-indazol-6-ylamino} -benzoic 1,2-Dimethoxymethane (2 ml) was added to 6-chloro-3- [2- (5-ethyl-pyridin-2-yl) - 72 vinyl] -1H-indazole (130 mg, 0.354 mmol), tris (dibenzylideneacetone) dipalladium (16 mg, 0.018 mmol), - (dicyclohexylphosphino) biphenyl (25 mg, 0.071 mmol), K3P04 (0.188 g, 0.885 mmol), and Methyl anthranilate (0.092 ml, 0.71 mmol). The vacuum was made by injecting argon into the reaction (4x) and then heating at 80 ° C for 19 hours. The reaction was diluted with ethyl acetate (20 ml) and filtered through a pad of silica gel. After washing with ethyl acetate (50 ml), the solvent was removed by rotary evaporator. The crude oil was purified by chromatography (40 g of silica gel, 30-40% ethyl acetate / hexanes) to yield the desired product (54 mg, 32%). Example 2 (f) 2 ^ 3- [2- (5-Ethyl-pyridin-2-yl) -vinyl] -1H-indazol-6-ylamino acid} -benzoic To a solution of 2- methyl ester. { 3- [2- (5-ethylpyridin-2-yl) -vinyl] -1 H -indazol-6-ylamino} -benzoic acid (50 mg, 0.104 mmol) in methanol (0.42 ml) and THF (0.10 ml) was added a solution of sodium hydroxide (12 mg, 0.311 mmol) in water (0.05 ml). The solution was heated to 60 degrees Celsius for 3.5 hours and then neutralized with saturated NH4Cl solution. The reaction was diluted with water (20 ml), and then extracted with ethyl acetate (2 x 20 ml). The combined extracts were dried first over Na 2 SO 4, and then the solids were removed by filtration. The desired product (48.7 mg, 73 100%) was recovered after evaporation with a rotary evaporator to remove the solvents. Example 2 (g) 2-. { 3- [2- (5-ethyl-pyridin-2-yl) -vinyl] -1 H -indazol-6-ylamino} -N-prop-2-inyl-benzamide To the acid 2-. { 3- [2- (5-ethyl-pyridin-2-yl) -vinyl] -1 H -indazol-6-ylamino} -benzoic acid (49 mg, 0.105 mmol) was added 2 ml of a 90: 10: 1 mixture of CH2Cl2: TFA: TES. The reaction was stirred under reflux conditions for 1 hour, and then diluted with toluene (20 mL). The solvent was removed by rotary evaporator to produce a thick oil. The oil was dissolved in DMF (1 mL) and to this solution was added TEA (0.072 mL, 0.52 mmol), propargylamine (0.014 mL, 0.208 mmol), and HATU (59 mg, 0.156 mmol). The reaction was stirred for three hours, and then purified by preparative HPLC to yield the desired product (29 mg, 66%). 1 H NMR (CDCl 3 -d): d 9.83 (1 H, s), 8.63 (2 H, s), 8.04 (2 H, m), 7.68 (2 H, s), 7.47 ( 1H, m), 7.32 (1 H, d, J = 1.51 Hz), 7.10 (1 H, dd, J1 = 8.67 Hz, J2 = 1.88 Hz), 6.93 ( 1H, m), 6.07 (2H, dd, J1 = 5.09 Hz, J2 = 2.26 Hz), 3.15 (1 H, t, J = 2.35 Hz), 2.97 (2H , s), 2.74 (1 H, s), 2.29 (1 H, s), 1, 27 (3H, t, J = 7.44 Hz) Anal. Caled, for C26H23N5O-0.3 H20-1, 2 TFA: C, 60.51; H, 4.43; N, 12.42. Found: C, 60.38; H, 4.73; N, 12.44. Example 2 (h) N-Cyclopropyl-2 - 3 - [(E) -2- (4-methyl-pyridin-2-yl) -vinyl] -1 H -indazol-6-ylamino} -benzamide 74 The title compound was prepared analogously to 2-. { 3- [2- (5-ethyl-pyridin-2-yl) -v-n-1] -1 H -indazol-6-ylamino} -N-prop-2-yl-benzamide described hereinabove, substituting 4-ethyl-2-methylpyridine for 2,4-dimethylpyridine in the step where 1- (6-chloro-1H was prepared -indazol-3-yl) -2- (5-ethyl-pyridin-2-yl) -ethanol, and using cyclopropylamine in place of propargylamine in the final step of the sequence. H NMR (DMSO-d6): d 9.85 (1 H, s), 8.56 (2H, m), 8.20 (3H, m), 7.53 (5H, m), 7.35 ( 1 H, s), 7.2 (1H, d, J = 6.5 Hz), 7.0 (1H, s), 2.83 (1H, m), 0.70 (2H, m), 0 , 56 (2H, m). ESIMS (+ H +): 410.3. Example 3 (a) N-methoxy-2- [3 - ((E) -2-pyridin-2-yl-vinyl) -1 H -ndazol-6-ylamino] -benzamide A solution of 2- [3- (2-pyridin-2-yl-vinyl) -1 H -indazol-6-ylamino] -benzoic acid (50.0 mg, 0.084 mmol), O-hydrochloride methylhydroxylamine (15 mg, 0.17 mmol), triethylamine (58 μl, 0.42 mmol), dissolved in DMF (0.8 ml), was treated with HATU (48 mg, 0.13 mmol). The mixture was stirred overnight, then purified by reverse phase HPLC affording 21.6 mg (67%) of the title compound as a yellow solid. 1 H NMR (DMSO-d 6): d 9.23 75 (1 H, s), 8.71 (1 H, d, J = 2.2), 8.05 (4H, m), 7.51 (5H, m), 7.25 (1 H, s) , 7.10 (1 H, d, J = 7.7 Hz), 6.91 (1 H, m), 5.98 (1 H, m), 4.31 (1 H, d, J = 14 , 3), 7.20 (1 H, d, J = 7.3), 4.42 (2H, d, J = 3.2). ESIMS (M + H +): 412.1. Example 3 (b) N-allyloxy-2- [3 - ((E) -2-pyridin-2-H-vinyl) -1 H -indazol-6-ylamino] -benzamide A solution of 2- [3- (2-pyridin-2-yl-vinyl) -1 H -indazol-6-ylamino] -benzoic acid (50.0 mg, 0.084 mmol), O-allyl-hydroxylamine hydrochloride ( 18.3 mg, 0.17 mmol), triethylamine (58 μl, 0.42 mmol), dissolved in DMF (0.8 ml), was treated with HATU (48 mg, 0.13 mmol). The mixture was stirred overnight, then purified by reverse phase HPLC yielding 25.5 mg (74%) of the title compound as a yellow solid. 1 H NMR (DMSO-d 6): d 9.28 (1 H, s), 8.67 (2 H, d, J = 3.4), 8.05 (4 H, m), 7.48 (5 H, m ), 7.23 (1 H, s), 7.04 (1 H, d, J = 7.6 Hz), 6.91 (1 H, m), 3.69 (3 H, s). ESIMS (M + H +): 386.1. Example 3 (c) N-isopropoxy-2- [3 - ((E) -2-pyridin-2-yl-v-n-1) -1 H -indazole-6-ylamino-benzamide A solution of 2- [3- (2-pyridin-2-yl-vinyl) -1H-indazol-6-ylamino] -benzoic acid (50.0 mg, 0.084 mmol), O-isopropyl-hydroxylamine hydrochloride ( 18.7 76 mg, 0.17 mmol), triethylamine (58 μl, 0.42 mmol), dissolved in DMF (0.8 ml), was treated with HATU (48 mg, 0.13 mmol). The mixture was stirred overnight, then purified by reverse phase HPLC yielding 17.4 mg (50%) of the title compound as a yellow solid. 1 H NMR (DMSO-d 6): d 9.23, (1H, s), 8.69 (H, d, J = 2.1), 8.03 (4H, m), 7.50 (5H, m ), 7.23 (1H, s), 7.04 (1 H, d, J = 6.7 Hz), 6.92 (1 H, m), 5.98 (1H, m), 4.13 (1 H, m), 1.29 (6H, d, J = 8.1). ESIMS (M + H +): 414.1. Example 3 (d) N-cyclopropyl-2- [3 - ((E) -2-pyridin-2-yl-vinyl) -1 H -indazol-6-ylaminoj-benzamide A solution of 2- [3- (2-pyridin-2-yl-vinyl) -1H-indazol-6-ylamino] -benzoic acid (50.0 mg, 0.084 mmol), cyclopropylamine (11.6 μ) 0.17 mmol), triethylamine (58 μl, 0.25 mmol), dissolved in DMF (0.8 ml), was treated with HATU (48 mg, 0.13 mmol). The mixture was stirred overnight, then purified by reverse phase HPLC yielding 11.7 mg (35%) of the title compound as a yellow solid. 1H NMR (DMSO-d6): d 9.81 1 H, s), 8.68 (1H, d, J = 1.7), 8.51 (1H, s), 8.01 (4H, m) , 7.50 (5H, m), 7.24 (1H, s), 7.03 (1H, d, J = 5.3), 6.89 (1H, t, J = 4.2), 2.84 (1H, m), 0.72 (2H, m), 0.56 (2H, m). ESIMS (M + H +): 396.1. Example 3 (f) N '- (1-2- [3 - ((E) -2-pyridin-2-yl-vinyl) -1 H -indazol-6-ylamino] -phenyl] -metanoyl) - 1-methyl-1H-pyrrol-2-carboxyHcoic acid hydrazide 77 A solution of 2- [3- (2-pyridin-2-yl-vinyl) -1 H -indazol-6-ylamino] -benzoic acid (50.0 mg, 0.084 mmol), 1-methyl-1-hydrazide H-pyrrole-2-carboxylic acid (23.3 mg, 0.17 mmol), triethylamine (58 μl, 0.42 mmol), dissolved in DMF (0.8 ml), was treated with HATU (48 mg, 13 mmol). The mixture was stirred overnight, then purified by reverse phase HPLC yielding 16.1 mg (40%) of the title compound as a yellow solid. 1 H NMR (DMSO-de): d 10.39 (1H, s), 10.00 (1H, s), 9.52 (1H, s), 8.67 (1H, d, J = 2.4) , 8.07 (4H, m), 7.77 (1 H, d, J = 5.2), 7.51 (4H, m), 7.32 (1H, s), 7.09 (H, d, J = 6.3), f), 98 (3H, m), 6.13 (1H, m), 3.87 (3H, s). ESIMS (M + H +): 478.1. Example 3 (g) N-benz [-2- [3 - ((E) -2-pyridin-2-yl-vinyl) -1 H -ndazol-6-ylamino] -benzamyria A solution of 2- [3- (2-pyridin-2-yl-vinyl) -H-indazol-6-ylamino] -benzoic acid [50.0 mg, 0.084 mmol), benzylamine (18.2) μl, 0.17 mmol), triethylamine (58 μl, 0.42 mmol), dissolved in DMF (0.8 ml), was treated with HATU (48 mg, 0.13 mmol). The mixture was stirred overnight, then purified by reverse phase HPLC yielding 45.2 mg (76%) of the title compound as a TFA salt (1.5 H20, 2.1 TFA, effective molecular weight = 711 , 98). 1 H NMR (DMSO- d 6): d 9.86 (1 H, s), 9.14 (1 H, t, J = 5.4), 8.73 (1 H, d, J 78 = 4.8), 8.29 (4H, m), 7.56 (1H, d, J = 7.0), 7.74 (2H, m), 7.89 (2H, m), 7, 31 (5H, m), 7.16 (1 H, d, J = 7.8), 6.93 (1H, t, J = 7.3), 4.46 (2H, d, J = 6, 1 ). ESIMS (M + H +): 446.5. Example 3 (h) N- (2-methoxy-benzyl) -2- [3 - ((E) -2-pyridin-2-yl-vinyl) -1 H -indazol-6-ylamino] -benzamide A solution of 2- [3- (2-pyridin-2-yl-vinyl) -1H-indazol-6-ylamino] -benzoic acid (50.0 mg, 0.084 mmol), o-methoxybenzylamine (21.8 μm) 0.17 mmol), triethylamine (58 μ ?, 0.42 mmol), dissolved in DMF (0.8 ml), was treated with HATU (48 mg, 0.13 mmol). The mixture was stirred overnight, then purified by reverse phase HPLC yielding 46 mg (81%) of the title compound as a TFA salt (1.5 H20, 1.5 TFA, effective molecular weight = 673.59. ). 1 H NMR (DMSO- d 6): d 9.83 (1H, s), 9.03 (1H, t, J = 3.4), 8.70 (1H, d, J = 3.7), 8, 08 (4H, m), 7.82 (1H, d, J = 7.4), 7.49 (4H, m), 7.21 (3H, m), 6.96 (4H, m), 4 , 48 (2H, d, J = 6.3). ESIMS (M + H +): 476.1. Example 3 (¡) N-furan-2-ylmethyl-2- [3 - ((E) -2-pyridin-2-yl-vinyl) -1 H -indazol-6-ylaminoj-benzamide A solution of 2- [3- (2-pyridin-2-yl-vinyl) -1H-indazol-6-ylamino] - 79 benzoic acid (50.0 mg, 0.084 mmol), C-furan-2-yl-methylamine (19 μl, 0.17 mmol), triethylamine (58 μl, 0.42 mmol), dissolved in DMF (0.8 mi), was treated with HATU (48 mg, 0.13 mmol). The mixture was stirred overnight, then purified by reverse phase HPLC yielding 45 mg (85%) of the title compound as a TFA salt (1.5 H20, 1.5 TFA, effective molecular weight = 633.52. ). 1 H NMR (DMSO- d 6): d 9.82 (1 H, s), 9.05 (1 H, t, J = 2.6), 8.73 (1 H, d, J = 3.7) , 8.13 (4H, m), 7.73 (1H, d, J = 6.8), 7.57 (2H, m), 7.26 (1H, s), 7.03 (1 H, d, J = 7.5), 6.40 (1 H, m), 6.28 (1 H, m), 4.48 (2H, d, J = 6.5). ESIMS (M + H +): 436.1. Example 3 (j) N-Cyclobutyl-2- [3 - ((E) -2 ^ -Rigin-2-yl-vinyl) -1 H -ndazol-6-ylamino] -benzamide A solution of 2- [3- (2-pyridin-2-yl-vinyl) -H-indazol-6-ylamino] -benzoic acid (50.0 mg, 0.084 mmol), cyclobutylamine (18.2 μl) , 17 mmol), triethylamine (58 μl, 0.42 mmol), dissolved in DMF (0.8 ml), was treated with HATU (48 mg, 0.13 mmol). The mixture was stirred overnight, then purified by reverse phase HPLC yielding 43.2 mg (92%) of the title compound as a TFA salt (1.5 H2O, 1.1 TFA, effective molecular weight = 561 , 92). H NMR (DMSO- de): d 9.78 (1 H, s), 8.72 (2H, m), 8.13 (4H, m), 7.70 (H, d, J = 7.1 ), 7.58 (2H, m), 7.41 (2H, m), 7.27 (1 H, s), 6.89 (1 H, t, J = 4.2), 2.84 ( 1 H, m), 0.72 (2H, m), 0.56 (2H, m). ESIMS (M + H +): 396.1. Example 3 (k) N- (2-methyl-allyl) -2- [3 - ((E) -2-pyridin-2-yl-vinyl) -1 H-indazole-6- 80 ilamino] -benzamide A solution of 2- [3- (2-pyridin-2-yl-vinyl) -1 H -indazol-6-ylamino] -benzoic acid (50.0 mg, 0.084 mmol), 2-methyl-allylamine (16, 4 μl, 0.17 mmol), triethylamine (58 μl, 0.42 mmol), dissolved in DMF (0.8 ml), was treated with HATU (48 mg, 0.13 mmol). The mixture was stirred overnight, then purified by reverse phase HPLC yielding 45 mg (91%) of the title compound as a TFA salt (1.6 H20, 1.3 TFA, effective molecular weight = 586.53 ). 1 H NMR (DMSO-d 6): 6 9.78 (1 H, s), 8.72 (2 H, m), 8.13 (4 H, m), 7.70 (H, d, J = 7.1 ), 7.58 (2H, m), 7.41 (2H, m), 7.27 (1 H, s), 7.06 (1 H, d, J = 7.1), 6.91 ( 1 H, t, J = 7.5), 4.42 (1 H, m), 2.22 (2H, m), 2.08 (2H, m), 1.68 (2H, m). ESIMS (M + H +): 410.1. Example 3 (l) 6-Nitro-3-pyridin-2-ylethynyl-1- (2-trimethylsilanyl-ethoxymethyl) -1H-indazole A mixture of 3-iodo-6-nitro-1- (2-trimethylsilanyl-ethoxymethyl) -1H-indazole (838 mg, 2.0 mmol), 2-ethynyl-pyridine (242 μl, 2.4 mmol) , and triethylamine (6.0 ml), were degassed and flooded under vacuum with argon atmosphere, then 81 treated with Cul (8 mg, 0.042 mmol), and Pd (PPh3) 2CI2 (16 mg, 0.023 mmol). The resulting mixture was stirred overnight at room temperature, while HPLC indicated that all of the starting material had been consumed. The mixture was purified by removing the volatiles under high vacuum, then passing the residue through a pad of silica eluted with ethyl acetate. The resulting product was used in the next step without further purification. ESIMS (M + H +): 395.1. Example 3 (m) 3-pyridine-2-ylethynyl-1- (2-trimethylsilanyl-ethoxymethyl) -1 H -indazol-6-ylamine A mixture of 6-n-thre-3-pyridin-2-ylethyl-1- (2-trimethylsilyanil-ethoxymethyl) -1 H-indazole (2 mmol), SnCl2 (1.37 g, 6, 0 mmol), water (0.5 ml), and MeOH (10 ml) were stirred in an oil bath at 60 degrees for 30 minutes while HPLC indicated complete reduction. To the resulting mixture, the methanol was distilled off, suspended in ethyl acetate (50 ml) and diluted with 1 M NaOH (18 ml). The resulting emulsion was carefully extracted with ethyl acetate (10 x 25 mL). The combined organic extracts were extracted with 1 M Na2CO3, brine, dried over MgSC, concentrated and filtered through a pad of silica eluted with ethyl acetate. The yield of the crude product for the two stages was 701 mg, 96% of the recovered mass. ESIMS (M + H +): 365.1. Example 3 (n) Methyl ester of 2- [3-pyridine-2-ylethynyl-1- (2-trimethylsilanyl- 82 ethoxymethyl) -1 H -indazol-6-ylamino] -benzoic acid A mixture of 3-pyridin-2-ylethyl-1- (2-trimethylsilyl-ethoxymethyl) -1 H -indazol-6-ylamine (560 mg, 1.54 mmol), 2- bromomethylbenzoate (647.5 μ \, 4.61 mmol), biphenyl-2-yl-dicyclohexyl-phosphine (107.8 mg, 0.308 mmol), Pd2 (dba) 3 (70.5 mg, 0.0768 mmol), K3PO4 (816 mg, 3.844 mmol), and dimethoxyethane (1.7 mL), was flooded under vacuum with a nitrogen atmosphere, then heated in an oil bath at 70 degrees Celsius for 24 hours. The black mixture was diluted with methylene chloride, and filtered, concentrated and chromatographed (20% to 40% ethyl acetate / hexanes). Yellow / orange oil production was 260 mg, 35% yield for all three stages. Example 3 (o) 2- [3-Pyridin-2-ylethynyl-1- (2-trimethylsilanyl-ethoxymethyl) -1H-indazol-6-ylamino] -benzoic acid 2- [3-Pyridin-2-ylethyl] -1- (2-trimethylsilyl-ethoxymethyl) -1H-indazol-6-ylamino] -benzoic acid methyl ester (253 mg, 0.517 mmol) was added to a solution NaOH (62 mg, 1.55 mmol); was dissolved in THF (1.0 mL), MeOH (2.25 mL), and water (0.5 mL). The reaction was stirred at room temperature during 83 1 hour, while the HPLC indicates that all the starting material has been consumed. The reaction was neutralized with 1 N HCl, extracted with ethyl acetate, which was then washed with brine and dried with MgSO4. After concentrating in vacuo, 249 mg of yellow solid (99% recovered mass) were obtained. This material was used without further purification. ESIMS (M-H "): 483.0, Example 3 (p) 2- [3-pyridin-2-bulletinyl-1H-indazol-6-ylamino] -benzoic acid A solution of 2- [3-pyridin-2-ylethynyl-1- (2-trimethylsilanyl-ethoxymethyl) -1H-indazol-6-ylamino] -benzoic acid (231 mg, 0.477), tetrabutylammonium fluoride 1M in THF (3.8 ml, 3.816 mmol), and ethylenediamine (127 μl, 1.908 mmol) were stirred in an oil bath at 80 degrees for 6 hours. The reaction was quenched with acetic acid (218 [mu] L, 3.816 mmol), diluted with water, and extracted with ethyl acetate (10 x 50 mL). The combined organic extracts were washed with brine and dried over MgSO4. After concentrating a solid formed which was triturated with CH2Cl2, giving the product as a yellow powder (124 mg, 73%). ESIMS (? -? - G): 353.0. Example 3 (q) N-prop-2-ynyl-2- [3 - ((E) -2-pyridin-2-yl-vinyl) -1 H -indazol-6-ylaminoj-benzamide 84 A solution of 2- (3-pyridin-2-ylenyl-1 H -indazol-6-ylamino) -benzoic acid (41 mg, 0.1 17 mmol), propargylamine (24 μm, 0.35 mmol) ), triethylamine (81 μl, 0.58 mmol), dissolved in DMF (0.5 ml), was treated with HATU (89 mg, 0.233 mmol). The mixture was stirred overnight, then purified by reverse phase HPLC yielding 27 mg (59%) of the title compound as a yellow solid. 1 H NMR (DMSO- d 6): d 9.78 (1H, s), 8.99 (1 H, m), 8.61 (H, d, J = 2.1), 7.88 (1 H, s), 7.72 (3H, m), 7.43 (4H, m), 7.29 (1H, s), 7.04 (H, d, J = 7.3), 6.91 ( 1H, t, J = 5.2), 4.04 (2H, s), 3.04 (H, s). ESIMS (M + H +): 392.1. Example 4 (a): 2-bromo-4,6-dimethyl-pyridine A solution of 48% HBr (aqueous) (Aldrich, 65 ml, 1.2 mol, 10 eq) was cooled to -5 ° C and treated with 4,6-dimethyl-pyridin-2-ylamine (Aldrich, 1985). , 0 g, 0.12 mol, 1.0 eq). The white coarse salt mixture was stirred with a mechanical stirrer while bromine was added dropwise (Aldrich, 19.7 ml, 0.38 mol, 3.1 eq). The resulting red mixture was treated with an aqueous solution (32 ml H20) of NaN02 (Aldrich, 22.1 g, 0.32 mol, 2.6 eq) for one hour. The temperature was kept below 5 ° C during the addition of nitrite, and then gradually heated to 20 ° C for 2 hours. The reaction mixture was adjusted to pH 14 with NaOH (aqueous), and extracted with MTBE. The organic extracts were washed with water, brine, dried over magnesium sulfate, filtered and concentrated under reduced pressure. The crude product (29 g of a red oil) 85 it was purified by flash chromatography (silica, 350 g) and eluted with 2-7% ethyl acetate-cyclohexane, which gave an orange oil (11.0 g, 48%). H NMR (DMSO- d 6 300 MHz) d 7.30 (1 H, s), 7.13 (1 H, s), 2.39 (3 H, s), 2.26 (3 H, s). 13 C NMR (DMSO- d 6, 75 MHz) d 159.4, 151.3, 140.9, 125.7, 124.0, 23.7, 20.3. ESI m / z 86/188 (M + H) +. Example 4 (b): 3- [2- (4, Bd.methyl-pyridin-2-yl) -v] nyl] -6-nitro-1 - (tetrahydro-pyran-2-yl) -1W -indazol A suspension of 2-bromo-4,6-dimethylpyridine (2.42 g, 3 mmol), 3-vinyl-6-nitro-1- (tetrahydro-pyran-2-yl) -1H-indazole (2.37 g) , 8.67 mmol), palladium acetate (0.145 g, 0.65 mmol), tri-ortho-tolylphosphine (0.791 g, 2.6 mmol), and diisopropylethylamine (2.4 mL, 13.8 mmol) in DMF. aqueous (85%, 34.5 ml) was degassed by bubbling with argon for 5 minutes, followed by sonication for 5 minutes before heating in a microwave oven (300 watts, 10% power) at 10 ° C for 40 minutes . After cooling, the mixture was added dropwise in cold water. The resulting yellow precipitate was collected by filtration. The solids were dissolved in ethyl acetate, dried (sodium sulfate), and concentrated under reduced pressure. The residue was purified on silica gel using a gradient of 0 to 20% ethyl acetate in a mixture of chloroform and hexanes (1: 1) as eluent. The products resulting from the chromatography were triturated with MTBE / hexanes to obtain a clean product in the form of a yellow solid. The mother liquor was repurified in a similar way in silica gel, followed by grinding to obtain more product 86 clean with a 68% yield. H NMR (CDCl 3): d 8.54 (1H, s), 8.15 (1H, d, J = 9.4 Hz), 8.08 (1H, dd, J = 9.04, 1, 9 Hz). ), 7.87 (1H, d, J = 16.6 Hz), 7.55 (H, d, J = 16.6 Hz), 7.14 (1H, s), 6.90 (1 H, s), 5.82 (1 H, dd, J = 9.0, 3.0 Hz), 4.08-4.01 (1H, m), 3.84-3.76 (1H, m), 2.56 (3H, s), 2.62-2.54 (1H, m), 2.34 (3H, s), 2.24-2.10 (2H, m), 1.88-1, 68 (3H, m). Example 5: 3- [2- (4,6-dimethy1-pyridin-2-yl) -vin1] -1- (tetrahydro-pyrn-2-yl) -1 H-indazole-6- ilamine A suspension of 3- [2- (4,6-dimethyl-pyridin-2-yl) -vinyl] -6-nitro-1- (tetrahydro-pyran-2-yl) -1H-indazole (4.22 g, 11.16 mmol), iron powder (2.71 g, 48.51 mmol) and saturated aqueous NH4Cl (25 mL) in 25 mL of ethanol was heated at 45 ° C for 18 hours. The reaction was cooled and filtered through filter paper washing with methanol. The solvents were removed under reduced pressure and the aqueous phase was extracted with ethyl acetate (2x). The combined organic phases were washed with brine, dried (MgSO4) and concentrated under reduced pressure to give 4.02 g (quantitative) of a rust-colored solid and used without further purification. 1 H NMR (DMSO- d 6) d 7.79 (1 H, s), 7.74 (1 H, d, J = 16.4 Hz), 7.35 (1 H, d, J = 16.4 Hz) , 7.29 (1H, s), 6.96 (H, s), 6.63 (2H, m), 5.57 (1H, dd, J = 2.4, 9.5 Hz), 5.44 (2H, broad s), 3.88 (1 H, m), 3.67 (1H, m), 2.45 (3H, s), 2.37 (1H, m), 2.29 (3H, s), 1.99 (2H, m), 87 1.73 (1 H, m), 1.57 (2H, m). Example 6: 2- [3- [2- (4,6-Dimethyl-pyridin-2-yl) -vinyl] -1- (tetrahydro-pyran-2-yl) -1H-indazole-6-methyl ester ilamino] -benzoic acid A stirred suspension of 3- [2- (4,6-dimethyl-pyridin-2-yl) -vinyl] -1- (tetrahydro-pyran-2-yl) -1 H -ndazol-6-ylamine ( 870 mg, 2.5 mmol), 2-bromo-benzoic acid methyl ester (0.44 ml, 3.12 mmol), R-BINAP (78 mg, 0.125 mmol), Pd2 (dba) 3 (29 mg, 0.03 mmol) and cesium carbonate (1.22 g, 3.75 mmol) in toluene (6 mL) was degassed and heated at 100 ° C for 18 hours. The reaction mixture was cooled, poured into saturated NaHCO3 and extracted with ethyl acetate (2x). The combined organic phases were washed with brine, dried (MgSC) and concentrated under reduced pressure. The residue was subjected to flash chromatography on silica gel eluting with a gradient of 5-10% ethyl acetate in CH 2 Cl 2 to give 964 mg (80%) of a yellow foam. 1 H NMR (DMSO- d 6) d 9.49 (1 H, s), 8.13 (1 H, d, J = 8.7 Hz), 7.94 (1 H, dd, J = 1.5, 8.0 Hz), 7.85 (1 H, d, J = 16.4 Hz), 7.58 (1 H, d, J = 1.5, Hz), 7.48 (1 H, d, J = 16.4 Hz), 7.47 (1 H, m), 7.37 (1 H, d, J = 7.7 Hz), 7.34 (1 H, s), 7.19 (1 H, dd, J = 1.7, 8.7 Hz), 6.99 (1H, s), 6.89 (1 H, t, J = 8.1 Hz), 5.83 (1 H, d , J = 7.2 Hz), 3.88 (3H, s), 3.75 (1H, m), 2.48 (3H, s), 2.41 (2H, m), 2.31 ( 3H, s), 2.02 (2H, m), 1.75 (1 H, m), 1.59 (2H, m). Anal. Caled, for 88 C 29 H 30 N 4 O 3 | 0.15 ethyl acetate: C, 71.71; H, 6.34; N, 11, 30 It was found: C, 71, 60; H, 6.14; N, 11, 37. Example 7: 2- [3- [2- (4) 6-Dimethyl-2-yl) -vinyl] -1- (tetrahydro-pyran-2-yl) -1H-indazol-6-ylamino acid ]-benzoic To a stirred solution of 2- [3- [2- (4,6-dimethyl-pyridin-2-yl) -vinyl] -1- (tetrahydro-pyran-2-yl) -1H-indazole methyl ester -6-ylamino] -benzoic acid (1.98 g, 4.11 mmol) in THF: eOH (12 mL, 3: 1) was added potassium hydroxide (1.15 g, 20.5 mmol) dissolved in water ( 3 mi). The reaction was heated to 70 ° C for 2 hours, cooled, concentrated under reduced pressure to about 5 ml and diluted with more water. The solution was neutralized with 2N HCl and the precipitate was collected by filtration and washed with water to give 2.00 g (quantitative) of a bright yellow solid. 1 H NMR (DMSO- d 6) or 13,12 (1 H, broad s), 9.82 (1 H, s), 8.13 (1 H, d, J = 8.7 Hz), 7.95 ( 1 H, dd, J = 1, 5, 8.0 Hz), 7.89 (1 H, d, J = 16.4 Hz), 7.60 (1 H, s), 7.50 (1 H, d, J = 16.4), 7.46 (1 H, d, J = 6.9), 7.37 (1 H, d, J = 7.7 Hz), 7.20 (1 H, d , J = 8.7 Hz), 7.06 (1 H, s), 6.86 (1 H, t, J = 6.9 Hz), 5.85 (H, d, J = 7.3 Hz ), 3.82 (2H, m), 2.50 (3H, s, obscured by the dmso signal), 2.48 (2H, m), 2.34 (3H, s), 2.03 (2H , m), 1, 76 (1 H, m), 1, 59 (2H, m). Anal. Caled, for C 28 H 28 N 4 O 3 | 0.5 KOH: C, 67.72; H, 5.79; N, 1, 28 It was found: C, 89 67.65; H, 5.88; N, 11, 07 Example 8: 2- p-Toluenesulfonate. { 3- [2- (4,6-d.methyl-pyridin-2-yl) -vinyl] -1 H -ndazol-6-ylamine} -benzoic A mixture of 2- [3- [2- (4,6-D-methyl-pyridin-2-yl) -vinyl] -1- (tetrahydropyran-2-yl) -1H-indazole-6 acid -amino] -benzoic acid (2 mmol) and p-toluene sulfonic acid (10 mmol) in aqueous methanol (90%, 20 mL) was stirred at 70 ° C for 18 hours. After cooling, the resulting thick yellow suspension was filtered, and the solids were washed with methanol to give 2- acid. { 3- [2- (4,6-Dimethyl-pyridin-2-yl) -vinyl] -1H-indazol-6-ylamino} -benzoic as the tosylate salt at an 85% yield as a pale yellow solid. H NMR (DMSO- d6) d 13.43 (1 H, s), 9.78 (1 H, s), 8.24-8.19 (2H, m), 8.09 (1 H, d, J = 9.04 Hz), 7.95 (1H, dd, J = 7.9, 1, 1 Hz), 7.62-7.55 (2H, m), 7.49-7.38 (5H , m), 7.20 (1H, dd, J = 9.0, 1.9 Hz), 7.09 (2H, d, J = 8.3 Hz), 6.86 (1H, dt, J = 7.9,, 1 Hz), 2.67 (3H, s), 2.54 (3H, s), 2.27 (3H, s). Example 9: N- [4- (ε-butyldιmethyl-silanyloxy) -but-2-ynyl] -2- [3- [2- (4,6-dimethyl-pyridin-2H) -vin L] -1- (Tetrahydro-iran-2-yl) -1H-indazol-6-Hamino] -benzamide 90 Prepared in a manner similar to that described for Example 33 (a) step (v), in U.S. patent application serial number 09 / 609,335, filed June 30, 2000, incorporated herein. by reference in its entirety for all purposes, except for the use of 4- (tert-butyl-dimethyl-silanyloxy) -but-2-iniamylamine and 2- [3- [2- (4,6-dimethyl) ^ iridin-2-H) -vinyl] -1- (tetrahydro-pyran-2-yl) -1 H -ndazole-6-benzoic acid. 1 H NMR (DMSO- d 6) d 9.56 (1 H, s), 9.01 (1 H, t, J = 5.7 Hz), 8.06 (1 H, d, J = 8.7 Hz ), 7.81 (1 H, d, J = 16.4 Hz), 7.66 (1 H, d, J = 7.5 Hz), 7.41 (4H, m), 7.32 (H , s), 7.09 (1 H, dd, J = 1, 8, 8.7 Hz), 6.98 (1 H, s), 6.89 (1 H, t, J = 8.0 Hz ), 5.79 (1 H, dd, J = 2.4, 9.2 Hz), 4.28 (2H, s), 4.09 (2H, m), 3.86 (1H, m), 3.72 (1H, m), 2.46 (3H, s), 2.42 (1H, m), 2.30 (3H, s), 2.08 (2H, m), 1.74 (1 H, m), 1.57 (2H, m), 0.80 (9H, s), 0.03 (6H, s). Anal. Caled, for C38H47N5O3YES · 0.7 H20: C, 68.89; H, 7.36; N, 10.57. It was found: C, 68.99; H, 7.36; N, 10.21. Example 10: 2 ^ 3 - [(E) -2- (4,6-dimethyl-iridin-2-yl) -vinyl] -1H-indazol-6-ylamino} -N- (4-hydroxy-but-2-ynyl) -benzamide 91 A stirred solution of N- [4- (fer-butyl-dimethyl-silane! Oxy!) -but-2-ynyl] -2- [3- [2- (4,6-dimethyl-pyridin-2-yl) -vinyl] -1- (tetrahydro-pyran-2-yl) -1 H -indazol-6-yl benzamide (737 mg, 1.13 mmol) and p-toluene sulfonic acid (8.2 ml, 12% in acetic acid) was heated at 70 ° C for 2 hours. The reaction was cooled, and carefully poured into saturated NaHCO 3 solution and extracted with ethyl acetate (2x). The combined organic phases were washed with brine (2x), dried (MgSO4) and concentrated under reduced pressure. The residue was subjected to flash chromatography on silica gel flowing with CH2Cl2: ethyl acetate: MeOH (1: 1: 0.1) to give 225 mg (44%) of a white solid. H NMR (DMSO- d6) d 12.91 (1 H, s), 9.84 (s, 1 H), 9.01 (1H, t, J = 5.3 Hz), 8.07 (1H, d, J = 8.7 Hz), 7.84 (H, d, J = 16.4 Hz), 7.70 (1 H, d, J = 7.2 Hz), 7.43 (3 H, m ), 7.31 (1 H, s), 7.26 (1 H, s), 7.02 (1 H, dd, J = 1, 6, 8.7 Hz), 6.97 (1 H, s), 6.89 (1 H, t, J = 6.7 Hz), 5.12 (1 H, t, J = 5.8 Hz), 4.10 (2 H, d, J = 5.3) Hz), 4.07 (2H, d, J = 5.8 Hz), 2.47 (3H, s), 2.31 (3H, s). Anal. Caled, for Car ^ sN ^ · 1, 1 H20: C, 68.80; H, 5.82; N, 14.86. It was found: C, 68.72; H, 5.81; N, 14.65. Example 11: 4- (ε-butyl-dimethyl-silanyloxy) -but-2-inylamine 92 To an ice-cooled and stirred solution of known 4- (fer-butyl-dimethylsilanyloxy) -but-2-yn-1-ol (3.14 g, 15.7 mmol) in THF (50 ml) was added DBU (2.6 mL, 17.4 mmol) and DPPA (3.8 mL, 17.6 mmol). The solution was warmed to room temperature and stirred under an inert atmosphere overnight. The reaction was poured into saturated NaHCO 3 and the phases were separated. The aqueous phase was reextracted with ethyl acetate (2x) and the combined organic phases were dried (Na2SO4), and concentrated in vacuo. Triphenylphosphine (4.61 g, 17.6 mmol) was added to this crude azide dissolved in THF (50 mL), followed by the addition of H20 (0.44 mL). The resulting solution was stirred overnight at room temperature, concentrated under reduced pressure, and the residue was suspended in a 1: 1 mixture of Et20 / petroleum ether. The solids were removed and the filtrate was concentrated and purified by flash chromatography on silica gel eluting with CH2Cl2 / MeOH (19: 1) to give an amber oil. 1 H NMR (CDCl 3): d 4,19 (2 H, t, J = 1, 9 Hz), 3.33 (2 H, t, J = 1, 9 Hz), 0.79 (9 H, s), 0, 00 (6H, s). Example 12: 2- [3- [2- (4,6-dimethyl-iridin-2-yl) -vinyl] -1- (tetrahydro-pyrn-2-yl) - 1H-indazol-6-ylamino] -N-prop-2-ynyl-benzamide Prepared in a manner similar to that described for example 6 above in this document, except for the use of 2- [3- [2- (4,6- 93 dimethyl-pyridn-2-yl) -v-n-1] -1- (tetrahydro-pyrn-2-yl) -1 H -indazol-6-ylamino] -benzoic acid and propargylamine. 1 H NMR (DMSO- d 6) d 9.87 (1 H, s), 9.04 (1 H, t, J = 5.8 Hz), 8.08 (1 H, d, J = 8.7 Hz ), 7.83 (1 H, d, J = 16.4 Hz), 7.69 (1 H, d, J = 7.5 Hz), 7.44 (4H, m), 7.34 (1 H, s), 7.12 (1 H, dd, J = 1, 7, 8.7 Hz), 6.99 (1 H, s), 6.91 (1 H, t, J = 5.8 Hz), 5.81 (1 H, dd, J = 2.4, 9.2 Hz), 4.07 (2H, dd, J = 2.5, 5.7 Hz), 3.88 (1 H , m), 3.74 (1 H, m), 3.12 (1 H, t, J = 2.5 Hz), 2.48 (3 H, s), 2.43 (1 H, s), 2.31 (3H, m), 2.01 (2H, m), 1.74 (1 H, m), 1.58 (2H, m). Anal. Caled, for C3iH3iN502 · 1, 1 H20 | 0.3 TBME: C, 70.73; H, 6.72; N, 12.69. It was found: C, 70.56; H, 6.45; N, 12.49. Example 13: N- (prop-2-yl) -2 ^ 3 - [(E) -2- (2,4-d.methyl-pyridin-2-yl) -vinyl] -1H-indazole- 6-ylamino} -benzamide Prepared in a manner similar to that described for example 7 above in this document, except for the use of A- (3-cyclopropyl-prop-2-ynyl) -2- [3- [2- (4,6-dimethyl) -pyridin-2-yl) -vinyl] -1- (tetrahydro-pyran-2-yl) -1H-indaylamino] -benzamide in place of N- [4- (fer-butyl-dimethyl-silanyloxy) - but-2-ynyl] -2- [3- [2- (4,6-dimethyl-pyridin-2-yl) -vinyl] -1- (tetrahydro-pyran-2-yl) -1H-indazole- 6-ilamin benzamide. 1 H NMR (DMSO- d 6) d 12.90 (1H, s), 9.78 (1H, s), 9.01 (1 H, t, J = 5.3 Hz), 8.06 (1 H, d, J = 8.3 Hz), 7.84 (1 H, d, J = 16.2 Hz), 7.68 (1 H, dd, J = 7.9, 1, 1 Hz), 7, 45-7.36 (3H, m), 7.30 (H, s), 7.25 (1 H, d, J = 1.5 Hz), 7.01 (1 H, dd, J = 8, 7, 1, 9 Hz), 6.96 (1 H, s), 6.88 (1 H, dt, J = 6.8, 1, 9 Hz), 4.04 (2H, dd, J = 94 S, 6, 2.6 Hz), 3.11 (1 H, t, J = 2.6 Hz), 2.46 (3 H, s), 2.29 (3 H, s). Example 14: 2- [3- [2- (4,6-D-methyl-pyridin-2-yl) -vin] -1- (tetrahydro-pyrn-2-yl) - 1 H -ndazole -6-ylamino] -N- (2-methyl-allyl) -benzamide Prepared in a manner similar to that described for example 6 above in this document, except for the use of 2- [3- [2- (4,6-dimethyl-iridin-2-yl) -vinyl] ] -1- (tetrahydro ^ and 2-methylallylamine, HNR (DMSO-d6) d 9.87 (1 H, s), 8.82 (1 H, t, J = 5.8 Hz), 8.07 ( 1 H, d, J = 8.7 Hz), 7.82 (1 H, d, J = 16.4 Hz), 7.74 (H, d, J = 7.3 Hz), 7.43 ( 4H, m), 7.33 (1H, s), 7.10 (1H, d, J = 8.7 Hz), 6.99 (1H, s), 6.92 (1H, t, J = 7.8 Hz), 5.80 (1 H, dd, J = 2.2, 9.2 Hz), 4.83 (2H, d, J = 11, 8 Hz), 3.83 (4H, m ), 2.47 (3H, s), 2.44 (1H, m), 2.31 (3H, s), 2.00 (2H, m), 1.75 (1H, m), 1 , 73 (3H, s), 1, 58 (2H, m) Anal Caled, for CaaHssNí. | 1, 09 H20: C, 71, 00; H, 6.92; N, 12.94. : C, 71, 40; H, 6.89; N, 12.54 Example 15: 2- [3- [2- (4,6-dimethyl-pyridin-2-yl) -vinyl] -1H-indazole -6-ylamino] -N- (2-methyl-allyl) -benzamide 95 Prepared in a manner similar to that described for example 7 above in this document, except for the use of A / - (2-methyl-allyl) -2- [3- [2- (4,6-dimethyl-pyridine- 2-yl) -vinyl] -1- (tetrahydro-pyran-2-yl) -1H-indazol-6-ylamino] -benzamide in place of N- [4 - (. Erc-butyl-dimethyl-silanyloxy) - but-2-ynyl] -2- [3- [2- (4,6-dimethyl-pyridin-2-yl) -vinyl] -1- (tetrahydro-pi an-2-yl) -1H-indazole-6 -amine benzamide. 1 H NMR (DMSO-ds) d 12.89 (1H, s), 9.75 (1 H, s), 8.79 (1H, t, J = 5.6 Hz), 8.05 (1H, s). , J = 8.7 Hz), 7.85 (1H, d, J = 16.2 Hz), 7.74 (1H, d, J = 7.9 Hz), 7.45-7.33 (4H , m), 7.23 (1H, d, J = 1.5 Hz), 7.00-6.97 (2H, m), 6.90 (1H, dt, J = 7.9, 1, 1 Hz), 4.81 (2H, d, J = 11, 3 Hz), 3.81 (2H, d, J = 5.6 Hz), 2.47 (3H, s), 2.30 (3H, s), 1.71 (3H, s). Alternative Synthesis Scheme PPI¾, HaO THF H2 Example 16 (a): Cyclopropyl-prop-2-in-1-ol HQ < To a round bottom flask containing 70 ml of anhydrous THF 96 Chilled in an ice bath at -10 ° C was added 65.6 ml of a 1.6M BuLi solution in hexanes (105 mmol). 5-Cioro-pent-1-ino (5.13 g, 50 mmol) was introduced slowly while maintaining the temperature at -10 to 0 ° C. The mixture was stirred at 0 ° C for 2 hours under argon. Paraformaldehyde (3 g, 100 mmol) was added in solid form. The mixture was slowly warmed to room temperature and stirred overnight under argon. The next day, water was added and approximately 50 ml of 1 N aqueous HCl was added. The mixture was extracted with ethyl acetate and the combined organic phases were washed with brine, dried over Na 2 SO 4, filtered and concentrated. The crude product was purified by a column eluting with 20% Et20 in hexanes to give 3 g of 3-cyclopropyl-prop-2-yn-1-ol as an oil (62% yield). 1 H NMR (CDCl 3): d 4.22 (dd, 2 H, J = 6.04, 2.01 Hz), 1.46 (t, 1 H, J = 6.04 Hz),, 26 (m, H ), 0.77 (m, 2H), 0.70 (m, 2H). Example 16 (b): 3-cyclopropyl-prop-2-inylazide 3-Cyclopropyl-prop-2-yn-1-ol (3.28 g, 34.1 mmol) was dissolved in 40 mL of toluene, DPPA (11.26 g, 40.9 mmol) was added, followed by DBU. (6.24 g, 40.9 mmol) while maintaining the temperature with a water bath. The mixture was stirred at room temperature for one hour and diluted with 100 ml of hexane and 15 ml of CH2Cl2. The mixture was washed with water four times and once with brine, dried over Na 2 SO 1, filtered and concentrated with a rotary evaporator with a cold water bath to remove most of the organic solvent, leaving something previously in this document, except for the use of 2- [3 - [(E) -2- (4,6-dimethyl-pyridin-2-yl) -vinyl] -1- (tetrahydro-pyran-) methyl ester. 2-yl) -1H-indazol-6-ylamino] -nicotinic acid instead of 2- [3- [2- (4,6-dimethyl-pyridin-2-yl) -vinyl] - methyl ester - 1- (tetrahydro-pyran-2-yl) -1 H -indazol-6-ylamino] -benzoic acid. H NMR (DMSO- d6) d 10.73 (1 H, s), 8.49 (1 H, d, J = 1, 9 Hz), 8.45 (1 H, s), 8.31 (1 H, dd, J = 7.7, 1.8 Hz), 8.16-7.97 (3H, m), 7.70 (1H, d, J = 16.4 Hz), 7.50 ( 1 H, d, J = 8.6 Hz), 7.37 (H, s), 6.96 (1 H, dd, J = 7.7, 4.8 Hz), 5.87 (H, d, J = 8.4 Hz), 3.95-3.90 (1 H, m), 3.79-3.70 (H, m), 2.63 (3H, s), 2.47 (3H, s), 2.07-1, 99 (2H, m), 1, 81-1, 62 (3H, m). Example 23: 2-. { 3 - [(E) -2- (4,6-dimethyl-pyridin-2-yl) -vin] -1 H -indazol-6-ylamino} -N- (4-hydroxy-but-2-ynyl) -nicotinamide A crude mixture of N- (4-hydroxy-but-2-ynI) -2- [3- [2- (4,6-dimethyl-pyridin-2-yl) -vinyl] -1 - (tetrahydro-pyran- 2-yl) -1 H -indazol-6-ylamino] -nicotinamide and N- [4-. { tert-butyl-d-methyl-silaloyloxy) -but-2-ynyl] -2- [3- [2- (4,6-dimethyl-pyridin-2-yl) -vinyl] -1- (tetrahydro- pyran-2-yl) -1 / - -indazol-6-ylamino] -nicotinamide was prepared from 2- [3 - [(E) -2- (4,6-dimethyl-1-pindin-2-yl)] -vinyl] -1- (tetrahydro-pyran-2-yl) -1H-indazol-6-ylamino] -nicotinic acid and 4- (ert-butyl-dimethyl-silanyloxy) -but-2-inylamine in a manner similar to that it is described for example 6 earlier in this document, and subsequently it becomes 2-. { 3 - [(E) -2- (4,6-dimethyl-pyridin-2-yl) -vinyl] -1 H -indazol-6-ylamino} -N- (4-hydroxy-but-2-ynyl) -nicotinamide in a manner similar to that described for Example 7 except in the use of a mixture of N- (4-hydroxy-but-2-ynyl) -2- [3- [2- (4,6-dimethyl-pyridin-2-yl) -vinyl] -1 - (tetrahydro-pyran- 2-yl) -1 H -ndazol-6-ylamino] -nicotinamide and N- [4- (ferc-butyl-dimethyl-s-ananyloxy) -but-2-ynyl] -2- [3- [2- (4 , 6-dimetH-pyridin-2-yl) -vin pyran-2-yl) -1 W-indazol-6-ylamino] -nicotamide instead of A / - [4- (fer-butyl-dimethyl-silanyloxy) ) -but-2-ynyl] -2- [3- [2- (4,6-dimethyl-pyrid-pyran-2-yl) -1W-indazol-6-ylamino] -benzamide. 1 H NMR (DMSO- d 6) d 12.99 (1 H, s), 11, 21 (1 H, s), 9.26 (1 H, t, J = 5.3 Hz), 8.50 (1 H, d, J = 1, 9 Hz), 8.41 (1 H, dd, J = 4.9, 1, 9 Hz), 8.16 (1 H, dd, J = 8.3, 1, 9 Hz), 8.04 (1 H, d, J = 9.0 Hz), 7.85 (1 H, d, J = 16.6 Hz), 7.42 (1 H, d, J = 16 , 6 Hz), 7.31 (1 H, s), 7.06 (1 H, dd, J = 8.7, 1.5 Hz), 6.96 (1 H, s), 6.93 ( 1 H, dd, J = 7.5, 4.9 Hz), 5.14 (1 H, t, J = 5.6 Hz), 4.16 (2 H, d, J = 5.6 Hz), 4.08 (2H, d, J = 7.2 Hz), 2.46 (3H, s), 2.30 (3H, s). Example 24: 2- [3- [2- (4,6-D-methyl-pyridin-2-yl) -vinyl] -1H-indazol-6-ylamino] -nicotinic acid p-toluenesulfonate Prepared in a manner similar to that described for example 5 except for the use of 2- [3 - [(E) -2- (4,6-dylmethyl-pyridin-2-yl) - vinyl] -1- (tetrahydro-pyran-2-yl) -1H-indazol-6-ylamino] -nicotinic acid instead of 2- [3- [2- (4,6-dimethyl- pyridin-2-yl) -vinyl] -1- (tetrahydro-pyran-2-yl) -1H-indazol-6-ylamino] -benzoic acid 1 H NMR (DMSO-d6) d 13.49 (1H, s), , 80 (1H, s), 8.63 (1H, d, J = 1.5 Hz), 8.49 (1H, dd, J = 4.8, 1.9 Hz), 8.31 (1H, dd, J = 7.7, 1.9 Hz), 8.24-8.19 (2H, m), 8.06 (1H, d, J = 8.8 Hz), 7.60-7.55 (2H, m), 7.46 (2H, d, J = 8.1 Hz), 7.22 (1H, dd, J = 8.8, 1.7 Hz), 7.09 (2H, d, J = 7.9 Hz), 6.95 (1H, dd, J = 7.7, 4.7 Hz), 2.66 (3H, s), 2.54 (3H, s), 2.27 ( 3H, s). Example 25: / V- (3-cyclopropyl-prop-2-ynyl) -2- [3 - [(e) -2- (4,6-dimethyl-pyridin-2-yl) -vinyl] -1A / - indazol-6-ylamino] -nicotinamide Prepared in a manner similar to that described for example 6 above in this document, except for the use of 2- p-toluenesulfonate. { 3- [2- (4,6-dimethyl-pyridin-2-yl) -vinyl] -1 / - / - indazol-6-ylamino} -nicotinic and 3-cyclopropyl-prop-2-inlamin. 1 H NMR (DMSO- d 6) d 13.01 (1H, s), 11.20 (1H, s), 9.19 (1H, ta), 8.51 (1H, s), 8.40 (1H, d, J = 4.9 Hz), 8.15 (1H, d, J = 7.5 Hz), 8.05 (1H, d, J = 8.7 Hz), 7.83 (1H, d, J = 16.4 Hz), 7.42 (1H, d, J = 16.4 Hz), 7.31 (1H, s), 7.05 (1H, d, J = 8.3 Hz), 6 , 96 (1H, s), 6.92 (1H, dd, J = 7.5, 4.9 Hz), 4.06 (2H, d, J = 4.14 Hz), 2.46 (3H, s), 2.29 (3H, s), 1.33-1.28 (1H, m), 0.77-0.72 (2H, m), 0.60-0.55 (2H, m) . Example 26: 4-methyl-2-vinyl-pyridine A yellow mixture of 2-bromo-4-methyl-pyridine (Aldrich, 5.2 g, 30.5 mmol, 1.0 eq), 2,6-di-tert-butyl-4-methyl-phenol (Aldrich, 67 mg, 0.3 mmol., 1 mol%), tributyl vinyl-stannan (Aldrich, 26.8 ml, 91.5 mmol, 3.0 eq) and tetrakis (triphenylphosphine) palladium (0) (Strem, 1.8 g, 1.5 mmol, 5 mol%) in toluene (100 ml) was degassed and purged with argon. An amber solution was obtained after the mixture was heated to 100 ° C. The reaction mixture was deactivated after 18 hours by the addition of 1.0 M HCl. The acid extract was washed with ether, adjusted to pH 9 with solid sodium bicarbonate, and extracted with ethyl acetate. The organic extracts were washed with brine, dried over magnesium sulfate, filtered and concentrated under reduced pressure. The crude product (3.7 g of a brown oil) was purified by flash chromatography (silica) and eluted with 0.5% ethyl acetate-dichloromethane, which gave a clear oil (1.9 g, 53%). . H NMR (DMSO-d6, 300 MHz) d 8.39 (1 H, d, J = 4.9 Hz), 7.33 (1 H, s), 7.10 (1 H, dd, J = 5 , 0, 0.8 Hz), 6.77 (1 H, dd, J = 17.5, 10.8 Hz), 6.20 (1 H, dd, J = 17.5, 1.7 Hz) , 5.44 (1 H, dd, J = 10.8, 1.8 Hz), 2.31 (3H, s). ESIMS m / z 120 (M + H) +. Example 27: 3- [2- (4-methyl-pyridin-2-M) -vinyl] -6-nitro-1 - (tetrahydro-pyran-2-yl) -1H-indazole 101 Prepared in a manner similar to that described for example 6 above in this document, except for the use of 2- [3- [2- (4-p-toluenesulfonate]], 6-dimethyl-pyridin-2-yl) -vinyl] -1H-indazoI-6-ylamino] -benzoic acid and 4-amino-but-2-ynyl ester of acetic acid. 1H NMR (CD3CN): or 11.00 (1 H, sa), 9.59 (1H, s), 7.99 (1 H, d, J = 8.6 Hz), 7.86 (1 H, d, J = 16.4 Hz), 7.58 (1 H, d, J = 7.8 Hz), 7.49-7.37 (4H, m), 7.32 (1 H, s), 7.21 (1 H, s), 7.06 (1 H, dd, J = 8.8, 1, 8 Hz), 6.96 (1 H, s), 6.90 (1 H, t, J = 7.8 Hz), 4.63 (2H, s), 4.16 (2H, d, J = 5.6 Hz), 2.49 (3H, s), 2.32 (3H, s) 2.01 (3H, s). Example 21: 2- [3 - [(E) -2- (4,6-dimethyl-pyridin-2-yl) -vinyl] -1 - (tetrahydro-pyran-2-yl) -1 H methyl ester -indazol-6-ylamino-nicotinic Prepared in a manner similar to that described for Example 3 above, except for the use of 2-bromo-nicotinic acid methyl ester in place of the 2-bromo-benzoic acid methyl ester. H NMR (DMSO- d6) d 10.36 (1H, s), 8.50 (1 H, dd, J = 4.7, 1, 9 Hz), 8.36 (1H, d, J = 1, 4 Hz), 8.30 (1 H, dd, J = 7.8, 2.0 Hz), 8.08 (1 H, d, J = 8.8 Hz), 7.83 (1 H, d, J = 16.4 Hz), 7.48 (1H, d, J = 7.5), 7.44 (1H, s), 7.33 (1H, s), 6.98-6.93 (2H , m), 5.80 (1 H, d, J = 7.0 Hz), 2.93 (3 H, s), 3.93-3.90 (1 H, m), 3.80-3, 75 (1H, m), 2.46 (3H, s), 2.30 (3H, s), 2.10-1, 97 (2H, m), 1, 89-1.60 (3H, m) . Example 22: 2- [3 - [(E) -2- (4J6-dimethyl-pyridin-2-yl) -vinyl] -1- (tetrahydro-) acid 102 piran-2-yl) -1H-indazol-6-ylamino] -nicotinic acid Prepared in a manner similar to that described for example 4 above in this document, except for the use of 2- [3 - [(E) -2- (4,6-dimethyl-pyridin-2-yl) methyl ester. ) -vinyl] -1- (tetrahydro-pyran-2-yl) -1 / 7-ynylamino] -nicotinic acid instead of 2- [3- [2- (4,6-dimethyl-pyridine-) methyl ester 2-yl) -vinyl] -1- (tetrahydro-pyran-2-yl) -1 H -indazol-6-ylamino] -benzoic acid. H NMR (DMSO- d6) d 10.73 (1H, s), 8.49 (1H, d, J = 1, 9 Hz), 8.45 (1 H, s), 8.31 (1H, dd) , J = 7.7, 1.8 Hz), 8.16-7.97 (3H, m), 7.70 (1H, d, J = 16.4 Hz), 7.50 (1H, d , J = 8.6 Hz), 7.37 (1 H, s), 6.96 (1 H, dd, J = 7.7, 4.8 Hz), 5.87 (1 H, d, J = 8 , 4 Hz), 3.95-3.90 (1 H, m), 3.79-3.70 (1H, m), 2.63 (3H, s), 2.47 (3H, s), 2.07-1, 99 (2H, m), 1, 81-1, 62 (3H, m). Example 23: 2-. { 3 - [(E) -2- (4,6-d.methyl-pyridin-2-yl) -vinyl] -1H-indazol-6-ylamino} -N- (4-hydroxy-but-2-ynyl) -nicotinamide 103 A crude mixture of N- (4-hydroxy-but-2-ynyl) -2- [3- [2- (4,6-dimethyl-pyridin-2-yl) -vinyl] -1 - (tetrahydro) -pran-2-yl) -1 / -ndazol-6-ylamino] -nicotamide and N- [4- (tert-butyl-dimethyl-silanyloxy) -but-2-yl ] -2- [3- [2- (4,6-dimethyl-pyridn-2-yl) -v] nyl] -1- (tetrahydro-pyran-2-yl) -1H- indazol-6-ylamino] -n-tacinamide was prepared from 2- [3 - [(E) -2- (4,6-dimethyl-pyridin-2-yl) -vinyl] -1- (tetrahydro- pyran-2-yl) -1 H -indazol-6-ylamino] -nicotinic acid and 4- (ert-butyl-dimethyl-silanyloxy) -but-2-inylamine in a manner similar to that described for Example 6 above in this document, and subsequently becomes 2-. { 3 - [(E) -2- (4,6-dimethyl-pyridin-2-yl) -vinyl] -1 H -indazol-6-ylamino} -N- (4-hydroxy-but-2-ynyl) -n-cotinamide in a manner similar to that described for example 7 except for the use of a mixture of N- (4-hydroxy-but-2-ynyl) ) -2- [3- [2- (4,6-Dimethyl-pyridin-2-yl) -vinyl] -1- (tetrahydro-pyran-2-yl) -1 H -indazol-6-ylamino] -nicotinamide and / V- [4- (1-tert-butyl-d-methyl-2-ylanyloxy) -but-2-ynyl] -2- [3- [2- (4,6-dimethyl-pyridin-2-yl) - vinyl] -1- (tetrahydro-pyran-2-yl) -1W-indazol-6-ylamino] -n-phenylamide in place of A / - [4- (tert-butyl-dimethyl-silanyloxy) -but-2 -inyl] -2- [3- [2- (4,6-dimethyl-pyridin-^ indazol-6-ylamino] -benzamide, H NMR (DMSO-d6) 6 12.99 (1 H, s) , 11, 21 (1 H, s), 9.26 (1 H, t, J = 5.3 Hz), 8.50 (1 H, d, J = 1, 9 Hz), 8.41 (1 H, dd, J = 4.9, 1, 9 Hz), 8.16 (1 H, dd, J = 8.3, 1, 9 Hz), 8.04 (1 H, d, J = 9, 0 Hz), 7.85 (1 H, d, J = 16.6 Hz), 7.42 (1 H, d, J = 16.6 Hz), 7.31 (1 H, s), 7, 06 (1 H, dd, J = 8.7, 1, 5 Hz), 6.96 (1 H, s), 6.93 (1 H, dd, J = 7.5, 4.9 Hz), 5.14 (1 H, t, J = 5.6 Hz), 4.16 (2H, d, J = 5.6 Hz), 4.08 (2H, d, J = 7.2 Hz), 2 46 (3H, s), 2.30 (3 H, s) Example 24: 2- [3- [2- (4,6-dimethyl-pyridin-2-yl) -vinyl] -1W-indazol-6-ylamino] -nicotinic acid p-toluene sulfonate 104 Prepared in a manner similar to that described for Example 5 except for the use of 2- [3 - [(E) -2- (4,6-dimethyl-pyridin-2-yl) -vinyl] -1- acid (tetrahydro-pyrn-2-yl) -1H-indazol-6-ylamino] -nicotinic acid instead of 2- [3- [2- (4,6-dimethyl-pyridin-2-yl) -vinyl] -1- (Tetrahydro-pyran-2-yl) -1H-indazol-6-ylamino] -benzoic acid. 1 H NMR (DMSO- d 6) 13.49 (1 H, s), 10.80 (1 H, s), 8.63 (1 H, d, J = 1.5 Hz), 8.49 (H) , dd, J = 4.8, 1.9 Hz), 8.31 (1H, dd, J = 7.7, 1, 9 Hz), 8.24-8.19 (2H, m), 8, 06 (1H, d, J = 8.8 Hz), 7.60-7.55 (2H, m), 7.46 (2H, d, J = 8.1 Hz), 7.22 (1H, dd) , J = 8.8, 1.7 Hz), 7.09 (2H, d, J = 7.9 Hz), 6.95 (1 H, dd, J = 7.7, 4.7 Hz), 2.66 (3H, s), 2.54 (3H, s), 2.27 (3H, s). Example 25: W- (3-cyclopropyl-prop-2-ynyl) -2- [3 - [(e) -2- (4,6-dimethyl-pyridin-2-yl) -vinyl] -1H- indazol-6-ylammon] -nlcotinamide 105 Prepared in a manner similar to that described for example 6 above in this document, except for the use of 2- p-toluenesulfonate. { 3- [2- (4,6-dimethyl-pyridin-2-yl) -vinyl] -1H-indazol-6-ylamino} -nicotinic and 3-cyclopropyl-prop-2-inylamine. 1 H NMR (DMSO- d 6) d 13.01 (1 H, s), 11.20 (1 H, s), 9.19 (H, ta), 8.51 (1 H, s), 8.40 ( 1H, d, J = 4.9 Hz), 8.15 (1H, d, J = 7.5 Hz), 8.05 (1H, d, J = 8.7 Hz), 7.83 (1H , d, J = 16.4 Hz), 7.42 (1H, d, J = 16.4 Hz), 7.31 (1H, s), 7.05 (1H, d, J = 8.3 Hz ), 6.96 (1 H, s), 6.92 (1 H, dd, J = 7.5, 4.9 Hz), 4.06 (2H, d, J = 4.14 Hz), 2 , 46 (3H, s), 2.29 (3H, s), 1, 33-1, 28 (1H, m), 0.77-0.72 (2H, m), 0.60-0.55 (2H, m). Example 26: 4-methyl-2-vinyl-pyridine A yellow mixture of 2-bromo-4-methyl-pyridine (Aldrich, 5.2 g, 30.5 mmol, 1.0 eq), 2,6-di-tert-butyl-4-methyl-phenol (Aldrich, 67 mg, 0.3 mmol., 1 mol%), tributyl vinyl-stannan (Aldrich, 26.8 ml, 91.5 mmol, 3.0 eq) and tetrakis (triphenylphosphine) palladium (0) (Strem, 1.8 g, 1.5 mmol, 5 mol%) in toluene (100 ml) was degassed and purged with argon. An amber solution was obtained after the mixture was heated to 100 ° C. The reaction mixture was deactivated after 18 hours by the addition of 1.0 M HCl. The acid extract was washed with ether, adjusted to pH 9 with solid sodium bicarbonate, and extracted with ethyl acetate. The organic extracts were washed with brine, dried over magnesium sulfate, filtered and concentrated 106 under reduced pressure. The crude product (3.7 g of a brown oil) was purified by flash chromatography (silica) and eluted with 0.5% ethyl acetate-dichloromethane, which gave a clear oil (1.9 g, 53%). . H NMR (DMSO-d6, 300 MHz) 6 8.39 (1 H, d, J = 4.9 Hz), 7.33 (H, s), 7.10 (1 H, dd, J = 5, 0, 0.8 Hz), 6.77 (1 H, dd, J = 17.5, 10.8 Hz), 6.20 (1H, dd, J = 17.5, 1.7 Hz), 5 , 44 (1 H, dd, J = 10.8, 1, 8 Hz), 2.31 (3H, s). ESIMS m / z 120 (M + H) +. Example 27: 3- [2- (4-methyl-pyridin-2-yl) -vin] 1 -6-nitro-1 - (tetrahydro-pyran-2-yl) -1 H-indazole A suspension of 4-methyl-2-vinyl-pyridine (example 23) (1.9 g, 15.97 mmol), 6-Nitro-1- (tetrahydro-pyran-2-yl) -3-vinyl- H-indazole (4.96 g, 13.3 mmol), Pd (OAc) 2 (149 mg, 0.66 mmol), P (o-tolyl) 3, and DIEA (3.5 mL, 19.96 mmol ) in degassed DMF (50 ml) was heated under argon at 100 ° C for 18 hours. The reaction mixture was cooled and the solids were removed by filtration by washing with ethyl acetate. The filtrate was diluted with ethyl acetate and washed with brine (2x), dried (MgSO 4) and concentrated under reduced pressure. The residue was chromatographed on silica gel flowing with hexanes: ethyl acetate (3: 1) to give 3.40 g (70%) of a bright yellow solid. H NMR (CDCl 3) d 8.56 (1 H, s), 8.50 (1 H, d, J = 5.0 Hz), 8.11 (2H, m), 7.89 (1 H, d , J = 16.3 Hz), 7.61 (1 H, s), 7.03 (1H, d, J = 4.3 Hz), 5.83 (H, dd, J = 2.6, 9 , 0 Hz), 4.06 (1 H, m), 3.82 (1 H, m), 2.58 (1 H, m), 2.39 (3 H, s), 2.18 (2 H, 107 m), 1, 78 (3H, m). Anal. Caled, for C2oH2oN403: C, 65.92; H, 5.53; N, 15.38. It was found: C, 65.80; H, 5.52; N, 15.15. Example 28: 3- [2- (4-Methy1-pyridin-2-yl) -vinyl] -1- (tetrahydro-pyran-2-yl) -1 H -indazol-6-ylamine Prepared in a manner similar to that described for example 2 above in this document, except for the use of [2- (4-methyl-pyridin-2-yl) -vin] 1 -6-nitro-1- (tetrahydro-pyran-2-yl) -1 H-indazole (example 24) in place of 3- [2- (4,6-dimethyl-pyridn-2-yl) -vin] -6-nitro-1- (tetrahydro-pyran-2-yl) -1 H-indazole. 1 H NMR (DMSO-de) 6 8.43 (1H, d, J = 4.8 Hz), 7.79-7.73 (2H, m), 7.50 (1 H, s), 7.39 (1 H, d, J = 16.4 Hz), 7.09 (1 H, d, J = 4.8 Hz), 6.64-6.62 (2H, m), 5.57 (1 H , dd, J = 9.8, 2.5 Hz), 5.48 (2H, sa), 3.92-3.85 (1 H, m), 3.72-3.64 (1 H, m ), 2.43-2.34 (1 H, m), 2.33 (3 H, s), 2.07-2.00 (1 H, m), 1, 96-1, 90 (1 H, m), 1, 79-1, 66 (1 H, m), 1, 60-1, 53 (2H, m). Example 29: 2- [3- [2- (4-Methyl-pyridin-2-yl) -vinyl] -1- (tetrahydro-pyran-2-yl) -1H-indazole-6-methyl ester ilamino] -benzoic acid 108 Prepared in a manner similar to that described for Example 3 except for the use of 3- [2- (4-methyl-pyridin-2-yl) -vinyl] -1- (tetrahydro-pyran-2-yl) -1 H-indazol-6-ylamine in place of 3- [2- (4,6-dimethyl-pyridin-2-yl) -vinyl] -1 - (tetrahydro-pyran-2-yl) -1 H-indazole- 6-laminate. H NMR (DMSO- d6) d 9.48 (1H, s), 8.45 (1H, d, J = 4.9 Hz), 8.13 (1H, d, J = 8.7 Hz), 7 , 93 (1H, dd, J = 8.3, 1.9 Hz), 7.86 (1H, d, J = 16.2 Hz), 7.58 (1 H, d, J = 1, 9 Hz ), 7.54-7.44 (3H, m), 7.36 (1H, d, J = 7.5 Hz), 7.18 (1H, dd, J = 8.7, 1, 9 Hz) , 7.11 (1 H, d, J = 4.9 Hz), 6.87 (1 H, t, J = 8.3 Hz), 5.83 (1 H, dd, J = 9.4, 2 , 3 Hz), 3.87 (3H, 1 H), 3.93-3.84 (1 H, m), 3.77-3.69 (1H, m), 2.46-2.37 ( 1H, m), 2.34 (3H, s), 2.10-1, 94 (2H, m), 1.81-1, 53 (3H, m). Example 30: 2- [3- [2- (4-Methyl-pyridin-2-yl) -vinyl] -1- (tetrahydro-pyran-2-yl) -1H-indazol-6-ylamino] - benzoic Prepared in a manner similar to that described for example 4 above in this document, except for the use of 2- [3- [2- (4-methyl-pyridin-2-yl) -vinyl] -1 methyl ester. - (Tetrahydro-pyran-2-yl) -1H-indazol-6-ylamino] -benzoic acid in place of 2- [3- [2- (4,6-dimethyl-pyridin-2-yl) methyl ester ) -vinyl] -1- (tetrahydro-pyran-2-yl) -1 H -indazol-6-ylamino] -benzoic acid (example 3). 1 H NMR (DMSO- d 6) d 13.17 (1 H, broad s), 9.83 (1 H, s), 8.51 (1 H, d, J = 5.2 Hz), 109 8.14 (1H, d, J = 8.7 Hz), 7.95 (1H, d, J = 16.4 Hz), 7.94 (1H, dd, J = 1.5, 8.0 Hz) ), 7.73 (H, s), 7.60 (1H, d, J = 1.5 Hz), 7.59 (1H, s), 7.54 (H, s), 7.46 (1H , m), 7.37 (H, d, J = 7.6 Hz), 7.23 (2H, m), 6.86 (1H, t, J = 6.9 Hz), 5.87 (1H , d, J = 7.6 Hz), 3.90 (1H, m), 3.76 (1H, m), 2.45 (1H, m), 2.41 (3H, s), 2.03 (2H, m), 1.77 (1H, m), 1.59 (2H, m). Example 31: 2. [3- [2. (4-Methyl-pyridin-2-ll) -vinyl] -1- (tetrahydro-pyran-2-yl) -1H-indazol-6-ylamino] -N-prop -2-inyl-benzamide Prepared in a manner similar to that described for example 6 above in this document, except for the use of propargylamine and 2- [3- [2- (4-methyl-pyridin-2-yl) -v] nyl] - 1- (Tetrahydro-pyran-2-yl) -1H-indazol-6-ylamino] -benzoic acid.1H NMR (DMSO- d6) d 9.87 (1H, s), 9.03 (1H, t, J = 5.5 Hz), 8.46 (H, d, J = 4.9 Hz), 8.08 (1H, d, J = 8.7 Hz), 7.86 (1H, d, J = 16, 4 Hz), 7.69 (1H, d, J = 7.3 Hz), 7.53 (1H, s), 7.44 (4H, m), 7.13 (2H, m), 6.91 (1H, t, J = 7.9 Hz), 5.81 (H, dd, J = 2.2, 9.6 Hz), 4.07 (2H, dd, J = 2.5, 5.5 Hz), 3.89 (1H, m), 3.75 (1H, m), 3.12 (1H, t, J = 2.5 Hz), 2.42 (H, m), 2.36 ( 3H, s), 2.00 (2H, m), 1.75 (1H, m), 1.58 (2H, m). Anal. Caled, for C30H29N5O2 | 0.25 TBME: C, 73.07; H, 6.28; N, 13.64. It was found: C, 72.95; H, 6.30; N, 13.64. Example 32: 2-. { 3 - [(E) -2- (4-methyl-pyridin-2-yl) -v] nyl] -1H-indazol-6-ylamino} -N- 110 prop-2-ini! -benzamide Prepared in a manner similar to that described for example 7 above in this document, except for the use of 2- [3- [2- (4-methyl-pyridin-2-yl) -vinyl] -1- (tetrahydro- pyran-2-yl) -1 H -indazol-6-ylamino] -N-prop-2-ynyl-benzamide in place of N- [4- (e-butyl-dimethyl-silanyloxy) -but-2-ynyl] -2- [3- [2- (4,6-dimethyl-pyridin-2-yl) -v] nyl] -1- (tetrahydro-pyran-2-yl) -1 H-indazole-6- Lamino] -benzamide. 1 H NMR (DMSO- d 6) d 12.93 (1 H, s), 9.79 (1 H, s), 9.02 (1 H, t, J = 5.4 Hz), 8.45 (1 H, d, J = 4.9 Hz), 8.08 (1 H, d, J = 8.7 Hz), 7.88 (1 H, d, J = 16.4 Hz), 7.69 (H , d, J = 7.7 Hz), 7.45 (4H, m), 7.27 (1 H, s), 7.10 (1 H, d, J = 4.9 Hz), 7.03 (1 H, d, J = 8.8 Hz), 6.90 (1 H, t, J = 7.9 Hz), 4.06 (2 H, dd, J = 2.4, 5.4 Hz) , 3.12 (1 H, t, J = 2.4 Hz), 2.35 (3H, s). Anal. Caled, for C-25H21N5O · 0.35 CH2Cl2: C, 69.64; H, 5.00; N, 16.02. It was found: C, 69.65; H, 5.15; N, 15.80. Example 33: N- (2-Methyl-allyl) -2- [3- [2- (4-methyl-pyridin-2-yl) -vinyl] -1 - (tetrahydro-pyran-2-yl) - 1 H-indazol-6-ylamino] -benzamide 111 Prepared in a manner similar to that described for example 6 above in this document, except for the use of 2-methyl-allylamine and 2- [3- [2- (4-methyl-pyridin-2-yl) - vinyl] -1- (tetrahydro-pyran-2-yl) -1 H -indazol-6-ylamino] -benzoic acid. H NMR (DMSO- d6) d 9.86 (1 H, s), 8.81 (1 H, t, J = 5.5 Hz), 8.46 (1 H, d, J = 4.9 Hz ), 8.07 (1 H, d, J = 8.9 Hz), 7.86 (1 H, d, J = 16.4 Hz), 7.75 (1 H, d, J = 7.7 Hz ), 7.54 (1 H, s), 7.50 (1H, d, J = 16.4 Hz), 7.43 (3H, m), 7.11 (2H, m), 6.92 ( 1 H, t, J = 8.1 Hz), 5.81 (1H, dd, J = 2.5, 9.8 Hz), 4.83 (2H, d, J = 11, 5 Hz), 3 , 81 (4H, m), 2.41 (1 H, m), 2.35 (3H, s), 2.00 (2H, m), 1.76 (1 H, m), 1.73 ( 3H, s), 1.58 (2H, m). Anal. Caled, for C31H33N5O2 | 0.80 TBME: C, 72.71; H, 7.43; N, 12.11. It was found: C, 72.43; H, 7.57; N, 12.02. Example 34: N- (2-methylal) -2-. { [(E) -2- (4-methyl-pyridin-2-yl) -vinyl] -1 H -ndazol-6-ylamino} -benzamide Prepared in a manner similar to that described for example 7, except that N- (2-methyl-allyl) -2- [3- [2- (4-methyl-pyridin-2-yl) -vinyl was used] -1- (Tetrahydro-pyran-2-yl) -1H-indazol-6-amyl] -benzamide in place of N- [4- (tert-butyl-dimethyl-silanyloxy) -but-2-ynyl ] -2- [3- [2- (4,6-dimethyl-pyridin-2-yl) -vinyl] -1- (tetrahydro-pi 1 H -indazol-6-ylammon] -benzamide. 1H NMR ( DMSO-efe) d 12.90 (1H, s), 9.76 112 (1 H, s), 8.80 (1 H, t, J = 5.5 Hz), 8.45 (1 H, d, J = 5.1 Hz), 8.07 (1 H, d, J = 8.9 Hz), 7.88 (1 H, d, J = 16.4 Hz), 7.75 (1 H, d, J = 7.9 Hz), 7.51 (1 H, s ), 7.48 (1 H, d, J = 16.4 Hz), 7.43 (2 H, m), 7.24 (1 H, s), 7.10 (1 H, d, J = 4, 9 Hz), 7.00 (1 H, dd, J =, 9, 8.9 Hz), 6.91 (1 H, t, J = 8.1 Hz), 4.82 (2H, d, J = 1, 3 Hz), 3.83 (2H, d, J = 5.8 Hz), 2.35 (3H, s), 1.73 (3H, s). Anal. Caled, for C26H25N5O · 0.20 H20: C, 73.11; H, 5.99; N, 16.40. It was found: C, 73.13; H, 6.03; N, 16.13. Example 35: W- (3-cyclopropyl ^ rop-2-ynyl) -2- [3- [2- (4-methyl-pyridin-2-yl) -vinyl] -1 - (tetrahydro-pyran-2-yl) ) -1H-indazol-6-ylamino] -benzamide Prepared in a manner similar to that described for example 6 above in this document, except for the use of 2- [3- [2- (4-methyl-pyridin-2-yl) -vinyl] -1- (tetrahydro) acid -piran-2-yl) -1 H -indazol-6-ylamino] -benzoic acid and 3-cyclopropyl-prop-2-inylamine. 1H NR (DMSO- d6) d 9.88 (1 H, sa), 8.93 (1 H, ta), 8.46 (1 H, d, J = 4.9 Hz), 8.08 (1H , d, J = 8.7 Hz), 7.85 (1 H, d, J = 16.4 Hz), 7.69 (1 H, d, J = 7.6 Hz), 7.54-7 , 40 (5H, m), 7.14-7.11 (2H, m), 6.90 (1 H, t, J = 6.1 Hz), 5.81 (1 H, d, J = 7 , 5, Hz), 4.02 (2H, d, J = 3.6 Hz), 3.95-3.85 (1 H, m), 3.79-3.72 (1 H, m), 2.49-2.35 (1 H, m), 2.35 (3H, s), 2.15-2.01 (2H, m), 1, 87-1, 55 (3H, m), 1 , 30-1, 25 (1 H, m), 0.77-0.70 (2H, m), 0.59-0.54 (2H, m). 113 Example 36: N- (3-cycloprop-2-ynyl) -2-. { 3 - [(E) -2- (4-methy1-pyridin-2-yl) -vinyl] -1 H -indazol-6-ylamino} -benzamide Prepared in a manner similar to that described for example 7 above in this document, except for the use of N- (3-cycloprop-2-ynyl) -2- [3 - [(E) -2- (4-methyl) -pyridin-2-yl) -vinyl] -1 ^ benzamide in place of N- [4- (tert-butyl-d-methyl-silaloyloxy) -but-2-yn] - 2- [3- [2- (4,6-DimetH-pyridin-2-yl) -vinyl] -1- (tetrahydro-pyran-2-yl) -1H-indazol-6-Hamino] -benzamide. 1 H NMR (DMSO- d 6) d 12.91 (1 H, s), 9.79 (H, t), 8.91 (1 H, d, J = 5.6 Hz), 8.44 (1 H , d, J = 4.9 Hz), 8.06 (1 H, d, J = 8.7 Hz), 7.87 (1 H, d, J = 16.6 Hz), 7.67 (1 H , dd, J = 7.9, 1.5 Hz), 7.50-7.35 (4H, m), 7.24 (1 H, d, J = 1, 9 Hz), 7.09 (1 H, d, J = 4.9 Hz), 7.00 (1 H, dd, J = 8.7, 1.5 Hz), 6.88 (1 H, dt, J = 4.1, 1, 5 Hz), 4.00 (2H, dd, J = 5.3, 1, 9 Hz), 2.34 (3H, s), 1, 31-1, 23 (1 H, m), 0.75 -0.69 (2H, m), 0.56-0.52 (2H, m). Example 37: 2- { 3- [2- (4-methyl-pyridin-2-yl) -vinyl] -1 H -indazol-6-ylamino} -N-pyridin-2-ylmethyl-benzamide 114 Prepared in a manner similar to that described for example 6 and example 7 above in this document except for the use of 2- [3- [2- (4-methyl-pyridin-2-yl) -vinyl] acid -1- (tetrahydro-pyran-2-yl) -1H-indazol-6-ylamino] -benzoic acid and C-pyridin-2-yl-methylamine. 1 H NMR (D SO 6, 300 MHz) d 12.91 (1 H, s), 9.77 (H, s), 9.19 (1 H, t, J = 5.8 Hz), 8, 50 (1 H, d, J = 4.1 Hz), 8.45 (1 H, d, J = 5.0 Hz), 8.06 (1 H, d, J = 8.8 Hz), 7 , 88 (1 H, d, J = 16.4 Hz), 7.82-7.70 (2H, m), 7.51-7.25 (7H, m), 7.10 (1H, d , J = 4.6 Hz), 6.98 (1 H, dd, J = 8.8, 1.8 Hz), 6.96-6.91 (1 H, m), 4.58 (2 H, d , J = 5.9 Hz), 2.35 (3H, s). ESIMS m / z 461 (M + H) +. Anal. Caled, for C28H24N60 x 0.3 MTBE: C, 72.71; H, 5.77; N, 17.25. It was found: C, 72.38; H, 5.80; N, 16.88. Example 38: 2 ^ 3- [2- (4-methyl-pyridin-2-yl) -vinyl] -1 H -indazol-6-ylamino} -N-pyridin-4-i! Methyl-benzamide Prepared in a manner similar to that described for example 6 and example 7 above in this document except for the use of 2- [3- [2- 115 (4-methy1-pyridin-2-yl) -vinyl] -1- (tetrahydro-pyran-2-yl) -1 H -ndazol-6-ylamino] -benzoi and C-pyridin-4 -yl-methylamiria. 1 H NMR (DMSO-d 6, 300 MHz) or 12.90 (1 H, s), 9.73 (1 H, s), 9.21 (1 H, t, J = 5.9 Hz), 8, 49-8.44 (3H, m), 8.06 (1H, d, J = 8.7 Hz), 7.88 (H, d, J = 6.4 Hz), 7.81 (1 H, d, J = 7.5 Hz), 7.51-7.40 (4H, m), 7.31 (2H, d, J = 5.9 Hz), 7.24 (1H, s), 7, 11 (1 H, d, J = 4.4 Hz), 7.00 (1 H, dd, J = 8.7, 1, 7 Hz), 6.97-6.92 (H, m), 4 , 50 (2H, d, J = 5.9 Hz), 2.35 (3H, s). ESIMS m / z 461 (M + H) +. Anal. Caled, for C28H24N60 x 0.4 H20 x 0.7 MTBE: C, 71, 36; H, 6.45; N, 15.85. It was found: C, 71, 27; H, 6.29; N, 15.53. Example 39: N- (6-methyl-iridin-2-ylmethyl) -2 ^ 3- [2- (4-methyl-iridin-2-yl) -vinyl] -1 H -indazol-6-ylamino} -benzamide Prepared in a manner similar to that described for example 6 and example 7 above in this document except for the use of 2- [3- [2- (4-methyl-pyridin-2-yl) -vinyl] -1 acid - (tetrahydro-pyran-2-yl) -1 / - / - ndazol-6-ylamino] -benzoic acid and C- (6-methyl-pyridin-2-yl) -methylamine. H NMR (DMSO-d6, 300 MHz) or 12.92 (1 H, s), 9.76 (1H, s), 9.20 (1H, t, J = 5.8 Hz), 8.44 ( H, d, J = 4.9 Hz), 8.05 (1 H, d, J = 8.6 Hz), 7.86 (1 H, d, J = 16.4 Hz), 7.81 (1 H, d, J = 7.7 Hz), 7.59 (1 H, t, J = 7.7 Hz), 7.49-7.37 (4H, m), 7.23 116 (1 H, s), 7.11-7.08 (3H, m), 6.99 (1 H, dd, J = 8.7, 1, 6 Hz), 6.95-6.90 (1 H, m), 4.51 (2H, d, J = 5.9 Hz), 2.42 (3H, s), 2.33 (3H, s). ESIMS m / z 475 (M + H) +. Anal. Caled, for x 0.4 DCM: C, 68.98; H, 5.29; N, 16.39. It was found: C, 68.84; H, 5.42; N, 16.20. Example 40: / V- (2,5-d-methyl-2H-pyrazole-3-methyl] -2 - [(E) -3- [2- (4-methyl-pyridin-2- il) -vinyl] -1- (tetrahydro-rann-2-yl) -1H-indazol-6-ylamino] -benzamide Prepared in a manner similar to that described for example 6 above in this document, except for the use of 2- [3- [2- (4-methyl-pyridin-2-yl) -vinyl] -1- (tetrah) acid Dro-pyran-2-yl) -1 H -indazol-6-ylamino] -benzoic acid and C- (2,5-dimethyl-2H-pyrazol-3-yl) -methylamine. 1 H NMR (DMSO- d 6) 6 9.81 (1 H, s), 9.05 (1 H, ta), 8.46 (1 H, d, J = 8.7 Hz), 7.85 (1 H, d, J = 16.4 Hz), 7.71 (H, d, J = 7.5 Hz), 7.54-7.40 (5H, m), 7.1 1-7.09 ( 2H, m), 6.91 (1 H, t, J = 6.9 Hz), 5.94 (1 H, s), 5.80 (1 H, d, J = 7.3 Hz), 4 , 45 (2H, d, J = 5.5 Hz), 3.93-3.85 (1 H, m), 3.78-3.69 (1 H, m), 3.73 (3H, s) ), 2.45-2.35 (1 H, m), 2.35 (3H, s), 2.07 (3H, s), 2.06-, 95 (2H, m), 1.85- 1.53 (m, 3H). Example 41: N- (2,5-dimethyl-2H-pyrazol-3-ylmethyl) -2-. { 3 - [(E) -2- (4-metll-pyridin-2-yl) -vinyl] -1H-indazol-6-ylamino} -benzamide 117 Prepared in a manner similar to that described for example 7 above in this document, except for the use of A / - (2,5-dimethyl-2H-pyrazol-3-ylmethyl) -2-. { 3 - [(E) -2- (4-Methyl-pyridin-2-yl) -vinyl] -1- (tetrahydro-pyran-2-yl) -1H-indazol-6-ylamino} -benzamide in place of N- [4- (tert-butyl-dimethyl-silanyloxy) -but-2-ynyl] -2- [3- [2- (4,6-dimethyl-pyridin-2-yl) -vini1 ] -1- (tetrahydro-pyran-2-yl) -1H-indazol-6-ylaminoj-benzamide. H NMR (DMSO- d6) d 12.90 (1 H, s), 9.70 (1 H, s), 9.03 (H, t, J = 6.0 Hz), 8.44 (1 H, d, J = 4.9 Hz), 8.06 (1 H, d, J = 9.0 Hz), 7.87 (1 H, d, J = 16.2 Hz), 7.70 (1H, d, J = 7.5 Hz), 7.50-7.38 (4H, m), 7.22 (1 H, s), 7.1 (1 H, d, J = 5.6 Hz), 6.99 (1 H, dd, J = 8.7, 1, 5 Hz), 6.90 (1 H, dt, J = 7.9, 1, 9 Hz), 5.91 (1H, s) , 4.43 (2H, d, J = 5.6 Hz), 3.72 (3H, s), 2.34 (3H, s), 2.05 (3H, s). Example 42: 1-methyl-H-benzoimidazole-2-carbaldehyde oxime To a stirred suspension of 1-methyl-1H-benzoimidazole-2-carbaldehyde (980 mg, 6.61 mmol) in H20 (10 mL) was added a solution of sodium acetate (3.25 g, 39.68 g). mmol) and hydroxylamine hydrochloride (1.38 g, 19.84 mmol) in 10 ml of H2O. The reaction was stirred at rt for 2 hours and the thick precipitate was collected by filtration, washed with water and dried under vacuum to give 1.02 g (94%) of a white solid. 1 H NMR (DMSO- d 6) d 12.06 (1 H, s), 8.28 (1 H, s), 7.65 (1 H, d, J = 7.5 Hz), 7.60 (1 H, d, J = 6.8 Hz), 7.32 (1 H, t, J = 7.2 118 Hz), 7.23 (1 H, t, J = 6.8 Hz), 4.00 (3H, s). Anal. Caled, for C9H9N30: C, 61, 70; H, 5.18; N, 23.99. It was found: C, 61, 80; H, 5.23; N, 23.98. Example 43: C- (1-methyl-H-benzoimidazol-2-yl) -methylamine dihydrochloride A Parr pressure bottle was charged with 1-methyl-1 H-benzoimidazole-2-carbaldehyde oxime M (267 mg, 1.6 mmol), 10% palladium on carbon (75 mg) with hydrochloric acid (2 drops) and ethanol (25 mi). The reaction mixture was shaken under 45 PSI (310.275 kPa) of H2 for 2 hours before the catalyst was removed by filtration. The filtrate was concentrated under reduced pressure and the residue was triturated with Et20 to give 340 mg (90%) of a white solid as the dihydrochloride salt and used without further purification. 1 H NMR (DMSO-d 6) 6 8.87 (2 H, broad s), 7.72 (2 H, m), 7.38 (2 H, m), 4.50 (2 H, s), 3.89 (3 H , s). Example 44: N 1 -methyl-1H-benzoimidazol-2-ylmethyl) -2- [3- [2- (4-methyl-pyridin-2-yl) -vin «l] -1 - (tetrahydro-iran-2 -yl) -1 H-indazol-6-ilarnino] -benzarnide 119 Prepared in a manner similar to that described for example 6 above in this document, except for the use of C- (1-methyl-1 H-benzoimidazol-2-yl) -methylamine N-hydrochloride and 2- [3 - [2- (4-Methy-pyridin-2-yl) -vinyl] -1- (tetrahydro-pyran-2-yl) -1 H -indazol-6-ylamino] -benzoic acid. 1 H NMR (DMSO-d 6) d 9.82 (1 H, s), 9.20 (1 H, t, J = 5.3 Hz), 8.46 (1 H, d, J = 4.9 Hz) , 8.07 (1 H, d, J = 8.9 Hz), 7.85 (1 H, d, J = 16.4 Hz), 7.74 (1 H, d, J = 7.3 Hz ), 7.58 (1 H, d, J = 7.2 Hz), 7.50 (6H, m), 7.19 (4H, m), 6.92 (1 H, t, J = 8, 1 Hz), 5.78 (1 H, dd, J = 2.5, 9.5 Hz), 4.79 (2H, d, J = 5.5 Hz), 3.89 (1 H, m) , 3.83 (3H, s), 3.71 (1H, m), 2.41 (1H, m), 2.35 (3H, s), 2.00 (2H, m), 1.74 (1 H, m), 1, 57 (2H, m). Anal. Caled, for C36H35N7O2 | 0.65 hexanes: C, 73.31; H, 6.80; N, 15.00. It was found: C, 72.92; H, 6.90; N, 14.71. Example 45: N- (1-methyl-1 H-benzoimidazol-2-ylmethyl) -2-. { 3 - [(E) 2- (4-methyl-iridin-2-yl) -vinyl] -1 H -indazol-6-ylamino} -benzamide Prepared in a manner similar to that described for example 7 above in this document, except for the use of N- (1-methyl-1 H-benzoimidazol-2-ylmethyl) -2- [3- [2- (4- methyl-pyridin-2-yl) -vinyl] -1- (tetrahydro-pyran-2-yl) -1 H -indazol-6-ylamino] -benzamide in place of N- [4- (tert-butyl-dimethyl- silanyloxy) -but-2-ynyl] -2- [3- [2- (4,6-dimethyl-pyridin-2-yl) -vinyl] -1- (tetrahydro-pyran-2-yl) -1r / - Ndazol-6-ylamino] -benzamide. H NMR (DMSO- d6) d 12.93 (1H, s), 9.73 (1 H, s), 9.19 (1 H, t, J = 5.3 Hz), 8.45 (1 H , d, J = 4.9 Hz), 8.06 (1 H, d, J = 8.5 Hz), 7.88 (1 H, d, J = 16.4 Hz), 7.74 (1 H, d, J = 7.9 Hz), 7.60-7.36 (6H, m), 7.29-7.14 120 (3H, m), 7.10 (1 H, d, J = 4.7 Hz), 7.04 (1 H, dd, J = 1, 8, 8.9 Hz), 6.91 (1 H , t, J = 7.3 Hz), 4.79 (2H, d, J = 5.3 Hz), 3.83 (3H, s), 2.35 (3H, s). Anal. Caled, for C31H27N7O | 1, 80 H20 0.40 CH2Cl2: C, 65.02; H, 5.46; N, 6.91. It was found: C, 64.97; H, 5.82; N, 7.09. Example 46: 1-methyl-1H-α-dadazol-2-carbaldehyde oxime Prepared in a manner similar to that described for example 39 except that 1-methyl-1H-imidazole-2-carbaldehyde was used instead of 1-methyl-1H-benzoimidazole-2-carbaldehyde. H NMR (DMSO- d6) 11, 50 (1 H, s), 8.05 (1 H, s), 7.28 (1 H, s), 6.95 (1 H, s), 3, 80 (3H, s). Anal. Caled, for C5H7N3O: C, 47.99; H, 5.64; N, 33.58. It was found: C, 48.22; H, 5.58; N, 33.45. Example 47: C- (1-metll-1H-ymidazol-2-yl) -methylamine dihydrochloride Prepared in a manner similar to that described for Example 40 except that 1-methyl-1 H-imidazole-2-carbaldehyde oxime was used instead of 1-methyl-H-benzoimidazole-2-carbaldehyde oxime. 1 H NMR (DMSO- d 6) d 7.45 (1 H, s), 7.29 (1 H, s), 4.25 (2 H, s), 3.79 (3 H, s). Example 48: N- (1 -methyl-1 H -imidazol-2-ylmethyl) -2- [3- [2- (4-methyl-pyridin-2-yl) -vinyl] -1- (tetrahydro- piran-2-yl) -1H-indazol-6-ylamino] -benzamide 121 Prepared in a manner similar to that described for example 6 above in this document, except for the use of C- (1-methyl-1 H-imidazol-2-yl) -methylamine hydrochloride and 2- [3- [ 2- (4-Methyl-pyridin-2-yl) -vinyl] -1- (tetrahydro-pyran-2-yl) -1 H -indazol-6-ylamino] -benzoic acid. H NMR (DMSO- d6) d 9.83 (1 H, s), 9.03 (1 H, t, J = 5.5), 8.45 (1 H, d, J = 4.7 Hz) , 8.09 (1H, d, J = 8.5 Hz), 7.85 (1 H, d, J = 16.5 Hz), 8.67 (1H, d, J = 7.3 Hz), 7.53-7.39 (4H, m), 7.11 (3H, m), 6.90 (1 H, d, J = 6.9 Hz), 6.86 (1 H, s), 5 , 79 (1 H, d, J = 8.9 Hz), 5.75 (1H, s), 4.54 (1 H, d, J = 5.5 Hz), 3.85-3.70 ( 2H, m), 3.66 (3H, s), 2.35 (3H, s), 2.10 (2H, m), 1.70 (2H, m), 1.60 (3H, m). Anal. Caled, for C 32 H 33 N 7 O 2 | 0.8 CH 2 Cl 2: C, 63.99; H, 5.672; N, 15.93. It was found: C, 63.95; H, 5.72; N, 16.01. Example 49: N- (1-methyl-1 H-imidazol-2-ylmethyl) -2- [3- [2- (4-methyl-pyridin-2-yl) -vinyl] -1H-indazole-6- ilamino] -benzamide Prepared in a manner similar to that described for example 7 above in this document, except that N- (1-methyl-1 H-imidazol-2-ylmethyl) -2- [3- [2- (4-methyl- pyridin-2-yl) -vinyl] -1- (tetrahydro-pyran-2-yl) -1 H-indazole-6- 122 ilamino] -benzamide was used in place of N- [4- (tert-butyl-dimethyl-silanyloxy) -but-2-ynyl] -2- [3- [2- (4, 6-dimethyl-pmdin ^ ilaminoj-benzamide. 1H NMR (DMSO- d6) 6 12.89 (1 H, s), 9.72 (1 H, s), 8.99 (H, t, J = 5.6 Hz) "8.44 (1H, s), d, J = 4.9 Hz), 8.05 (H, d, J = 8.7 Hz), 7.86 (1 H, d, J = 16.4 Hz), 7.66 (1 H, d, J = 6.7 Hz), 7.49-7.36 (4H, m), 7.24 (1 H, m), 7.09 (2H, d, J = 8.1 Hz), 7 , 02 (1 H, d, J = 8.8 Hz), 6.88 (1 H, t, J = 6.9 Hz), 6.81 (1 H, s), 4.52 (2H, d , J = 5.5 Hz), 3.29 (3H, s), 2.34 (3H, s). Anal. Caled, for C27H25N7O | 0.35 CH2CI2: C, 66.59; H, 5.25; N, 19.88. It was found: C, 66.48; H, 5.65; N, 19.56. Example 50: W- (4-hydroxy-but-2-ynyl) -2- [3- [2- (4-methyl-irdin-2-yl) -vinyl] -1- (tetrahydro-pyran- 2-yl) -1 H -indazol-6-ylamino] -benzamide Prepared in a manner similar to that described for example 6, except in the use of 2- [3- [2- (4-methyl-pyridin-2-yl) -vinyl] -1- (tetrahydro-pyr -2-il) -1 H- indazol-6-ylammon] -benzoic acid and 4- (tert-butyl-dimethylsilanyloxy) -but-2-inylamine. 1 H NMR (CDCl 3) d 9.48 (H, s), 8.46 (1 H, d, J = 5.3 Hz), 7.92 (1 H, d, J = 9.0 Hz), 7 , 83 (1 H, d, J = 16.2 Hz), 7.52 (1 H, d, J = 16.6 Hz), 7.46-7.41 (2H, m), 7.34- 7.31 (3H, m), 7.12 (1 H, dd, J = 8.7, 1, 9 Hz), 6.99 (1 H, d, J = 4.9 Hz), 6.81 (1H, t, J = 6.8 Hz), 6.40 (1 H, t, J = 4.9 Hz), 5.62 (1H, dd, J = 9.4, 3.0 Hz), 4.28-4.23 123 (4H, m), 4.08-4.01 (1H, m), 3.76-3.67 (1H, m), 2.63-2.49 (1H, m), 2.38 ( 3H, s), 2.22-2.06 (2H, m), 1, 80-1, 60 (3H, m). Example 51: 2- { 3 - [(E) -2- (4-methyl-pyridin-2-yl) -vinyl] -1 H -indazol-6-ylamino} -N- (4-hydroxy-but-2-ynyl) -benzamide Prepared in a manner similar to that described for example 7, except in the use of a mixture of A / - (4-hydroxy-but-2-ynyl) -2- [3- [2- (4-methyl-pyro Din-2-yl) -vinyl] -1 - (tetrahydro-pyran-2-yl) -1 H -indazol-6-ylamino] -benzamide and N- [4- (tert-butyl-dimethyl-silanyloxy) - but-2-yl] -2- [3- [2- (4-me 2-yl) -1H-indazol-6-ylamino] -benzamide in place of N- [4- (tert-butyl-dimethyl- silanyloxy) -but-2-ynyl] -2- [3- [2- (4,6-dimethyl-pyridin-2-yl) -vinyl] -1- (tetrahydro-pyran-2-yl) -1H-indazole -6-ylamino] -benzamide. H NMR (DMSO- d6) d 12.92 (1 H, s), 9.83 (1 H, s), 9.00 (1 H, t, J = 5.3 Hz), 8.44 (1 H , d, J = 4.9 Hz), 8.06 (1 H, d, J = 9.0 Hz), 7.87 (1 H, d, J = 16.6 Hz), 7.68 (1 H , d, J = 7.9 Hz), 7.50-7.38 (4H, m), 7.26 (1 H, s), 7.09 (1H, d, J = 5.3 Hz), 7.01 (1H, dd, J = 8.7, 1.5 Hz), 6.88 (1 H, dt, J = 6.8, 1.5 Hz), 5.11 (1 H, t, J = 3.0 Hz), 4.10-4.04 (4H, m), 2.34 (3H, s). Example 52: 2- [3- (Pyrrol-1-yliminomethyl) -1- (2-trimethylsilanyl-ethoxymethyl) -H-indazol-6-ylamino] -benzoic acid methyl ester 124 Prepared in a manner similar to that described for example 2 and example 3 above in this document except that starting with 6-n-t-3-styryl-1- (2-trimethylsilyl-ethoxymethyl) -1 H -indazole instead of 6-iodo-3-styryl-1- (2-trimethylsilanyl-ethoxymethyl) -1H-indazole. This material was collected as a crude mixture of product and 2-amino-benzoic acid methyl ester in the next step. Example 53: 2- [3- (Pyrrol-1-yliminomethyl) -1- (2-trimethylsilyl-ethoxymethyl) -1 H -ndazol-6-ylamino] -benzoic acid Isolated as a byproduct of the reaction of N- [4- (tert-butyl-dimethylsilaloxy) -but-2-ynyl] -2- [3- (pyrrol-1-yliminomethyl) -1- (2- trimethylsilanyl-ethoxymethyl) -1 H -ndazol-6-ylamino] -benzamide and TBAF using a procedure similar to example 11 in the United States document with serial number 125 09 / 609,335, filed on June 30, 2000, hereby incorporated in its entirety for all purposes. 1 H NMR (DMSO- d 6) d 13.19 (1 H, broad s), 10.00 (1 H, s), 9.13 (1 H, s), 8.37 (1 H, d, J = 8, 7 Hz), 8.06 (1H, d, J = 7.5 Hz), 7.75 (1 H, s), 7.64 (2H, t, J = 2.3 Hz), 7.54 ( 2H, m), 7.35 (1 H, dd, J = 1, 9, 8.7 Hz), 6.99 (1 H, m), 6.33 (2H, t, J = 2.3 Hz), 5.89 (2H, s), 3.68 (2H, t, J = 8.1 Hz), 0.94 (2H, t, J = 8.1 Hz), 0.00 (9H, s). Example 54: N- (3-Cyclopropyl-prop-2-ynyl) -2- [3- (pyrrol-1-yliminomethyl) -1 - (2-trimethylsilanyl-ethoxymethyl) -1H-indazol-6-ylamino] -benzamide Prepared in a manner similar to that described for example 6 above in this document, except for the use of 2- [3- (pyrrol-1-yliminomethyl) -1- (2-trimethylsilane-1-ethoxymethyl) -1 H acid -indazol-6-ylamino] -benzoic acid and 3-cyclopropyl-prop-2-inylamine. 1H NMR (DMSO- d6) d 9.93 (1H, s), 8.99 (1H, s), 8.95 (1H, d, J = 5.6 Hz), 8.20 (1H, d, J = 8.9 Hz), 7.68 (1H, d, J = 8.1 Hz), 7.51 (4H, m), 7.37 (1H, t, J = 6.8 Hz), 7 , 14 (1 H, d, J = 9.0 Hz), 6.91 (1 H, t, J = 7.5 Hz), 6.21 (2H, t, J = 2.3 Hz), 5 , 74 (2H, s), 4.00 (2H, dd, J = 2.0, 5.6 Hz), 3.55 (2H, t, J = 7.9 Hz), 1, 26 (1H, m), 0.82 (2H, t, J = 7.9 Hz), 0.72 (2H, m), 0.54 (2H, m), -0.12 (9H, s). Example 55: N- (3-Cyclopropyl-prop-2-ynyl) -2- [3- (pyrrol-1-yliminomethyl) -1H-indazol-6-ylamino] -benzamide 126 Prepared in a manner similar to that described for Example 1 1 in U.S. Patent Application Serial No. 09 / 609,335, filed June 30, 2000, incorporated by reference in its entirety for all purposes, except wherein N- (3-cyclopropyl-prop-2-ynyl) -2- [3- (pyrrol-l-iminomethyl) -1 - (2-trimethylsilanyl-ethoxymethyl) -1 H -indazol-6-ylamino] -benzamide is used instead of N-methyl-N-. { 3-styryl-1 - [(2-trifatyl-silanyl) -ethoxymethyl] -1 H -indazol-6-yl} -benzene-1, 3-diamine. 1 H NMR (DMSO- d 6) d 13.29 (1 H, s), 9.83 (1 H, s), 8.98 (1 H, s), 8.95 (1 H, t, J = 5 , 5 Hz), 8.19 (1H, d, J = 8.9 Hz), 7.68 (1H, d, J = 7.5 Hz), 7.52 (2H, t, J = 2, 3 Hz), 7.43 (2H, m), 7.29 (1 H, s), 7.07 (1 H, dd, J = 1, 9, 8.7 Hz), 6.91 (1 H , t, J = 7.4 Hz), 6.21 (2H, t, J = 2.3 Hz), 4.01 (2H, dd, J = 1, 7, 5.5 Hz), 1, 27 (1 H, m), 0.73 (2H, m), 0.55 (2H, m). Anal. Caled, for C25H22N6O · 0.05 hexanes · 0.30 H20: C, 70.31; H, 5.43; N, 19.45. It was found: C, 70.63; H, 5.38; N, 19.18. Example 56: N- [4- (tert-butyl-d.methyl-silanyloxy) -but-2-ynl] -2- [3- (pyrrol-1-y1iminomethyl) -1- ( 2-trimethylsilanyl-toxymethyl) -1H-indazol-6-ylamino] -benzamide 127 Prepared in a manner similar to that described for example 6 above in this document, except for the use of 2- [3- (pyrroyl-1-yliminomethyl) -1- (2-trimethylsilanyl-ethoxymethyl) -1 H -indazol-6-ylamino] -benzoic acid and 4- (tert-butyl-dimethyl-silanyloxy) -but-2-inylamine. 1 H NMR (DMSO- d 6) d 10.04 (1H, s), 9.16 (1 H, t, J = 5.3 Hz), 9.10 (1H, s), 8.31 (1H, d, J = 8.7 Hz), 7.78 (1 H, d, J = 7.9 Hz), 7.67 (4H, m), 7.49 (1H, t, J = 8.5 Hz ), 7.24 (1 H, dd, J = 1, 7, 8.7 Hz), 7.03 (1 H, t, J = 7.4 Hz), 6.33 (2H, t, J = 2.3 Hz), 5.85 (2H, s), 4.83 (2H, s), 4.19 (2H, d, J = 5.5 Hz), 3.66 (2H, t, J = 7, 9 Hz), 0.94 (2H, m), 0.89 (9H, s), 0.13 (6H, s), 0.00 (9H, s). Example 57: N- (4-hydroxy-but-2-yl) -2- [3- (pyrrol-1-ylminomethyl) -1 H -indazol-6-ylamino] -benzamide Prepared in a manner similar to that described for example 11 in the United States patent application serial number 09 / 609,335, filed on June 30, 2000, incorporated by reference in its 128 whole for all purposes, except that N- [4- (tert-butyl-dimethyl-silanyloxy) -but-2-ynyl] -2- [3- (pyrrol-1-yliminomethyl) -1 - (2-trimethylsilanyl) -ethoxymethyl) -1 H -indazol-6-ylamino] -benzamide was used in place of N-methyl-N-. { 3-styryl-1- [2-trimethyl-slanyl) -ethoxymethyl] -1 H -indazol-6-yl} -benzene-1, 3-diamine. 1 H NMR (DMSO- d 6) d 13.30 (1 H, s), 9.87 (1 H, s), 9.04 (1 H, t, J = 5.3), 8.99 (1 H , s), 8, 9 (1 H, d, J = 8.5 Hz), 7.70 (1 H, d, J = 7.3 Hz), 7.46 (4 H, s), 7.31 (1H, m), 7.08 (1 H, dd, J = 1.7, 8.7 Hz), 6.91 (1 H, t, J = 7.3 Hz), 6.21 (2H, t, J = 2.1 Hz), 5.14 (1 H, t, J = 5.8 Hz), 4.10 (2H, d, J = 5.5 Hz), 4.06 (2H, d, J = 5.8 Hz). Anal. Caled, for C23H20 6O2 | 0.35 hexanes | 0.20 H20: C, 67.45; H, 5.86; N, 18.81. It was found: C, 67.70; H, 5.73; N, 8.56. Example 58: 2,5-dimethyl-2H-pyrrazol-3-carbonitrile 2,5-dimethyl-2H-pyrazole-3-carbontrile was prepared from 1,3-dimethylpyrazole-5-carboxylic acid ethyl ester according to published procedures for 1-methyl-pyrazole-5-carbonitrile by Castellanos , María and Montserrat, Llinas, JCS Perkins Trans I (1985) 1209-1215. 1 H NMR (CDCl 3) d 6.52 (1 H, s), 3.96 (3 H, s), 2.27 (3 H, s). Example 59: C- (2,5-dimethyl-2H-pyrazol-3-yl) -methylamine A suspension of 2,5-dimethyl-2H-pyrazole-3-carbonitrile (654 mg, 5.4 129 mmol) and 10% palladium on carbon (200 mg) in ethanol (15 ml) was shaken in a Parr hydrogenation apparatus under 45 psi (310.275 kPa) of H2 for 17 hours. The mixture was filtered through celite and the filtrate was concentrated under reduced pressure to give 608 mg of an oil which was used without any further purification. 1 H NMR (CDCl 3) d 5.19 (1 H, s), 3.81, 3.73 (2 H, 2 s), 3.75 (3 H, s), 2.21 (3 H, s). Example 60: / V- (2,5-Dimethyl-2H-pyrazol-3-ylmethyl) -2- [3- (pyrrol-1 -fflminomethyl) -1- (2-trimethylsilanyl-ethoxymethyl) -1H-indazole-6 -amino] -benzamide Prepared in a manner similar to that described for example 6 above in this document, except for the use of 2- [3- (pyrrol-1-yliminomethyl) -1- (2-trimethylsilanyl-ethoxymethyl) -1H-indazole. -6-ylamino] -benzoic acid and C- (2,5-dimethyl-2-tf-pyrazol-3-yl) -metholamine. 1 H NMR (CDCl 3) d 9.56 (1 H, s), 8.68 (1 H, s), 8.30 (1 H, d, J = 8.7 Hz), 7.49 (1 H, d , J = 8.3 Hz), 7.43 (1 H, dd, J = 7.9, 1.5 Hz), 7.36-7.31 (2H, m), 7.23 (2H, t , J = 2.6 Hz), 7.17 (1H, dd, J = 8.7, 1, 9 Hz), 6.83 (1 H, t, J = 7.2 Hz), 6.32 ( 1 H, ta), 6.29 (2H, t, J = 2.3 Hz), 6.01 (1H, s), 5.67 (2H, s), 4.61 (2H, d, J = 5.6 Hz), 3.60 (3H, s), 3.58 (2H, t, J = 8.3 Hz), 2.22 (3H, s), 0.90 (2H, t, J = 8.7 Hz), 0.06 (9H, s). Example 61: W- (2,5-limethyl-2W-irazol-3-methylmet) -2- [3- (pyrrol-1 -liminomethyl) - 130 1 H-indazol-6-ylamino-J-benzamide Prepared in a manner similar to that described for Example 1 1 in U.S. Patent Application Serial No. 09 / 609,335, filed June 30, 2000, incorporated by reference in its entirety for all purposes, except wherein A / - (2,5-dimethyl-2H-pyrazol-3-ylmethyl) -2- [3- (pyrrol-1-yliminomethyl) -1 - (2-trimethylsilanyl-ethoxymethyl) -1H-indazole-6 -ylaminoj-benzamide was used in place of N-methyl-N-. { 3-styryl-1 - [(2-trimethyl-silanyl) -ethoxymethyl] -1 H -indazol-6-yl} -benzene-1, 3-diamine. 1 H NMR (DMSO- d 6) 6 13.27 (1 H, s), 9.72 (1 H, s), 9.05 (1 H, t, J = 5.3 Hz), 8.97 (1 H, s), 8.16 (1 H, dd, J = 8.7 Hz), 7.68 (1 H, dd, J = 8.3, 1, 9 Hz), 7.50 (2H, t , J = 2.6 Hz), 7.46-7.38 (2H, m), 7.25 (1H, s), 7.05 (1H, dd, J = 8.7, 1.9 Hz) , 6.91 (H, t, J = 6.80 Hz), 6.20 (2H, t, J = 2.3 Hz), 5.91 (1 H, s), 4.43 (2H, d , J = 5.6 Hz), 3.71 (3H, s), 2.04 (3H, s). Example 62: 2- [3- (Pyrrol-1-yliminoethyl) -1 H -indazol-6-ylamino] -benzoic acid 131 Prepared in a manner similar to that described for Example 11 in U.S. Patent Application Serial No. 09 / 609,335, filed June 30, 2000, incorporated by reference in its entirety for all purposes, except in that 2- [3- (pyrrol-1 -liminomethyl) -1- (2-trimethylsilanyl-ethoxymethyl) -H-indazol-6-ylamino] -benzoic acid is used in place of N-methyl-N-. { 3-styryl-1 - [(2-trimethyl-silanyl) -ethoxymethyl] -1 H -indazol-6-yl} -benzene-1, 3-diamine. 1H NMR (DMSO- d6) d 13.12 (1H, s), 12.70 (1H, s), 8.94 (1 H, s), 8.10 (1H, d, J = 8.7 Hz ), 7.91 (1 H, dd, J = 1, 7, 7.7 Hz), 7.50 (2H, t, J = 2.3 Hz), 7.36 (1 H, d, J = 7.9 Hz), 7.27 (1 H, d, J = 1.5 Hz), 7.16 (1 H, t, J = 7.5 Hz), 6.94 (1 H, dd, J = 1, 7, 8.7 Hz), 6.68 (1 H, t, J = 7.5 Hz), 6.19 (2H, t, J = 2.3 Hz). Example 63: N-prop-2-ynyl-2- [3- (pyrrolid-1-yliminomethyl) -1H-indazol-6-ylamino] -benzamide Prepared in a manner similar to that described for example 6 above in this document, except for the use of 2- [3- (pyrrol-1-yliminomethyl) -1 H -indazol-6-ylamino] -benzoic acid and propargylamine. 1 H NMR (DMSO-d 6) d 13.30 (1H, s), 9.82 (1 H, s), 9.04 (1H, t, J = 5.6 Hz), 8.98 (1H, s) ), 8.19 (1H, 132 d, J = 8.6 Hz), 7.69 (1 H, d, J = 7.9 Hz), 7.45 (4H, m), 7.31 (1 H, s), 7.08 ( 1 H, d, J = 8.6 Hz), 6.91 (1 H, t, J = 7.6 Hz), 6.21 (2H, s), 4.05 (2H, s), 3, 13 (1 H, s). Anal. Caled, for C22Hi8N60 | 0.40 H20 | 0.05 hexanes: C, 67.97; H, 5.01; N, 21, 33. It was found: C, 67.91; H, 4.78; N, 21, 00 Example 64: N- (4-hydroxy-but-2-yl) -2- [3- (2 ^ iridin-2-yl-vinyl) -1H-indazol-6-ylaminoj-benzamide Prepared in a manner similar to that described for example 6 above in this document, except for the use of 2- [3- [2- (pyridin-2-yl-vinyl] -1 H -indazol-6-ylamino] ] -tetrabutylammonium benzoate and 4-amino-but-2-in-1-ol. 1H NMR (DMSO-d6) d 12.95 (H, s), 9.84 (1 H, s), 9.02 (1 H, t J = 5.6 Hz), 8.59 (1 H, d, J = 4.9 Hz), 8.08 (1 H, d, J = 8.7 Hz), 7, 90 (1 H, d, J = 16.2 Hz), 7.80 (1 H, t, J = 7.2 Hz), 7.70-7.64 (2H, m), 7.51 (1 H, d, J = 16.2 Hz), 7.45-7.36 (2H, m), 7.27-7.24 (2H, m), 7.02 (1 H, d, J = 9 , 0 Hz), 6.88 (1 H, t, J = 7.2 Hz), 5.13 (1 H, t, J = 5.6 Hz), 4.10-4.04 (4H, m Example 65: W- (2,5-dimethyl-2W ^ irazol-3-methylmethyl) -2- [3- (2 ^ iridin-2-yl-vinyl) -1 H -indazol-6-ylamino] -benzamide 133 Prepared in a manner similar to that described for example 6 above in this document, except for the use of 2- [3- [2-pyridin-2-yl-vinyl] -1 - / - indazol-6-ylamino ] -tetrabutylammonium benzoate and C- (2,5-dimethyl-2H-pyrazol-3-yl) -methylamine. 1 H NMR (DMSO- d 6) d 12.93 (1 H, s), 9.70 (1 H, s), 9.04 (1 H, ta), 8.58 (1 H, d, J = 4, 0 Hz), 8.07 (1 H, d, J = 8.8 Hz), 7.88 (1 H, d, J = 16.4 Hz), 7.79 (1 H, t, J = 8.6 Hz), 7.71-7.64 (2H, m), 7.50 (1H, d, J = 16.4 Hz), 7.44-7.39 (2H, m), 7.28-7 , 23 (2H, m), 7.00 (1 H, d, J = 8.8 Hz), 6.90 (1H, t, J = 8.0 Hz), 5.91 (1H, s), 4.43 (2H, d, J = 5.5 Hz), 3.71 (3H, s), 2.04 (3H, s). The activities of the compounds set forth as examples described hereinabove can be tested using the assays described hereinafter. BIOLOGICAL TEST: ENZYMATIC ESSAYS The stimulation of cell proliferation by growth factors such as VEFG, FGF and others depends on their induction of autophosphorylation of each of their respective receptor tyrosine kinases. Therefore, the ability of a protein kinase inhibitor to block autophosphorylation can be measured by the inhibition of peptide substrates. To measure the inhibitory activity of protein kinases of the compounds, the following constructions were made. VEGF-R2 construction for testing. This construction determines the ability of a test compound to inhibit tyrosine kinase activity. 134 A construct (VEGF-R2A50) of the cytosolic domain of human vascular endothelial growth factor receptor 2 (VEGF-R2) lacking 50 central residues of the 68 residues of the kinase insertion domain was expressed in a baculovirus cell system /insect. Of the 1356 residues of full-length VEGF-R2, VEGF-R2A50 contains residues 806-939 and 990-1171, and also a point mutation (E990V) in the kinase insertion domain relative to wild-type VEGF-R2. The autophosphorylation of the purified construct was performed by incubating the enzyme at a concentration of 4 μ? in the presence of 3 mM ATP and 40 mM MgCl 2 in 100 mM HEPES, pH 7.5, containing 5% glycerol and 5 mM DTT, at 4 ° C for 2 hours. After autophosphorylation, this construct has been shown to possess catalytic activity essentially equivalent to the construction of the wild-type autophosphorylated kinase domain. See Parast et al., Biochemistry, 37, 16788-16801 (1998). Construction FGF-R1 for assay: The intracellular kinase domain of FGF-R1 was expressed using the baculovirus vector expression system starting from the methionine residue 456 endogenous to that of glutamate 766, according to the residue numbering system of Mohammadi et al., Mol. Cell. Biol., 16, 977-989 (1996). In addition, the construct also has the following 3 amino acid substitutions L457V, C488A and C584S. LCK construction for assay: LCK tyrosine kinase was expressed in insect cells as an N-terminal deletion starting at amino acid residue 223 until the end of the protein at residue 509, with the following two amino acid substitutions at the N-terminus: P233M and C224D. Construction CHK1 for testing: full length human CHK1 135 (abbreviated FL-CHK1) labeled with His at the C terminus was expressed using the baculovirus / insect cell system. It contains 6 histidine residues (6 x His tag) at the C-terminus of human CHK1 of 476 amino acids. The protein was purified by conventional chromatographic techniques. CDK2 / cyclin A construct for assay: CDK2 was purified using published methodology (Rosenblatt et al., J. Mol.S / o /., 230, 1317-1319 (1993)) of insect cells that had been infected with a baculovirus expression vector. Cyclin A was purified from E. coli cells expressing full length recombinant cyclin A, and a truncated cyclin A construct was generated by limited and purified proteolysis as previously described (Jeffrey et al., Nature, 376, 313-320 (1995)). Construction CDK4 / cyclin D for assay: a complex of human CDK4 and cyclin D3, or a cyclin D1 complex and a fusion protein of human CDK4 and glutathione-S-transferase (abbreviated GST-CDK4), was purified using biochemical chromatographic techniques traditional from insect cells that had been coinfected with the corresponding baculovirus expression vectors. FAK construction for testing: The catalytic domain of human FAK (FAKcd409) was expressed using the baculovirus vector expression system. The expressed 280 amino acid domain comprises the methionine 409 residues up to glutamate 689. There is a substitution of an amino acid (P410T) relative to accession number L136 6 of the sequence published by Whithey, GS et al., DNA Cell Biol, 9, 823-30 (1993). The 136 Protein was purified using classical chromatographic techniques. TIE-2 Construction (TEK) for assay: TIE-2 tyrosine kinase domain was expressed in insect cells as a deletion at the N terminus starting from the amino acid residue 774 to the end of the protein at residue 1124. This construct also it carries a R774M mutation, which serves as the rest of the methionine initiator of the translation. VEGF-R2 assay Coupled spectrophotometric assay (FLVK-P) The production of ADP from ATP that accompanies phosphoryl transfer was coupled to the oxidation of NADH using phosphoenolpyruvate (abbreviated in English PEP) and a system having pyruvate kinase (briefly in English PK) and lactic dehydrogenase (abbreviated in English LDH). Oxidation of NADH was monitored following the decrease in absorbance at 340 nm (e340 = 6.22 cm "1 mM'1) using a Beckman DU 650 spectrophotometer. Test conditions for phosphorylated VEGF-R2A50 (indicated as FLVK-P in the tables below) were as follows: 1 mM PEP, 250 μg NADH, 50 units of LDH / ml, 20 units of PK / ml, 5 mM DTT, 5.1 mM poly (E4Yi), 1 mM ATP; and 25 mM MgCl 2 in 200 mM HEPES, pH 7.5 The test conditions for non-phosphorylated VEGF-R2A50 (indicated as FLVK in the tables) were as follows: 1 mM PEP, 250 μg NADH, 50 LDH units / ml, 20 units of PK / ml, DTT 5 mM, poIi (E4Yi) 20 mM, 3 mM ATP, and 60 mM MgCl2 and 2 mM MnCl2 in 200 mM HEPES, pH 7.5 The assays were initiated with enzyme 5 a 40 nM The values of K i were determined by measuring the enzymatic activity in the presence of varying concentrations of the 137 test compounds. The data was analyzed using enzymatic kinetics software and Kaleidagraph. ELISA assay The formation of phosphogastrin was monitored using peptide (1-17) of biotinylated gastrin as a substrate. The biotinylated phosphogastrin was immobilized using 96-well microtiter plates coated with streptavidin followed by detection using anti-phosphotyrosine antibody conjugated to horseradish peroxidase. The horseradish peroxidase activity was controlled using the diammonium salt of 2,2'-azino-di- [3-ethylbenzathiazoline sulfonate (6)] (abbreviated in English ABTS). Typical assay solutions contained: 2 μ? Biotinylated gastrin peptide; 5 mM DTT; ATP 20 μ ?; 26 mM MgCl 2; and 2 mM MnCl2 in 200 mM HEPES, pH 7.5. The assay was started with 0.8 nM phosphorylated VEGF-R2A50. The horseradish peroxidase activity was assayed using 10 mM ABTS. The horseradish peroxidase reaction was inactivated by the addition of acid (H2SO4), followed by reading the absorbance at 405 nm. The Ki values were determined by measuring the enzyme activity in the presence of varying concentrations of the test compounds. The data was analyzed using enzymatic kinetics software and Kaleidagraph. FGF-R Assay The spectrophotometric assay was carried out as described above for VEGF-R2, except for the following changes in concentration: FGF-R = 50 nM, ATP = 2 mM and poly (E4Y1) = 15 mM. LCK assay The spectrophotometric assay was carried out as described 138 previously for VEGF-R2, except for the following changes in concentration: LCK = 60 nM, MgCl2 = 0 mM, poly (E4Y1) = 20 mM. CHK1 assay The production of ADP from ATP that accompanies the transfer of phosphoryl to the synthetic substrate peptide Syntide-2 (PLARTLSVAGLPGKK) was coupled to the oxidation of NADH using phosphoenolpyruvate (abbreviated in English PEP) by the actions of pyruvate kinase ( abbreviated in English PK) and lactic dehydrogenase (abbreviated in English LDH). Oxidation of NADH was monitored by following the decrease in absorbance at 340 nm (e340 = 6.22 cm "mM" 1) using an HP8452 spectrophotometer. Typical reaction solutions contained: 4 mM PEP; 0.15 mM NADH; 28 units of LDH / ml; 16 units of PK ml; 3 mM DTT; 0.125 mM Syntide-2; 0.15 mM ATP; 25 mM MgCl 2 in 50 mM TRIS, pH 7.5; and 400 mM NaCl. The assays were started with 10 nM FL-CHK1. The K i values were determined by measuring the initial enzymatic activity in the presence of varying concentrations of the test compounds. The data was analyzed using enzymatic kinetics software and Kaleidagraph. CDK2 / Cyclin A assays v CDK4 / Cyclin D Cyclin-dependent kinase activity was measured by quantifying the time-dependent, enzymatically catalyzed incorporation of radioactive phosphate of [32 P] ATP into a recombinant fragment of the retinoblastoma protein. Unless otherwise indicated, the assays were performed in 96-well plates in a total volume of 50 μl, in the presence of 10 mM HEPES (N- [2-hydroxyethyl] piperazine-N '[2-ethanesulfonic acid]) ( pH 7.4), MgC ^ 10 mM, adenosine triphosphate (abbreviated in English ATP) 25 μ ?, 1 mg / ml 139 of ovalbumin, 5 pg / ml leupeptin, 1 mM dithiothreitol, 10 mM yff-glycerophosphate, 0.1 mM sodium vanadate, 1 mM sodium fluoride, ethylene glycol-bis? -aminoethyl ether) -N, N, N'N'- tetraacetic (abbreviated in English EGTA) 2.5 mM, 2% (v / v) dimethyl sulfoxide and 0.03 - 0.2 pCi [32 P] ATP. From the substrate (0.3 - 0.5 pg) a fragment of the retinoblastoma recombinant protein (abbreviated Rb) (residues 386-928 of the native retinoblastoma protein; 62.3 kDa, containing most of the sites) was purified. of phosphorylation found in the native 106 kDa protein, as well as a marker of six histidine residues to facilitate purification). The reactions were initiated with CDK2 (50 nM CDK2 / cyclin A 50 nM complex) or CDK4 (50 nM CDK4 / cyclin D3 complex), incubated at 30 ° C, and finalized after 20 minutes by the addition of ethylenediaminetetraacetic acid (abbreviated in English). EDTA) 250 mM. The phosphorylated substrate was then captured on a nitrocellulose membrane using a 96-well filtration collector and the unincorporated radioactivity was removed by repeated washing with 0.85% phosphoric acid. The radioactivity was quantified by exposing the dried nitrocellulose membranes to an imager by phosphorescence. The apparent values of K i were measured by assaying the enzymatic activity in the presence of different concentrations of compound and subtracting background radioactivity measured in the absence of enzyme. The kinetic parameters (kcat, Km for ATP) were measured for each enzyme under the usual assay conditions determining the dependence of the initial amounts on the ATP concentration. The data were fitted to an equation for competitive inhibition using Kaleidagraph (Synergy Software), or were fitted to an equation for competitive tight binding inhibition using the KineTic software (BioKin, Ltd.). The measured values of 140 K, for known inhibitors against CDK4 and CDK2 agreed with published CI5o values. The specific activity of CDK4 was the same if complexed to full-length cyclin D3 or to the construction of truncated cyclin D3; both complexes also produced very similar values of K, for selected inhibitors. FAK assays FAK HTS used the fluorescence polarization assay provided by LJL Biosystems. The kinase reaction contained: 100 mM Hepes, pH 7.5, 10 mM MgCl 2; 1 mM DTT, 1 mM ATP and poly Glu-Tyr 1 mg / ml (4: 1). The reaction is initiated by the addition of 5 nM FAKcd409. The reaction was terminated by the addition of EDTA followed by the addition of fluorine-labeled peptide and anti-phosphotyrosine antibody, both provided by LJL Biosystems. The results of the inhibition are read in an Analyst detector (LJL). TIE-2 Spectrophotometric Assays The kinase-catalyzed production of ADP from ATP that accompanies the transfer of phosphoryl to the poly (Glu4Tyr) random copolymer was coupled to the oxidation of NADH by the activities of pyruvate kinase (abbreviated in English PK) and lactate dehydrogenase (abbreviated LDH). The conversion of NADH to NAD + was controlled by the decrease in absorbance at 340 nm (e = 6.22 cm "1 mM" 1) using a Beckman DU650 spectrophotometer. Typical reaction solutions contained: 1 mM phosphoenolpyruvate; 0.24 mM NADH; 40 mM MgCl 2, 5 mM DTT, 2.9 mg / ml poly (Glu 4 Tyr), 0.5 mM ATP, 15 units / ml PK, 15 units / ml LDH in 100 mM HEPES, pH 7.5. The trials were started with the addition of Tie-2 141 phosphorylated 4 to 12 nM (amino acids 775-1122). The percent inhibition was determined in triplicate at an inhibitor level of 1 μ ?. DELFIA TIE-2 Assay Phosphotyrosine formation was monitored using the biotinylated p34cdc2 peptide (amino acids 6-20 = KVEKIGEGTYGVVYK) as the substrate. The biotinylated peptide was immobilized using 96-well microtiter plates coated with NeutrAvidin ™ followed by detection using anti-phosphotyrosine antibody (PY20) conjugated to europium chelate N1. Typical assay solutions contained: biotinylated p34cdc2 peptide 1μ ?, ATP 150μ ?, 5mM MgCl2.; 1 mM DTT, 0.01% BSA, 5% glycerol, 2% DMSO, 25 mM HEPES pH 7.5. The assay was initiated on the NeutrAvidin plate with 50 nM TIE2 intracellular domain. The kinase reaction was terminated with 50 mM EDTA. The plates were then washed, and europium antibody was added. After incubation, they were washed again and DELFIA ™ enhancing solution was added. The plates were read in Europium time resolution patterns (ex 340 nm, em 615 nm, delay 400 μ sec, window 400 μ sec). Percent inhibition was calculated with reference to the intraplate wells to which DMSO had been added in place of the compound in DMSO, the background being removed from both the experiment and the control with reference to an intraplate well to which EDTA had been added before the enzyme addition. HUVEC Proliferation Assay This assay determines the ability of a test compound to inhibit proliferation stimulated by the human umbilical vein endothelial cell growth factor (abbreviated in English as "HUVEC"). 142 HUVEC cells (3-4 passes, Clonetics, Corp) were thawed in EGM2 culture medium (Clonetics Corp) in T75 flasks. The fresh EGM2 medium was added to the flasks 24 hours later. Four or five days later, the cells were exposed to another culture medium (F12K medium supplemented with 10% fetal bovine serum (abbreviated in English FBS), 60 pg / ml endothelial cell growth supplement (abbreviated in English ECGS ), and 0.1 mg / ml heparin). The exponentially growing HUVEC cells were used in later experiments. Between ten and twelve thousand HUVEC cells were seeded in 96-well plates in 100 μ? of enriched culture medium (described above). The cells were allowed to bind for 24 hours in this medium. Then the medium was removed by aspiration and 105 μ? of starvation medium (F12K + 1% FBS) to each well. After 24 hours, 15 μ? of test agent dissolved in 1% DMSO in starvation medium or this vehicle alone in each treatment well; the final concentration in DMSO was 0.1%. One hour later, 30 pl of VEGF (30 ng / ml) was added to all wells in starvation medium except for those containing untreated controls; the final concentration of VEGF was 6 ng / ml. Cell proliferation was quantified 72 hours later by reduction of the MTT dye, at which time the cells were exposed for 4 hours to MTT (Promega Corp.). The reduction of the dye was stopped by the addition of a stop solution (Promega Corp.) and the absorbance was determined at? of 595 in a 96-well plate reader spectrophotometer. The IC 50 values were calculated by fitting the curve to the response of A595 at various concentrations of the test agent; 143 Typically, seven separate semilogarithmic concentrations were used, with triplicate wells at each concentration. For the analysis of the plates of the library of the compounds, one or two concentrations were used (one well per concentration), and the% inhibition was calculated by the following formula:% inhibition = (control - assay) ÷ (control - starvation) where control = A595 when VEGF is present without assay agent assay = A595 when VEGF is present with starvation assay agent = A595 when VEGF and the test agent are both absent. PK assay in mice The pharmacokinetics (for example, absorption and elimination) of drugs in mice were analyzed using the following experiment. The test compounds were formulated in the form of a solution or suspension in a vehicle 30:70 (PEG 400: H20 acidified) or in the form of a suspension in 0.5% CMC. This was administered orally (abbreviated p.o.) and intraperitoneally (abbreviated i.p.) at variable doses to two different groups (n = 4) of females of B6 mice. The blood samples were collected by orbital bleeding at the instants: 0 hours (before the dose), 0.5 hours, 1.0 hours, 2.0 hours and 4.0 hours and 7.0 hours after the dose. Plasma was obtained from each sample by centrifugation at 2500 rpm for 5 minutes. The test compound was extracted from the plasma by a process of precipitation of organic proteins. For each bleeding time, 50 μ? of plasma with 1.0 ml of acetonitrile, was stirred in 144 a vortex apparatus for 2 minutes and then centrifuged at 4000 rpm for 15 minutes to precipitate the protein and extract the test compound. Next, the supernatant in acetonitrile (the extract containing the test compound) was poured into new test tubes and evaporated on a hot plate (25 ° C) in a stream of N2 gas. To each tube containing the extract of the dry test compound were added 125 μ? of mobile phase (60:40, NH4H2P04 0.025 M + 2.5 ml / l of TEA: acetonitrile). The test compound was resuspended in the mobile phase by shaking in a vortex apparatus and more protein was removed by centrifugation at 4000 rpm for 5 minutes. Each sample was poured into an HPLC vial for analysis of the test compound in a Hewlett Packard 1100 series HPLC with UV detection. From each sample, 95 μ? in a 150 x 3 column, 2 mm, C-18 reverse phase Phenomenex-Prodigy and eluted with 45-50% acetonitrile gradient carrying it out for 10 minutes. Plasma concentrations of the test compound (pg / ml) were determined by comparison with a standard curve (peak area vs. g / ml concentration) using known concentrations of the test compound extracted from plasma samples in the manner described above. Together with the patterns and not known, three groups (n = 4) of quality controls (0.25 pg / ml, 1.5 pg / ml, and 7.5 pg / ml) were carried out to ensure consistency of the analysis. The standard curve had a value of R2 >; 0.99 and the quality controls were all between 10% of their expected values. The quantified test samples were plotted for visual exposure using Kalidagraph software and their pharmacokinetic parameters were determined using the WIN NONLIN software. Example 1 (a) provided 145 the following results: 0.69 (pK of mice, AUC, ip, g-h / ml); 0.33 (pK of mice, AUC, po, pg-h / ml). KDR phosphorylation assay ÍVEGFR2) in PAE-KDR cells This assay determines the ability of a test compound to inhibit the autophosphorylation of KDR in porcine aortic endothelial cells (PAE) -KDR. PAE cells overexpressing human-type KDR were used in this assay. The cells were cultured in Ham's F12 medium supplemented with 10% fetal bovine serum (abbreviated in English as FBS) and 400 pg / ml of G418. Thirty thousand cells were seeded in each well of a 96-well plate in 75 μ? of growth medium and allowed to adhere for 6 hours at 37 ° C. The cells were then exposed to the starvation medium (Ham's F12 medium supplemented with 0.1% FBS) for 16 hours. After the end of the starvation period, 10 μ? of assay agent in 5% DMSO in starvation medium to the assay wells and 10 μ? of the vehicle (5% DMSO in the middle of starvation) to the control wells. The final concentration of DMSO in each well was 0.5%. The plates were incubated at 37 ° C for 1 hour and then the cells were stimulated with 500 ng / ml of VEGF (commercially available from R &D System) in the presence of 2 mM Na3VO4 for 8 minutes. The cells were washed once with 1 mM Na3VO4 in HBSS and lysed by adding 50 μ? per well of lysis buffer. Then one hundred μ? of dilution buffer to each well and the diluted cell lysate was transferred to a 96-well plate coated with goat anti-rabbit (commercially available from Pierce) which was precoated with rabbit anti-human anti-flk-C-20 antibody (commercially available from Santa Cruz). The plates were incubated 146 room temperature for 2 hours and washed seven times with 1% Tween 20 in PBS. HRP-PY20 (commercially available from Santa Cruz) was diluted and added to the plate for incubation for 30 minutes. The plates were then washed again and TMB peroxidase substrate (commercially available from Kirkegaard &Perry) was added for a 10 minute incubation. One hundred μ? of 0.09 N of H2SO4 were added to each well of the 96-well plates to stop the reaction. The phosphorylation status was evaluated by reading in a spectrophotometer at 450 nm. Cl50 values were calculated by fitting to a curve using a four parameter analysis. Phosphorylation assay of PAE-PDGFRff in PAE-PDGFRB cells This assay determines the ability of a test compound to inhibit the autophosphorylation of PDGFR? in endothelial cells (PAE) - porcine aortic PDGFR. PAE cells that overexpress PDGFR? human were used in this trial. The cells were cultured in Ham's F12 medium supplemented with 10% fetal bovine serum (abbreviated in English as FBS) and 400 pg / ml of G418. Twenty thousand cells were seeded in each well of a 96-well plate in 50 μ? of growth medium and allowed to adhere for 6 hours at 37 ° C. The cells were then exposed to the starvation medium (Ham's F12 medium supplemented with 0.1% FBS) for 16 hours. After the end of the starvation period, 10 μ? of assay agent in 5% DMSO in starvation medium to the assay wells and 10 μ? of the vehicle (5% DMSO in the middle of starvation) to the control wells. The final concentration of DMSO in each well was 0.5%. The plates were incubated at 37 ° C for 1 hour and then the cells were 147 stimulated with 1 μ? /? t ?? of PDGF-BB (R &D System) in the presence of 2 mM Na3V04 for 8 minutes. The cells were washed once with 1 mM Na3V04 in HBSS and lysed by adding 50 μl per well of lysis buffer. Then one hundred μ? of dilution buffer to each well and the diluted cell lysate was transferred to a 96-well plate coated with goat anti-rabbit (Pierce), which was previously coated with rabbit anti-human antibody PDGFR? (Santa Cruz). Plates were incubated at room temperature for 2 hours and washed seven times with 1% Tween 20 in PBS. HPR-PY20 (Santa Cruz) was diluted and added to the plate for incubation for 30 minutes. The plates were then washed again and T B peroxidase substrate was added (Kirkegaard &; Perry) for a 10 minute incubation. One hundred μ? of 0.09 N of H2SO4 were added to each well of the 96-well plates to stop the reaction. The phosphorylation status was evaluated by reading in a spectrophotometer at 450 nm. The IC 50 values were calculated by fitting to a curve using a four parameter analysis. Human liver microsome assay (HLM) The metabolism of the compounds in human liver microsomes was measured by analytical assay procedures by LC-MS as follows. First, human liver microsomes (abbreviated HLM) were thawed and diluted to 5 mg / ml with cold 100 mM potassium phosphate buffer (KP04). Adequate amounts of KP04, NADPH regenerating solution (containing B-NADP, glucose-6-phosphate, glucose-6-phosphate dehydrogenase and MgCfe) and HLM were preincubated in 13 x 100 mm glass tubes at 37 ° C for 10 minutes (three tubes per test compound - triplicate). The test compound (5 μ final) was added to each tube to 148 Start the reaction and mix by gentle stirring in a vortex apparatus, followed by incubation at 37 ° C. At t = 0.2 h, a 250 μ sample was withdrawn? of each incubation tube to separate 12 x 75 mm glass tubes containing 1 ml of cold acetonitrile with 0.05 μ reserpine. The samples were centrifuged at 4000 rpm for 20 minutes to precipitate proteins and salt (Beckman Allegra 6KR, S / N ALK98D06, No. 634). The supernatant was transferred to new 12 x 75 mm glass tubes and evaporated by a Speed-Vac centrifugal vacuum evaporator. The samples were reconstituted in 200 μl 0.1% formic acid / acetonitrile (90:10) and vortexed vigorously to dissolve. The samples were then transferred to separate polypropylene microcentrifuge tubes and centrifuged at 14,000 x g for 10 minutes (Fisher Micro 14, S / N M0017580). For each replica (n ° 1 - 3) at each time (0 and 2 h) an aliquot sample of each test compound was collected in a single HPLC vial insert (a total of 6 samples) for LC-MS analysis, described below. The assembled composite samples were injected into the LC system - MS, consisting of a Hexlett-Packard HP 1100 diode array HPLC and a triple quadruple Micromass Quatro II mass spectrometer operating in positive electrospray SIR mode (programmed to scan specifically for the molecular ion of each test compound) . Each peak of test compound was integrated at each instant. For each compound, the peak area was averaged at each instant (n = 3), and the mean value of this peak area in 2 h was divided by the mean value of the peak area at the instant 0 hours to obtain the percentage of the test compound at 2 h. 149 The results of the test of the compounds using various tests are summarized in the table below, where an annotation of "% @" indicates the percentage of inhibition at the established concentration, the values "*" represent K¡ (nM) or% of inhibition at a compound concentration of 1 μ? for * or 50 nM for **, unless otherwise indicated. "NE" indicates a non-significant or not tested inhibition. Table 1 Continuation of table 1 150 Continuation of table 1 151 In vivo test of retinal vascular development in neonatal rats. The development of retinal vascular in rats occurs from day 1 postnatal until postnatal day 14 (P1 - P1). This method depends on the activity of VEGF (J. Stone et al., J. Neurosa., 15, 4738 (1995). Previous work has shown that VEGF also acts as a factor of survival of the retinal vessels during the early vascular development (Alon et al., Nat. Med., 1, 1024 (1995)). To assess the ability of specific compounds to inhibit VEGF activity in vivo, compounds were formulated in a suitable vehicle, usually 50% polyethylene glycol, average molecular weight 400 daltons, and 50% 300 mM sucrose solution in deionized water. Typically, two microliters (2 μm) of the drug solution was injected into the middle vitreous of the rat pup's eye on postnatal day 8 or 9. Six days after the intravitreal injection the animals were sacrificed and the free retinas were dissected of the remaining ocular tissue. The isolated retinas were then subjected to a histochemical staining protocol that specifically stained endothelial cells (Lutty and McLeod, Arch. Ophthalmol., 110, 267 (1992)), which reveal the degree of vascularization in the tissue sample. Then the individual retinas are fixed on slides and examined to determine the degree of vascularization. The effective compounds inhibit the further development of the retinal vasculature and induce a regression of all major vessels in the retina. The amount of vascular regression was used to assess the relative potency of the compounds after in vivo administration. Vascular regression is graded on a subjective scale of one to three pluses, judging a plus as approximately 25 percent or less of the detectable regression, judging that two pluses are approximately 25 -75% regression and three pluses give retinas with almost total regression (approximately 75% or greater). For additional quantitative regression analysis, the ADPase staining images, the fixed retinas were captured with a digital camera attached to a dissecting microscope. Then the retinal images were imported into an image analysis software (Imagen Pro PLus 4.0, Media Cibernetics, 153 Silver Spring, MD). The software was used to determine the percentage of the area of the retina that contained stained vessels. This value for the experimental eye was compared with that measured for the injected vehicle, contralateral eye of the same animal. The reduction in vascular area observed in the eye receiving the compound compared to the eye injected with vehicle was then expressed as the "regression percentage" for that sample. Percentages of regression values were averaged for groups of 5-8 animals. In samples in which observation by the microscope indicated almost total regression, a value of the regression percentage of 65-70% was usually measured. This was due to deposits of dye inside the retinal folds, folds that were induced by the vehicle used for injection of the drug. The image analysis software interpreted these folds containing colorant as vessels. No attempt was made to correct these folds since they varied from eye to eye. In this way, it will be observed that the percentage of the indicated regression values results from a conservative measurement that exactly classifies the compounds in order, but underestimates their absolute power. In vivo assay of retinal vascular development in the neonatal rat model of premature retinopathy A second model of VEGF-dependent retinal neovascularization was used to evaluate the activities of this series of compounds. In this model (Penn et al., Invest. Ophthalmol, Vis. Sci., 36, 2063 (1995)), rat pups (n = 16) with their mother were placed in a computer controlled chamber that regulates the concentration of oxygen. The animals were exposed 154 for 24 hours at a concentration of 50% oxygen followed by 24 hours at a concentration of 10% oxygen. This alternating cycle of hyperoxia followed by hypoxia is repeated 7 times after which animals are removed to ambient air (P14). The compounds are administered by intravitreal injection after taking them into the ambient air and the animals are sacrificed 6 days later (P20). The isolated retinas are then isolated, stained, fixed and analyzed as detailed previously in the development model.

The effectiveness also graduated as described for the development model. The exemplary compounds described above can be formulated into pharmaceutical compositions according to the following general examples.

Example 1: Parenteral composition To prepare a parenteral pharmaceutical composition suitable for administration by injection, 100 mg of a water-soluble salt of a compound of formula I are dissolved in DMSO and then mixed with 10 ml of sterile 0.9% saline. The mixture is incorporated into a suitable unit dosage form for administration by injection. Example 2: Oral composition To prepare a pharmaceutical composition for oral distribution by injection, 100 mg of a compound of formula I are mixed with 750 mg of lactose. The mixture is incorporated into an oral unit dosage form, such as a hard gelatin capsule. , which is suitable for oral administration. Example 3: Intraocular Composition In order to prepare a sustained release pharmaceutical composition for intraocular distribution, a compound of formula I is suspended in a 155 isotonic, neutral solution of hyaluronic acid (1.5% conc.) in phosphate buffer (pH 7.4) to form a 1% suspension. It is understood that the foregoing description is exemplary and of an explanatory nature, and is intended to illustrate the invention and its preferred embodiments. Through routine experimentation, the technician will recognize obvious modifications and variations that can be made without departing from the spirit of the invention. In this way, the invention is intended to be defined not only by the previous specification, but by the following claims and their equivalents.

Claims

156 Having described the invention as above it is declared as property described in the following CLAIMS What is claimed is: 1. A compound, pharmaceutically acceptable prodrug, pharmaceutically active metabolite, or pharmaceutically acceptable salt, selected from the group consisting of

1 7 25 ?? ??? 160

2. A compound represented by the formula or a pharmaceutically acceptable prodrug, pharmaceutically active metabolite, or pharmaceutically acceptable salt thereof.

3. A method of using a therapeutically effective amount of a compound, pharmaceutically acceptable prodrug, pharmaceutically active metabolite, or pharmaceutically acceptable salt as defined in claim 1 or 2 for treating macular degeneration relative to age in a mammal.

4. A method of using a therapeutically effective amount of a compound, pharmaceutically acceptable prodrug, pharmaceutically active metabolite, or pharmaceutically acceptable salt as defined in claim 1 or 2 for treating choroidal neovascularization in a mammal. 161

5. A method of using a therapeutically effective amount of a compound, pharmaceutically acceptable prodrug, pharmaceutically active metabolite, or pharmaceutically acceptable salt as defined in claim 1 or 2 for treating retinopathy in a mammal.

6. The method of claim 5 wherein the retinopathy comprises diabetic retinopathy, vitreoretinopathy, or retinopathy of prematurity.

7. A method of using a therapeutically effective amount of a compound, pharmaceutically acceptable prodrug, pharmaceutically active metabolite, or pharmaceutically acceptable salt as defined in claim 1 or 2 for treating retinitis in a mammal.

8. The method of claim 7 wherein the retinitis comprises cytomegalovirus retinitis.

9. A method of using a therapeutically effective amount of a compound, pharmaceutically acceptable prodrug, pharmaceutically active metabolite, or pharmaceutically acceptable salt as defined in claim 1 or 2 for treating macular edema in a mammal.

10. A method of using a therapeutically effective amount of a compound, pharmaceutically acceptable prodrug, pharmaceutically active metabolite, or pharmaceutically acceptable salt as 162 defined in claim 1 or 2 for treating an ophthalmic disease in a mammal.

1. A pharmaceutical composition comprising: (a) a therapeutically effective amount of a compound, pharmaceutically acceptable prodrug, pharmaceutically active metabolite, or pharmaceutically acceptable salt of claims 1 or 2; and (b) an excipient, diluent or vehicle thereof.

12. A method of using a therapeutically effective amount of a compound, pharmaceutically acceptable prodrug, pharmaceutically active metabolite, or pharmaceutically acceptable salt as defined in claim 1 or 2 for treating a condition of a mammalian disease mediated by protein kinase activity.

13. A method according to claim 12, wherein the disease condition of the mammal is associated with tumor growth, cell proliferation, or angiogenesis.

14. A method of modulating the activity of a protein kinase receptor, comprising contacting the kinase receptor with an effective amount of a compound, pharmaceutically acceptable prodrug, pharmaceutically active metabolite, or pharmaceutically acceptable salt as defined in claim 1 or 2. 163

15. A method according to claim 14, wherein the protein kinase receptor is a VEGF receptor.